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General Introduction and 




This thesis addresses the increasing problem of multidrug resistant microorganisms 
causing infections in healthcare, especially hospital-acquired infections, in countries that are less 
well developed compared to most Western European and North American countries. Healthcare-
associated infections constitute a sizable burden of disease, are associated with increased 
mortality and with increased costs of health care. Unfortunately, healthcare infections are also 
increasingly caused by certain species of microorganisms that display multiple resistances against 
commonly used antimicrobial agents.  
The emergence of multidrug-resistant hospital pathogens is part of the worldwide 
emergence of resistance against antimicrobial agents among all microorganisms exposed to them. 
Antimicrobial agents as they have been and still are applied by humans in all sectors of society, 
including animal husbandry. This global emergence of antimicrobial resistance has reached such 
pandemic proportions that, in the year 2014 , it has been recognized  as a special threat to 
mankind by the World Health Organization (WHO) and, in a special assembly on September 21st , 
2016, it was declared ‘the greatest and most urgent global risk’ by the United Nations. Under 
WHO’s guidance all countries are now addressing this threat.(1)  
However, not all regions of the world are equally affected by this calamity, the burden of 
antimicrobial resistance is likely to be much higher among less well-developed countries in Asia 
and Africa.(2) Indonesia is one of the most populous countries belonging to the so called lower-
middle income countries (LMIC) in South East Asia where antibiotic use and resistance to 
antibiotics are increasing rapidly (3), but where little research on the determinants of usage and 
of the emergence of antimicrobial resistance has taken place. When focusing on healthcare-
associated infections, patients on intensive care units (ICUs) are especially vulnerable to 
infections acquired during their stay. As evident from our scoping review, presented and fully 
referenced in Chapter 2, patients in ICUs in LMIC, although little studied, may have ICU-acquired 
infections at rates comparable to or somewhat higher than patients in ICU’s in high income 
countries. However, the mortality rates in LMIC ICU’s are generally higher, almost twice as high 
as in high income countries. In addition, the spectrum of causative microorganisms and the level 
of multidrug resistance among them may be significantly different and higher, respectively, when 
compared to the pathogens causing ICU infections in high income countries. 
The research presented in this thesis directly addresses the problem of ICU-acquired 
infections caused by multidrug-resistant pathogens in an Indonesian setting, i.e. ICUs in the 
national referral hospital in Jakarta, Indonesia. It aimed to provide better insight into the 
epidemiology of multidrug-resistant pathogens, and to explore ways to reduce the risk of 
acquiring such pathogens in this setting. The research was focused on the three most prevalent 
species of bacterial pathogens, Acinetobacter baumanni, Pseudomonas aeruginosa and Klebsiella 
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pneumoniae that caused the majority of serious ICU infections in this low-resource setting at the 
time of initiation of the studies presented here. Increasingly, clinical isolates of these three species 
from patients in ICUs were resistant to multiple classes of antimicrobial agents, including the last 
resort agents such as the carbapenem class of beta-lactam antibiotics.(4-6)  
Carbapenems constitute a novel class of beta-lactam antibiotics that were discovered 
almost 40 years ago by Kahan et al. (JAC 1983;12(D):1-35) as a product of Streptomyces 
cattleya.(7) The first carbapenem, imipenem-cilastatin, was introduced into clinical practice only 
in the late eighties of the previous century, at a time that the global emergence of resistance 
against most classes of antibiotics was starting to become recognized.(8) Carbapenems quickly 
became the drug of choice in treating infections by bacteria that had become resistant to third 
generation cephalosporins – a much used class of beta-lactam antibiotics since their introduction 
in the early eighties of the previous century -. Resistance to third generation cephalosporins was 
due to the acquired ability of many bacteria to produce so called extended spectrum beta-
lactamase (ESBL) enzymes that can degrade most beta-lactam antibiotic available at that time. In 
contrast, carbapenems are not degraded by ESBL enzymes. Unfortunately, but predictably, the 
introduction of carbapenems and their popularization led, within 10 years, to an increasing 
number of reports on the emergence of resistance against carbapenems, especially among Gram-
negative bacilli causing healthcare-associated infection. Carbapenem resistance was found to be 
due to multiple mechanisms, paramount among which was the acquired ability by several species 
of pathogenic bacteria to produce carbapenemases, i.e. enzymes that are able to degrade 
carbapenem molecules. As with ESBL, many types of such carbapenemases have since been 
discovered over the past two decades.(9) 
Collaborative studies between Indonesia and the Netherlands on this topic have been 
performed since the inception in 1997 of the Science Program Indonesia Netherlands (SPIN), a 
granting system jointly executed by the Dutch and Indonesian Academies of Sciences, KNAW and 
AIPI, respectively. Together with Diponegoro University in Semarang, Airlangga University in 
Surabaya, Leiden University Medical Centre, Radboud University Medical Center in Nijmegen, and 
Erasmus University Medical Center in Rotterdam, the Antimicrobial Resistance in Indonesia 
(AMRIN) study started in the year 2000. Little antibiotic resistance was detected among 
commensal Gram-negative bacilli isolated from community dwellers but many patients admitted 
to hospitals became colonized with Gram-negative bacilli resistant to multiple antibiotics 
indicating that Indonesian hospitals were important sites for the acquisition and spread of 
antibiotic resistance.(10) In a later study over a 4-month study period (January – April 2005) in 
Dr Soetomo Hospital, Surabaya, the authors found resistance to third generation cephalosporins 
– phenotypically due to  ESBL production - in 28.5 % (115/403) of E.coli and in 35.7% (104/291)
K. pneumoniae strains.(11, 12)  Saharman et al. reported in 2008 on 129 ICU patients using
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mechanical ventilator in the national referral hospital RS dr Cipto Mangunkusumo (RSCM) in 
Jakarta, that 46 of them (36%) suffered from ventilator associated pneumonia (VAP).(12) 
Microorganisms isolated from oropharyngeal swabs of these patients yielded Acinetobacter 
anitratus (now called A. baumannii) (in 23%), Klebsiella pneumoniae (15%), Pseudomonas 
aeruginosa (13%) and methicillin-resistant Staphylococcus aureus (MRSA) (1,4%). Bacteria 
isolated from quantitative culture of bronchoscopically retrieved specimens revealed a similar 
distribution: A. anitratus (32,4%), P. aeruginosa (24.7%), K. pneumoniae (10.4 %), and MRSA 
(2.6%). The prevalence of resistance to carbapenem class antibiotics among the Gram-negative 
bacterial species isolated from ICU patients in RSCM was already quite high at that time, varying 
from 21.9 % for P. aeruginosa to 27.6% for Enterobacterial species and 50.5% for A. baumannii 
(13). 
 
Aims and outline of the studies presented in this thesis. 
As stated above the work presented in this thesis focused on the epidemiology of 
multidrug-resistant pathogens in ICUs in RSCM, and on the prevention of acquisition and spread 
of A. baumannii, P. aeruginosa and K. pneumonia, especially of isolates that were carbapenem-non-
susceptible. The ultimate aim was to reduce the emergence and spread of multidrug-resistant 
organisms in an ICU setting with relatively low resources. More specifically, the goals and aims of 
the research described in this thesis were: 
1. To obtain a baseline insight into the epidemiology and the phenotypic and genetic 
characteristics of carbapenem-non-susceptible strains of Acinetobacter baumannii, 
Pseudomonas aeruginosa and Klebsiella pneumoniae in a low resource ICU setting. 
2. To develop an intervention - feasible to be applied in a low-resource ICU setting - that may 
significantly reduce the risk of acquisition and infection by carbapenem-non-susceptible 
A. baumannii, P. aeruginosa and K. pneumoniae. 
3. To apply and determine the efficacy of the intervention (developed as specified above/ 
under 2) in a low resource ICU setting. 
 
These issues and goals were addressed in ICUs of the RSCM, the national referral hospital situated 
in Jakarta, Indonesia, and are described in the following parts and chapters of this thesis: 
 
Part I contains the Introduction to this thesis with a separate accompanying systematic scoping 
review of the literature regarding infections and antimicrobial resistance in Intensive Care Units 
in Lower-Middle Income countries (chapter 2).The scoping review is up-to-date, it covers 
literature published in high quality in the period 2005-2018, effectively including the time when 
most of the research presented in this thesis was performed.  
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Part II of the thesis contains chapters describing the molecular epidemiology of carbapenem-non-
susceptible strains of Acinetobacter baumannii (chapter 3), Klebsiella pneumoniae (chapter 4) and 
Pseudomonas aeruginosa (chapter 5) in two separate ICUs in RSCM, Jakarta, Indonesia. The 
methods developed and applied for detailed genomic analysis of the carbapenem-non-susceptible 
P. aeruginosa isolates is presented in chapter 6. 
 
Part III of the thesis describes the design and application of a multimodal intervention aimed to 
reduce the rate of acquisitions of carbapenem-non-susceptible strains of A. baumannii, P. 
aeruginosa and K. pneumoniae by patients admitted to two ICUs of RSCM. The effect of a 
multifaceted hand hygiene improvement program – part of the intervention – is presented in a 
separate paper (chapter 7). However, the impact of introducing the whole intervention bundle on 
the rate of acquisitions of carbapenem-non-susceptible strains of the three species is presented 
in Chapter 8. In chapter 9 we explored in more detail the effects of the intervention on the clonal 
composition of P. aeruginosa in these two ICUs. 
 
Part IV contains a summarizing discussion of the results of the studies presented, provides a 
perspective on their application in clinical practice and contains suggestions for further research 
on the issue of preventing ICU acquired infections by multidrug resistant bacteria. It also contains 
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Carbapenem-nonsusceptible A. baumannii-calcoaceticus complex have emerged worldwide, but 
the epidemiology in Indonesian hospitals has not been studied.  
Methods:  
A prospective observational study was performed on the intensive care units (ICUs) of the national 
referral hospital in Jakarta-Indonesia, in 2013 and 2014. All consecutive adult patients admitted 
and hospitalized for >48 hours in ICUs were included. Basic and clinical data at admission were 
recorded. carbapenem-nonsusceptible A. baumannii-calcoaceticus complex from clinical cultures 
and standardized screening were included. Environmental niches and healthcare workers (HCWs) 
were also screened. PCR was used to detect carbapenemase genes, and Raman spectroscopy as 
well as multilocus sequence typing (MLST) for typing. 
Results:  
Of 412 included patients, 69 (16.7%) carried carbapenem-nonsusceptible A. baumannii-
calcoaceticus complex on admission, and 89 (25.9%) became positive during ICU stay. The 
acquisition rate was 43 per 1,000 patient-days at risk. Six isolates were cultured from 
environment and one from a HCW. Acquisition of carbapenem-nonsusceptible A. baumannii-
calcoaceticus complex was associated with longer ICU stay (median interquartile range [IQR]: 11 
days [5-18], adjusted hazard ratio [aHR]: 2.56 [99% confidence interval (CI):1.76-3.70]), but not 
with mortality rate (adjusted odds ratio: 1.59 [99%CI: 0.74-3.40] at the chosen level of 
significance). The blaOXA-23-like gene was detected in 292/318 (91.8%) isolates, including isolates 
from the environment and HCW. Typing revealed five major clusters. Sequence types (ST)195, 
ST208, ST218, ST642 as well as new STs were found. The dominant clone consisted of isolates 
from patients and environment throughout the study period. 
Conclusions:  
Carbapenem-nonsusceptible A. baumannii-calcoaceticus complex are endemic in this setting. 
Prevention requires source control and limiting transmission of strains. 
Trial registration:  
The study was retrospectively registered at www.trialregister.nl (No:5541). Candidate number: 
23527, NTR number: NTR5541, Date registered NTR: 22nd December 2015 
 
Keywords: 
Acinetobacter baumannii-calcoaceticus complex, Intensive Care Unit, Carbapenems, Antimicrobial 
resistance, Carbapenemase, Indonesia. 
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INTRODUCTION 
Multidrug-resistant Acinetobacter baumannii-calcoaceticus complex has emerged as one 
of the most problematic pathogens in hospitals. Their natural habitat is in the environment, 
including niches in the hospital from which they can spread to patients. [1] Risk factors for 
colonization and infection with multidrug-resistant A. baumannii-calcoaceticus complex include 
length of hospital stay, admission to an intensive care unit (ICU), mechanical ventilation, 
antimicrobial exposure, and several other factors. [2] Carbapenem-nonsusceptible A. baumannii-
calcoaceticus complex is considered a significant health problem because of the limited options 
remaining for antibiotic treatment. [3]  
In 2013, the Centers for Disease Control and Prevention of the United States reported an 
estimated 12,000 healthcare-associated Acinetobacter infections. Nearly 7,000 of these were 
caused by multidrug-resistant isolates. [4] In 2008, Lagamayo et al. reported that between 2-77% 
of all clinical isolates of Acinetobacter spp. in Asian countries were resistant to imipenem, and that 
multidrug-resistant Acinetobacter spp. were highly prevalent, particularly in Thailand and India, 
but not in the Philippines [5]. 
To date, there have been no data on the epidemiology of carbapenem-resistant or -
nonsusceptible A. baumannii-calcoaceticus complex from Indonesia, the fourth most populous 
country in the world. This study was designed to delineate the clinical and molecular 
epidemiology of carbapenem-nonsusceptible A. baumannii-calcoaceticus complex in two ICUs of 
the national referral hospital in Jakarta, Indonesia. 
PATIENTS AND METHODS 
Study Design 
A prospective observational study was performed at the Dr. Cipto Mangunkusumo General 
Hospital a 1,000-bed teaching hospital in Jakarta, Indonesia, from April-October 2013 and from 
April-August 2014. We conducted this study in two ICUs: the 12-bedded adult ICU and the 8-
bedded Emergency Room (ER)-ICU with an average of 1,010 and 415 admissions per year, 
respectively. The adult ICU is an open ward with mechanical ventilation facilities, admitting 
patients with mixed medical and surgical indications, and one designated nurse per patient during 
first shifts (7am-3pm) and a 1:1.5 nurse/patient ratio during other shifts. The ER-ICU has the same 
design, and the nurse-to-patient ratio in the morning shifts is 1:1 and during the other shifts 1:2. 
The populations served by these two ICUs were identical, and there was also no difference in the 
service provided.  
The study was performed in the framework of a larger study that focused on carbapenem-
nonsusceptible Klebsiella pneumoniae, Pseudomonas aeruginosa, and A. baumannii-calcoaceticus 
complex. All adult patients (≥18 years old) admitted to one of the two ICUs and hospitalized for 
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more than 48 hours were eligible for enrollment in this study. The first screening cultures were 
taken on the day of admission, and if a patient was discharged before 48 hour, he or she was 
excluded. Informed consent was obtained from the patient or their relatives as applicable. 
Demographic and clinical characteristics such as age, gender, medical or surgical indication, 
underlying diseases, hospitalization history, and previous use of antibiotics were recorded on 
admission.  
Systemic inflammatory response syndrome (SIRS) criteria on admission were used as a 
screening tool to assess (severity of) septic illness. The SIRS criteria were calculated and included 
in the study, as this was practice at the time of the study.[6] 
The quick Sequential Organ Failure Assessment (qSOFA) score is a new bedside prompt that may 
identify patients with suspected infection and helps to determine sepsis in all healthcare 
environments. The qSOFA score assigns one point for each of the following conditions: systolic blood pressure ≤100 mmHg, respiratory rate ≥22 breaths per minute, and altered mentation (Glasgow coma scale <15). A qSOFA score ≥2 at the onset of infection is associated with a greater 
risk of death and prolonged ICU stay. [6]  
The primary outcome measure was acquisition of a carbapenem-nonsusceptible A. 
baumannii-calcoaceticus complex. Acquisition is defined as a screening culture or clinical culture 
with first detection of A. baumannii-calcoaceticus complex, with reduced susceptibility to a 
carbapenem, that was not present within the first 48 hours of admission. Secondary outcome 
measures were length of stay in the ICU, and mortality during ICU stay. 
Environmental samples (Supplementary Table 1), were taken twice (in October 2013 and 
December 2014), simultaneously in both ICUs. Screening of healthcare workers (HCWs) was 
performed once. HCWs were defined as all personnel including doctors, nurses and other people 
(cleaning staff, administration staff, porters, nutritionist) working in one of the two ICUs during 
the study period. 
 
Screening Method 
From patients enrolled, screening cultures were obtained from throat and rectum or stools 
by experienced ICU nurses who had been trained for the task of taking the samples, on the day of 
admission, at the time of discharge from the ICU, and weekly if the patient was admitted for seven 
days or more. Sampling was performed using sterile cotton-tipped swabs, and swabs were 
transported to the laboratory in Amies transport medium (Oxoid, Basingstoke, UK). The swabs 
were transported in clean, closed boxes at ambient temperature to the laboratory on the same 
day. All swabs were processed in the laboratory within 24 hours. 
Clinical samples were collected on indication from patients under aseptic precautions 
from the lower respiratory tract, blood, urine, tissue, or wound.  Environmental samples were 
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taken from various sites, including wash basins, bed rails, bedside cabinet tables, ventilators, and 
monitor screens (Supplementary Table 1), with sterile cotton-tipped swabs and placed in Amies 
transport medium. All HCWs working in one of the ICUs were sampled once over the course of one 
month (September 2013) with sterile cotton-tipped swabs, which were transported to the 
laboratory in Amies transport medium. 
 
Microbiological Methods 
Isolation and Identification 
In the Clinical Microbiology Laboratory of Faculty of Medicine Universitas Indonesia, 
Jakarta, each swab was placed in 5 ml trypticase soy broth (TSB) supplemented with cefotaxime 
2 mg/L plus vancomycin 50 mg/L and incubated overnight. The next day, a loop of broth (10 µl) 
was subsequently subcultured onto MacConkey agar (Oxoid) and incubated aerobically at 370C 
for 16-24 hours, following which identification using the VITEK2®system (bioMérieux, Lyon, 
France) and susceptibility testing of colonies suggestive of A. baumannii-calcoaceticus complex 
was performed. All swabs, i.e. from patients, healthcare workers (HCWs), and environmental 
screening were processed in the same day. 
Blood cultures were collected in BACTEC® (BD, Franklin Lakes, NJ, USA) bottles as per 
manufacturer’s instructions at the discretion of attending clinicians with a minimum of 10 ml of 
blood collected from at least two puncture sites. Other clinical specimens were inoculated onto 
blood and MacConkey agar plates and incubated for 24 hours at 37°C. Subsequently, all colonies 
that had been cultured were examined for morphology by Gram stain and identified using the 
VITEK2®system. 
Strains were stored in duplicate in -80°C in TSB with glycerol 10%. One tube of each strain 
was sent to the Department of Medical Microbiology and Infectious Diseases, Erasmus MC, 
Rotterdam, the Netherlands, which laboratory holds an ISO 15189 accreditation, for further 
analysis. The other tube of each strain remained in the Indonesian laboratory. In the Netherlands, 
the identity of strains was confirmed using matrix-assisted laser desorption/ionisation (Maldi 
Biotyper, Bruker Microflex LT, London, UK). 
The quality control strains used for this part of the study in Indonesia were Escherichia 
coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853, in the laboratory in Erasmus MC 
multiple quality control strains were used. 
 
Antimicrobial Susceptibility Testing  
The susceptibility of the screening isolates to imipenem and meropenem was investigated 
by standard Kirby-Bauer disc diffusion technique using Mueller-Hinton agar plates (BD). For the 
isolates from clinical cultures, approximation of the minimum inhibitory concentrations (MICs) of 
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antibiotics was determined by the VITEK2® system. Carbapenem zone sizes and MICs were 
interpreted according to EUCAST (2013) using the following breakpoints: meropenem zone size 
<21mm and MIC >2 mg/L, imipenem zone size <23 mm and MIC >2 mg/L.[7] For this part of the 
study, quality control strains as described above were used.  
DNA Extraction and Carbapenemase Gene Detection 
DNA from the isolates was extracted by a cell lysis step and boiling using the InstaGene 
Matrix (Bio-Rad Laboratories, USA) according to the manufacturer’s instructions. PCR-based 
detection of Ambler class B metallo-beta-lactamases (blaNDM), class D beta-lactamases (blaOXA-23-
like, blaOXA-24-like, blaOXA-51-like and blaOXA-58-like) and ISAba1 were carried out using a T3000 
Thermocycler (Biometra-Whatman, Goettingen). The upstream location of the ISAba1 insertion 
element of the blaOXA-23-like gene was demonstrated by using the ISAba1 forward primer and the 
blaOXA-23-like reverse primer. PCR primers and reaction conditions for PCR were as described 
previously [8-11]. Amplified PCR products were resolved by electrophoresis at 250 V for 30 
minutes on 1.5% agarose gels with 0.5 x Tris (89mM)-boric acid (89mM)-EDTA(2mM) buffer 
containing SyBr® Safe DNA Gel Stain and visualized under UV light and photographed. In each run, 
a positive and negative control was included.  
Clonal relatedness 
Raman spectroscopy (SpectraCell RA® Bacterial Strain Analyzer, RiverD International BV, 
Rotterdam, The Netherlands) was applied as a first typing method. [12, 13] All isolates were 
grown overnight on trypticase soy agar (TSA; BD). Samples were prepared and submitted to 
spectrometry as described previously.[13] Raman light scatterings were analyzed by 
SpectraCellRA software version 1.9.0.13444:24. The similarity between pairs of spectra was 
calculated using the squared Pearson correlation coefficient (R2-values), multiplied by 100 and 
expressed as a percentage. The similarity threshold for this study was set at 91% so that two 
isolates with an R2 below this threshold were considered to be different and were designated 
different Raman types. Two isolates with an R2-value above 99.5% were considered 
indistinguishable and were considered to have the same Raman type. In case of an R2-value 
between of 90 % and 99.5%, these isolates were considered highly related but not identical. 
Correlation matrices displayed as 2D plots diagram were created using MATLAB version 7.1 (The 
MathWorks, Natick, MA, USA).  
Multilocus sequence typing (MLST) was used as a second typing method for a subset of 
isolates, including isolates from the largest clones of Raman spectroscopy, and all isolates from 
blood cultures (one per patient). These isolates were subjected to whole genome sequencing 
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(WGS) using Illumina chemistry. MLST typing results were deduced from the WGS data and 
assigned based on the Oxford database (pubmlst.org/abaumannii). 
Statistical Analysis 
Statistical analyses were done using SPSS Version 24.0 (SPSS, Chicago, IL, USA). Patients 
admitted to adult ICU were compared to ER-ICU using Chi square or Fisher Exact and Mann-
Whitney as appropriate. One-way ANOVA was used to compare patient characteristics according 
to their A. baumannii-calcoaceticus complex status. Univariate and  multivariate analyses were 
performed to establish risk factors associated with mortality using a multivariate logistic 
regression model with backward selection and inclusion of variables with a p-value <0.1 in the 
univariate analysis. Cox proportional regression was used to analyse risk factors for length of stay. 
Kaplan-Meier method was performed to construct survival curves. P-values of less than 0.01 were 
considered significant. [14] 
RESULTS 
Patient Characteristics 
During the 11-month study period, 1,211 patients were hospitalized in the ICUs (Adult 
ICU: 863, ER-ICU: 348). Supplementary Table 2 shows baseline characteristics of patients in each 
ICU. Of the 412 included patients, 188 were admitted to the adult ICU and 224 to the ER-ICU. There 
were no significant differences in characteristics between patients in both ICUs, except that in the 
adult ICU most of the patients had been referred from another ward in the same hospital 
(Supplementary Table 2). Therefore, we analyzed the data from the ICUs both separately and 
pooled.  
Overall, 158/412 (38.3%) patients had a positive culture with carbapenem-
nonsusceptible A. baumannii-calcoaceticus complex, the remaining 254 patients were free from 
carbapenem-nonsusceptible A. baumannii-calcoaceticus complex on admission and remained so 
during their ICU stay. Sixty-nine patients (69/412; 16.7%) already carried carbapenem-
nonsusceptible A. baumannii-calcoaceticus complex as revealed by screening cultures taken on the 
day of ICU admission, 89/343 (25.9%) patients who were initially culture-negative acquired 
carbapenem-nonsusceptible A. baumannii-calcoaceticus complex during their ICU stay 
(Supplementary Figure 1). Of the total of 158 patients with positive cultures, the positive cultures 
were obtained from screening specimens in only 80 patients, from clinical specimens in only 34 
patients and from both screening and clinical samples in 44 patients. Interestingly, of the patients 
that were positive on ICU admission, 17 (24.6%) were admitted directly from the emergency unit. 
Six patients had one or more blood cultures with carbapenem-nonsusceptible A. baumannii-
calcoaceticus complex, and three of them died on the ICU. The dynamics of acquisition of 
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carbapenem-nonsusceptible A. baumannii-calcoaceticus complex in the ICU is shown in Figure 1, 
60% of patients that became positive for Carbapenem-nonsusceptible A. baumannii-calcoaceticus 
complex during their ICU stay did so in the first week of ICU stay. There were no differences in the 
dynamics of carbapenem-nonsusceptible A. baumannii-calcoaceticus complex acquisition 
between the two ICUs (median acquisition day in adult ICU: 7, in ER-ICU: 6). The acquisition rate 
for carbapenem-nonsusceptible A. baumanni-calcoaceticus complex was 43 per 1,000 patient-
days at risk overall, with an average of 43 per 1,000 patient-days in adult ICU and  43 per 1,000 
patient-days in ER-ICU. 
 Patient outcomes were clearly associated with carbapenem-nonsusceptible A. baumanni-
calcoaceticus complex status of patients. Patients who acquired carbapenem-nonsusceptible A. 
baumannii-calcoaceticus complex during their ICU stay had a significantly longer length of stay 
(median [interquartile range (IQR)]: 11 [5-18], adjusted hazard ratio [aHR]: 2.56 [99% confidence 




Figure 1. Acquisition of carbapenem-nonsusceptible Acinetobacter baumannii-calcoaceticus complex in 
ICUs. Note: The solid line represents the cumulative percentage of patients by first day of culture being 
positive for carbapenem-nonsusceptible A. baumannii-calcoaceticus complex during ICU stay. In total, data 
from 89 patients are included in this figure. The median acquisition day (day 7, 60% of patients positive) is 
shown as well.  
 
that became positive before the day of their discharge (median [IQR] 13 [8-23] days, p<0.001, Figure 2) compared to the other groups of patients, of which ≥80% were discharged from the ICU 
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within ten days. Interestingly, these latter groups not only included the patients that were always 
free from carbapenem-nonsusceptible A. baumannii-calcoaceticus complex, but also included 
patients that already carried carbapenem-nonsusceptible A. baumannii-calcoaceticus complex at 
the time of admission to the ICU, and patients that remained free of carbapenem-nonsusceptible 
A. baumannii-calcoaceticus complex until they were found to be positive by screening on the day
of their discharge from the ICU (Figure 2).
Figure 2. Cumulative percentage of length of stay for patients according to their carbapenem-nonsusceptible 
Acinetobacter baumannii-calcoaceticus complex status. Note: Lengths of stay (days) represent total days 
patients were hospitalized in the ICU. The red line represents patients that were always carbapenem-
nonsusceptible A. baumannii-calcoaceticus complex negative during their ICU stay. The blue line represents 
patients already carbapenem-nonsusceptible A. baumannii-calcoaceticus complex positive on the day of 
admission. The green line represents patients that were carbapenem-nonsusceptible A. baumannii-
calcoaceticus complex positive only at the time of discharge and the black line represents patients that 
became positive for carbapenem-nonsusceptible A. baumannii-calcoaceticus complex during their ICU stay 
before the day of discharge. P value: comparison between patients that became positive with carbapenem-
nonsusceptible A. baumannii-calcoaceticus complex before the day of discharge and the other groups. 
Acquisition of carbapenem-nonsusceptible A. baumannii-calcoaceticus complex was not 
associated with mortality, 23.2% of patients that remained free of carbapenem-nonsusceptible A. 
baumannii-calcoaceticus complex died versus 42.7% of patients that acquired carbapenem-
nonsusceptible A. baumannii-calcoaceticus complex during their ICU stay (Figure 3, 
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Supplementary Table 3, for adjusted Odds Ratio (aOR):1.59 [99%CI: 0.74-3.40], p=0.066). 
Importantly, the admission SIRS and qSOFA scores of patients with or without A. baumannii-
calcoaceticus complex acquisition did not differ (Table 1), indicating that the difference in the risk 
of dying was not present at the time of ICU admission but emerged later during their ICU stay 
(SIRS: crude Odds Ratio (cOR):1.69 [99%CI:0.55-5.22], p=0.230; qSOFA:cOR: 1.45[99%CI:0.68-
3.08], p=0.211, Supplementary Table 3). 
 
Figure 3. Survival analysis of ICU patients according to their carbapenem-nonsusceptible Acinetobacter 
baumannii-calcoaceticus complex status. Note: Survival of patients with carbapenem-nonsusceptible A. 
baumannii-calcoaceticus complex acquired during their ICU stay (blue line) compared with the survival of 
patients that remained negative for carbapenem-nonsusceptible A. baumannii-calcoaceticus complex in 
their screening and clinical cultures (green line). 
 
 Patients that were free of carbapenem-nonsusceptible A. baumannii-calcoaceticus 
complex during their entire ICU stay were less likely to have had prior exposure to antibiotics, 
especially carbapenems (p<0.01), they were more likely to have had a surgical indication for their 
admission to the ICU, and less likely to have had cerebrovascular disease (Table 1). Patients that 
acquired carbapenem-nonsusceptible A. baumannii-calcoaceticus complex during ICU stay had 
undergone a procedure (mechanical ventilation), had medical device (central venous catheter or 
urine catheter) or had received carbapenem therapy more often than the other groups in the 
univariate analysis (p<0.01) (Table 1). In a multivariate comparison of patients who acquired 
carbapenem-nonsusceptible A. baumannii-calcoaceticus complex to patients that were always 
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negative only carbapenem therapy during ICU admission  could be identified as a risk factor (aOR: 
3.37 [99%CI: 1.68-6.77], p<0.01) 
 
Carbapenem-nonsusceptible A. baumannii-calcoaceticus Complex and Molecular 
Characterization 
 In total, we collected 318 carbapenem-nonsusceptible isolated from 158 patients, six 
carbapenem-nonsusceptible A. baumannii-calcoaceticus complex isolates cultured from the 
environment (table, bed rails, sinks, and tapwater), and a single isolate from a healthcare worker 
(throat) that was carbapenem-nonsusceptible as well (Supplementary Table 5). 
The blaOXA-23-like gene was demonstrated in 292/318 (91.8.0%) isolates including isolates from 
patients, the environment and from the healthcare worker. The blaOXA-24-like gene was detected in 
a single isolate. Coexistence of OXA-23 with other oxacillinases and carbapenemases was found: 
OXA-23/OXA-58 (1 isolate), and OXA-23/NDM-1 (4 isolates). The blaOXA-23-like gene was always 
demonstrated in combination with the ISAba1 insertion element upstream to the OXA-23 β-
lactamase. The intrinsic A. baumannii-calcoaceticus complex gene blaOXA-51-like was demonstrated 
in all isolates. In the subset of isolates that were subjected to WGS (n=14), the blaOXA-51-like gene 
involved blaOXA-66 in 13 isolates and blaOXA-68 in one isolate (Table 2). 
 
Clonal relatedness  
Raman spectroscopy analysis performed for all of the isolates, revealed the presence of 
multiple types within the collection of A. baumannii-calcoaceticus complex. In total, 51 Raman 
types were identified. Interestingly, the majority of strains belonged to one of five major clusters 
(Supplementary Figure 2). The largest cluster (designated CIPTO-31) consisted of 111 isolates 
obtained from 69 patients (screening and clinical specimens) and four isolates from the 
environment. The sources of the five major clusters are specified in Supplementary Table 4. 
Strains belonging to the dominant cluster CIPTO-31 were present in both ICUs throughout the 
study period, whereas other clones seemed to wax and wane over time (Figure 4). Patients were 
colonized with carbapenem-nonsusceptible A. baumannii-calcoaceticus complex irrespective of 
the location of their bed in these ICUs indicating that spreading of carbapenem-nonsusceptible A. 
baumannii-calcoaceticus complex in the ICUs was not restricted to only a part of the ICU 
(Supplementary Figure 3). 
MLST, performed for a subset of 14 isolates, revealed the presence of multiple sequence 
types (STs), which corresponded closely to the Raman spectroscopy clustering (Table 2). Four 
previously identified STs (ST195, ST208, ST218, and ST642) as well as several new STs, and a new 













































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4. Persistence of Raman clones of carbapenem-nonsusceptible Acinetobacter baumannii-
calcoaceticus complex in two ICUs of Dr. Cipto Mangunkusomo General Hospital, Jakarta, 
Indonesia. Note: Endemic curves of the five biggest clusters of carbapenem-nonsusceptible A. 
baumannii-calcoaceticus complex in each ICU, April–October 2013 and April–August 2014. The 
dark blue bars represent cluster CIPTO-30. The red bars represent CIPTO-31. The green bars 
represent CIPTO-45. The yellow bars represent CIPTO-46 and the light blue bars represent CIPTO-




 This is the first report of a study on the clinical and molecular epidemiology of 
carbapenem-nonsusceptible A. baumannii-calcoaceticus complex in two ICUs in a large academic 
hospital in Jakarta, Indonesia. These two ICUs can be considered to have endemic carbapenem-
nonsusceptible strains belonging to A. baumannii-calcoaceticus complex, i.e. entrenched by a few 
carbapenem-nonsusceptible clones, whose acquisition by patients may be associated with a 
prolonged ICU stay. 
 Carbapenem-nonsusceptible A. baumannii-calcoaceticus complex has emerged globally as 
a hospital-acquired pathogen, causing many outbreaks, especially in ICUs. [3] In Asia, 
carbapenem-resistant A. baumannii-calcoaceticus complex were found to dominate in Vietnam, 
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[15] Thailand, [16] Malaysia, [17] and also China. [18] Similar to these studies, we found that
38.3% of the patients had colonization or infection with carbapenem-nonsusceptible A.
baumannii-calcoaceticus complex. By screening on ICU admission 16.7% of the carbapenem-
nonsusceptible A. baumannii-calcoaceticus complex positive patients were already colonized with
this species prior to their admission. This suggests that patients may become colonized with such
strains elsewhere in the same hospital or in another hospital from which they are referred, or may
come with such strain directly from the community, possibly having acquired their strain during
a previous healthcare contact. Thus, the ICUs in this study experience a regular influx of patients
carrying carbapenem-nonsusceptible A. baumannii-calcoaceticus complex strains into their
setting. Our findings also raise questions about carriage of A. baumannii-calcoaceticus complex in
the community, a finding that was also reported in a recent study from Semarang, Central Java,
Indonesia. From the nasopharynx of 14 healthy people, A. baumannii-calcoaceticus complex was
isolated in that study [19].  This requires further investigation.
Screening cultures can, therefore, be considered very helpful for early detection, infection 
control, and rational antibiotic use. A study in South Florida found that patients with positive 
surveillance cultures had a 8.4-fold higher risk of developing a subsequent A. baumannii-
calcoaceticus complex infection compared with patients who remained negative on surveillance 
cultures.[20] 
Our data also show that many patients acquire carbapenem-nonsusceptible A. baumannii-
calcoaceticus complex during their ICU stay and that these acquisitions are associated with 
significantly longer ICU stay but not with mortality (at the chosen level of significance) compared 
to patients who did not acquire carbapenem-nonsusceptible A. baumannii while in the ICU. This is 
in agreement with a study from the USA, which showed an independent association between 
multidrug-resistant A. baumannii-calcoaceticus complex and increased hospital and ICU length of 
stay, but not an increased mortality. [21] However, a recent systematic review and meta-analysis 
to examine the association between carbapenem-resistant A. baumannii-calcoaceticus complex 
(CRAB) and mortality found that patients with CRAB had a significantly higher risk of mortality 
than patients with carbapenem-susceptible A. baumannii-calcoaceticus complex (crude OR = 2.22; 
95% CI = 1.66- 2.98). [22]  
The most prevalent mechanisms of carbapenem-nonsusceptibility in A. baumannii-
calcoaceticus complex are acquired OXA-type carbapenem-hydrolyzing beta-lactamases of the 
OXA-23, OXA-24 and OXA-58 subfamilies, and the New Delhi metallo-beta-lactamases (NDM). [23-
25] Our study found that 91.8% of the isolates carried the blaOXA-23-like gene in combination with
the upstream presence of the ISAba1 insertion element, enhancing carbapenem resistance. blaOXA-
24-like, blaOXA-58-like, and blaNDM-like genes were rarely present. The dissemination of OXA-23
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producing carbapenem-nonsusceptible A. baumannii-calcoaceticus complex isolates has 
previously been reported in Asia and throughout the world. [26-28] 
Carbapenem-nonsusceptible A. baumannii-calcoaceticus complex colonizing/infecting ICU 
patients may originate from the patient her/himself, but may also come from contaminated 
hospital equipment and environment, staff and other patients. Multiple reported outbreaks of 
multidrug-resistant A. baumannii-calcoaceticus complex infection were associated with 
environmental contamination. [29-31] There should be a focus on the prevention of nosocomial 
transmission of these microorganisms from these environmental sources to patients. 
We performed Raman spectroscopy as a first bacterial typing method. [12] This analysis 
revealed five clusters, with the largest one (CIPTO-31), responsible for more than one third of all 
isolates, persisting in both ICUs throughout the study period. Geographical analysis of cluster 
CIPTO-31 isolates showed spreading of this clone throughout both ICUs. The isolates were found 
in and around all the beds regularly occupied by patients. MLST of four CIPTO-31 isolates revealed 
that these could be assigned to two new STs. Another nine isolates from the largest Raman clusters 
could be assigned to ST195, ST208, or ST218, or a new ST based on a new allele for the gpi gene 
(http://pubmlst.org/abaumannii/). A blood culture isolate that was unique in the Raman 
spectroscopy typing belonged to ST642. ST195, ST208, ST218, and ST642 have all previously been 
identified in Asian countries [32], including China [33], Malaysia [34], and Japan [35]. The 
epidemiology of carbapenem-nonsusceptible A. baumannii-calcoaceticus complex in this 
Indonesian hospital was a combination of several known dominant Asian clones and new clones. 
 Our study has certain limitations. First, our study was a single-center study during a 
situation of endemic carbapenem-nonsusceptible A. baumannii-calcoaceticus complex 
colonisation and infection. Therefor, our data should not representative for the whole country. 
Second, we did not evaluate the effect of other possible confounders, such as dialysis, need for 
inotropes, surgery, and previous admission to a hospital. 
 
CONCLUSIONS 
 In summary, this study is the largest to date that describes the characteristics and outcome 
of carbapenem-nonsusceptible A. baumannii-calcoaceticus complex in ICUs of a referral hospital 
in Indonesia. Colonization or infection with carbapenem-nonsusceptible A. baumannii-
calcoaceticus complex during hospitalization was independently associated with prolonged LOS 
in the ICU. Prevention of A. baumannii-calcoaceticus complex colonization and infection requires 
interventions directed to source control and limiting the transmission of such strains to and 
between patients. 
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SUPPLEMENTAL MATERIALS 
Supplementary Table 1.  List of environmental samples 
Sample site Number of samples 
Adult ICU ER-ICU 
Washbasin on ICUs ward 10 5 
Monitor 14 10 
Ventilator 15 5 
Ambu bag 8 
Stethoscope 10 9 
Drawer handle bedside cabinet  21 
Plastic multi-purpose container next to 
each bed 
18 8 
Stainless steel container 8 15 
Flowmeter  15 
Infusion stand   11 8 
Infusion pump  9 6 
Bed rails 20 14 
Tap water (washbasin on ICU ward) 10 8 
Chart paper on bedside cabinet 11 6 
Bedside cabinet table 15 11 
Cleaning room: washbasin 9 
Cleaning room: sink countertop 3 
Cleaning room: mug 2 
Cleaning room: dish rack 3 
Mattress 5 4 
Comb 3 
Water from siphon of washbasin  10 5 
Water from mug next to each bed 10 6 
Massage oil 5 
Chlorine solution after use  3 
Cleaning wipes 3 4 
Wall  3 2 
Drawer of bedside cabinet 3 
Water from suction  7 
Suction connector/container 3 
Water from humidifier 1 
Water after cleaning a floor 2 
Floor 2 
Nurse station 1 1 
Abbreviations: ICU,Intensive Care Unit. 
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Supplementary Table 2. Baseline characteristics of patients admitted to the adult and 
Emergency Room (ER) ICUs 
  Adult ICU  ER-ICU p value 
Number of patients enrolled 188 224   
Age (years), median (IQR) 49 (38-58) 43 (30-58) 0.041 
Gender       
Male (%) 91 (48.4) 123 (54.9) 0.188 
Female (%) 97 (51.6) 101 (45.1)   
Underlying diseases       
Cardiovascular (%) 12 (6.4) 13 (5.8) 0.806 
Cerebrovascular (%) 10 (5.3) 19 (8.5) 0.211 
Chronic kidney disease (%) 15 (8) 18 (8.0) 0.983 
Diabetes mellitus (%) 80 (42.6) 38 (17.0) 0.000** 
Malignancy (%) 62 (32.9) 120 (53.6) 0.000** 
Indication for ICU admission     0.039 
Medical (%) 54 (28.7) 86 (38.4)  
Surgical (%) 134 (71.3) 138 (61.6)   
Referral from     0.000** 
Other ward this hospital (%) 144 (76.6) 78 (34.8)  
Other hospital (%) 20 (10.6) 57 (25.4)  
Directly from Emergency Unit (%) 24 (12.8) 89 (39.8)   
Antibiotic exposure (before admission to ICU)       
Any antibiotic (%) 146 (77.7) 165 (73.7) 0.349 
Carbapenem (%) 40 (21.3) 39 (17.4) 0.321 
SIRS Score, (%)     0.992 
Score >2 172 (91.5) 205 (91.5)  
Score <2 16 (8.5) 19 (8.5)  
qSOFA Score, (%)     0.158 
Score >2 158 (84.0) 176 (78.6)  
Score <2 30 (16.0) 48 (21.4)   
Procedures (during ICU admission)     
Mechanical ventilation (%) 170 (90.4) 201 (89.7) 0.815 
Mechanical ventilation (days), median (IQR) 4 (1.5-9) 3 (2-7) 0.591 
     >5 days (%) 87 (26.3) 95 (42.4) 0.431 
     <5 days (%) 101 (53.7) 129 (57.6)  
Central venous catheter (%) 166 (88.3) 197 (87.9) 0.913 
Central venous catheter (days), median (IQR) 5.5 (3-10) 5 (3-8.5) 0.150 
     >5 days (%) 106 (56.4) 117 (52.2) 0.400 
     <5 days (%) 82 (43.6) 107 (47.8)  
Urine catheter (%) 188 (100) 224 (100) N/A 
Urine catheter (days), median (IQR) 6 (3-11) 5 (3-9) 0.181 
     >5 days (%) 118 (62.8) 133 (59.4) 0.486 
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Adult ICU ER-ICU p value 
     <5 days (%) 70 (37.2) 91 (40.6) 
Antibiotic therapy (during ICU admission) 
Any antibiotic (%)  188 (100) 218 (97.3) 0.034 
Carbapenem (%) 99 (52.7) 100 (44.6) 0.105 
Outcomes 
  Length of stay (days), median (IQR) 5 (3-10.75) 5 (3-8) 0.024 
  Death (%) 52 (27.7) 67 (29.9) 0.616 
Abbreviations: ER-ICU, Emergency room Intensive Care Unit; ICU, Intensive Care Unit; IQR, 
Interquartile range; qSOFA, quick Sepsis-related Organ Failure Assessment; SIRS, Systemic 
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Supplementary Table 5. Source of detection of the carbapenem-non-susceptible A. 
baumannii-calcoaceticus complex isolates collected in the study 
Culture Number of patients Isolates 
Only screening 80 131 
Only clinical specimen 34 49 
Screening and clinical specimen 44 131 
Environment 6 
Healthcare worker screening 1 
Total 158 318 
Supplementary Table 6. Sources of the five major Raman clusters of carbapenem-non-





Origin of strain 
Patients Environment 
Adult ICU ER-ICU Adult ICU ER-ICU 
Screening Clinical Screening Clinical 
CIPTO-30 23 (14) 12 6 4 1 
CIPTO-31 111 (69) 35 17 33 26 4 
CIPTO-45 33 (19) 8 4 17 4 
CIPTO-46 36 (27) 7 10 10 9 
CIPTO-48 40 (29) 12 9 14 5 1 
Abbreviation: ER-ICU, Emergency room Intensive Care Unit; ICU, Intensive Care Unit.  




Supplementary Figure 1. Carbapenem-nonsusceptible Acinetobacter baumannii-calcoaceticus 
complex carriage of included patients admitted to adult and ER-ICUs of Dr. Cipto Mangunkusomo 
General Hospital, Jakarta, Indonesia. 
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Supplementary Figure 2. Raman spectroscopy-based cluster analysis of Acinetobacter baumannii-
calcoaceticus complex isolates from adult and ER-ICUs. Note: Raman spectra correlation matrix of 
carbapenem-nonsusceptible A. baumannii-calcoaceticus complex isolates. Isolates are shown in a 
color-scale (red-orange-yellow-grey) based on their similarity of correlation coefficient value. Red 
clusters (91–100%) indicate isolates that are indistinguishable according to the cut-off value. Grey 
areas (≤70%) indicate isolates that are not related. The potentially related isolates are shown by 




Supplementary Figure 3. The bed-clone analysis of cluster CIPTO-31 carbapenem-nonsusceptible 
Acinetobacter baumannii-calcoaceticus complex. Note: The bed-clone analysis from cluster CIPTO-
31 carbapenem-nonsusceptible A. baumannii-calcoaceticus complex showed spreading of 115 
isolates in both ICUs. The isolates were found in patients from almost all the beds. A red diamond 
represents an environmental isolate. 
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A prospective observational study was performed to assess the epidemiology and clinical impact 
of carbapenem-non-susceptible Klebsiella pneumoniae (CNKP) in intensive care units (ICUs) of 
the national referral hospital in Jakarta, Indonesia. 
Materials/methods:  
Adult patients consecutively hospitalized for >48 hours in two ICUs of the national referral 
hospital were included from April until October 2013 and from April until August 2014. K. 
pneumoniae from clinical cultures and standardized screening of rectum and throat on admission, 
discharge and weekly if hospitalized >7 days were collected. Environmental niches and 
healthcare workers (HCWs) were also screened. Susceptibility was determined phenotypically 
and the presence of carbapenemase genes by PCR. Raman spectroscopy as well as multiple-locus 
variable number tandem repeat analysis (MLVA) were used for typing. 
Results:  
Twenty-two out of 412 (5.3%) patients carried CNKP on admission and 37/390 (9.5%) acquired 
CNKP during ICU stay. The acquisition rate was 24.7/1,000 patient-days at risk. One out of 31 
(3.2%) environmental isolates was a CNKP. None of the HCWs carried CNKP. Acquisition of 
CNKP was associated with longer ICU stay (adjusted hazard ratio: 2.32 [CI99: 1.35-3.68]). ICU 
survival was lower among patients with CNKP compared to patients with carbapenem-
susceptible K. pneumoniae (aHR 2.57, p=0.005). Ninety-six of the 100 (96%) CNKP isolates 
carried a carbapenemase gene, predominantly blaNDM. Raman typing revealed three major 
clusters among 48 Raman types identified, whereas MLVA distinguished six major clusters among 
a total of 30 different genotypes. 
 Conclusions:  
NDM-producing CNKP are introduced into these ICUs and some strains expand clonally among 
patients and the environment, resulting in endemic CNKP. CNKP acquisition was associated with 
prolonged ICU stay and may affect ICU survival. 
Trial registration:  
The study was registered at Netherlands Trial Register http://www.trialregister.nl (No: 5541). 




Klebsiella pneumoniae, microbial drug resistance, carbapenemase, intensive care unit, mortality, 
Indonesia. 
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INTRODUCTION 
Carbapenems are the antibiotics of choice for treatment of life-threatening infections due 
to multidrug-resistant Gram-negative bacilli. However, the worldwide emergence of 
carbapenem-non-susceptible Klebsiella pneumoniae, especially in intensive care units (ICUs), has 
become a major challenge. Non-susceptibility to carbapenems in K. pneumoniae may be due to production of Ambler class A β-lactamases (e.g. KPC), class B metallo-β-lactamases (MBLs, e.g. 
VIM, IMP, NDM) or class D oxacillinases (e.g. OXA-48 like enzymes).(1-3)  
Although carbapenemase-producing K. pneumoniae have emerged globally, geographic 
variations do exist. K. pneumoniae producing KPCs have initially mainly been reported in the USA 
and Israel, but more recently also from China and Taiwan.(1, 2, 4, 5) K. pneumoniae strains 
carrying OXA-48-like carbapenemases were first described in Turkey in 2003. Currently, K. 
pneumoniae with OXA-48-like carbapenemases are spreading rapidly in many European 
countries, in addition to being endemic in the Middle East and in Northern Africa. (1, 4, 5) Bacteria 
with the New Delhi metallo-β-lactamase (NDM) enzyme, which was first identified in Sweden 
from a patient who had travelled from New Delhi, India, have attained endemic levels in countries 
of the Indian subcontinent including India, Pakistan, Bangladesh and Sri Lanka.(1, 4-8) This gene 
is also encountered in bacteria, including K. pneumoniae, in some countries in the South East 
Asian region, including Singapore (9), Thailand (10) and Vietnam (1). However, so far there have 
been few data on the epidemiology of carbapenem-non-susceptible K. pneumoniae reported from 
Indonesia, the fourth most populous country in the world. In 2011, 27.6% of the 
Enterobacteriaceae isolated from specimens at two ICUs in Jakarta was carbapenem-resistant, 
including one K. pneumoniae harboring the blaNDM gene.(11) In 2014-2015, the prevalence of 
resistance to meropenem among K. pneumoniae from urinary tract infections in clinical and 
outpatient clinical settings was 21.6%, but no further analysis of these isolates was performed. 
(12) The aim of the present study was to delineate the clinical and molecular epidemiology of
carbapenem-non-susceptible K. pneumoniae isolated in two ICUs of the Dr. Cipto Mangunkusumo
General Hospital, the national referral teaching hospital in Jakarta.
MATERIALS AND METHODS 
Study design 
A prospective observational study was performed in a 1,000-bed national referral 
teaching hospital with 34,000 admissions per year in Jakarta, Indonesia, from April until October 
2013 and from April until August 2014. Two ICUs participated, the adult ICU and the Emergency 







admissions in 2014, respectively. The adult ICU is a 12-bed open ward with mechanical 
ventilation facilities, admitting patients with various medical and surgical indications, and one 
designated nurse per patient during morning shifts and a 1:1.5 nurse/patient ratio during other 
shifts. It is also used as post-anaesthetic care unit. The ER-ICU has the same design, but 8 beds, 
and the nurse per patient ratio in the morning shifts is 1:1 and during the other shifts 1:2. This 
ICU is also used for short observations. All adult patients (≥18 years old) admitted to one of the two ICUs and hospitalized for 
more than 48 hours were eligible for enrollment in this study. Informed consent was obtained 
from the patient or their relatives as applicable. Demographic and clinical characteristics such as 
age, gender, medical or surgical indication, underlying diseases, hospitalization history, and 
previous use of antibiotics on admission were recorded.  
Systemic inflammatory response syndrome (SIRS) criteria on admission were used as a 
screening tool to assess (severity of) septic illness. The "Acute Physiology and Chronic Health 
Evaluation II" score was not feasible in this low-resource setting. SIRS is defined as two or more 
of the following: fever >38°C or <36°C, heart rate >90 beats per minute, respiratory rate >20 
breaths per minute or PaCO2 <32 mmHg, abnormal white blood cell count (>12,000/mm3 or 
<4,000/mm3 or >10% bands). (13) 
The quick Sequential Organ Failure Assessment (qSOFA) score is a newer bedside prompt 
that may identify patients with suspected infection and helps to determine sepsis in all healthcare 
environments. The qSOFA score assigns one point for each of the following conditions: systolic blood pressure ≤100 mmHg, respiratory rate ≥22 breaths per minute, and altered mentation (Glasgow coma scale <15). The score ranges from 0 to 3 points. A qSOFA score ≥2 at the onset of 
infection is associated with a greater risk of death and prolonged ICU stay. This score was included 
as well. (13) 
Acquisition is defined as a screening culture (throat or rectum/stool) or clinical culture 
with a first detection of K. pneumoniae with reduced susceptibility to a carbapenem, that was not 
present in cultures taken from the patient on admission or in the first 48 hours of admission. 
Outcome measures were acquisition of a carbapenem-susceptible and carbapenem-non-
susceptible K. pneumoniae (independent of resistance to other classes of antibiotics), length of 
stay in the ICU, and mortality during ICU stay. 
Environmental samples were taken twice (in October 2013 and December 2014), 
simultaneously in both ICUs. Screening of healthcare workers (HCWs) was performed once. HCWs 
were defined as all personnel including doctors, nurses and other people (cleaning staff, 
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Sampling 
From patients enrolled, screening cultures were obtained from throat and rectum or 
stools by experienced ICU nurses on the day of admission, at the time of discharge from the ICU, 
and weekly if the patient was admitted for seven days or more. The samples were collected with 
sterile cotton-tipped swabs and placed in Amies transport medium (Oxoid, Basingstoke, UK). The 
swabs were transported in clean, closed boxes at ambient temperature to the laboratory on the 
same day. All swabs were processed in the laboratory within 24 hours. 
Clinical samples were collected from a patient when the ICU physician suspected the 
patient of having an infection. Specimens were taken under aseptic precautions from the lower 
respiratory tract, blood, urine, tissue, or wound, on indication.  
Environmental samples were taken from various sites, including wash basins, bed rails, 
bedside cabinet tables, ventilators, and monitor screens (Supplementary Table 1), with sterile 
cotton-tipped swabs and placed in Amies transport medium.(14) All HCWs working in one of the 
ICUs were sampled (rectal and throat) once over the course of one month (September 2013) with 
sterile cotton-tipped swabs, which were transported to the laboratory in Amies transport 
medium. 
Microbiological Methods 
Isolation and identification of bacteria 
In the laboratory, each screening swab was placed in a trypticase soy broth (TSB) 
supplemented with cefotaxime 2 mg/L plus vancomycin 50 mg/L and incubated overnight. The 
next day, a loop of broth was sub-cultured on MacConkey agar (Oxoid).  
Blood cultures were collected in BACTEC (BD, Franklin Lakes, NJ, USA) bottles as per 
manufacturer’s instructions with a minimum of 10 mL of blood collected from at least two 
puncture sites. Other clinical specimens were inoculated onto blood and MacConkey agar plates 
(Oxoid) and incubated for 24 hours at 37°C. All morphologically different colonies were 
examined by Gram stain and identified using the VITEK2® system (bioMérieux, Lyon, France). 
Strains were stored in duplicate in -80°C in TSB with glycerol 10%. One tube of each strain 
was sent to the Department of Medical Microbiology and Infectious Diseases, Erasmus MC, 
Rotterdam, the Netherlands, for further analysis. The other tube of each strain remained in the 
Indonesian laboratory. In the Netherlands, the identity of strains was confirmed using matrix-
assisted laser desorption/ionisation (Maldi Biotyper, Bruker Microflex LT, Bruker, London, UK). 
The quality control strains used for this part of the study in Indonesia were Escherichia 
coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853, in the laboratory of Erasmus MC 
multiple quality control strains were used. 
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Antimicrobial susceptibility testing 
Imipenem and meropenem susceptibility tests on isolates from screening cultures were 
performed by standard Kirby-Bauer disc diffusion technique using Mueller-Hinton agar plates 
(BD) based on EUCAST Disc Diffusion Method for Antimicrobial Susceptibility Testing- Version 
3.0 (April 2013). Minimum inhibitory concentrations (MICs) of antibiotics were determined by 
VITEK2® for clinical isolates. Carbapenem MICs and zone sizes were interpreted according to 
EUCAST (2013) using the following breakpoints for non-susceptibility: meropenem >0.25 mg/L 
(<24mm), imipenem >1 mg/L (<22 mm).(15) For this part of the study, quality control strains as 
described above were used. 
String test 
In order to determine hyper-muco-viscosity, the string assay was performed for all K. 
pneumoniae isolates. For this, the strains were inoculated onto 5% sheep blood agar (BD) and 
kept overnight at 37°C. An individual colony was then touched with a 1 μL disposable loop which was subsequently pulled up slowly. The string test was deemed positive if a string of ≥5 mm was 
formed between the colony and the loop.(16)  
Phenotypic detection of carbapenemase 
A phenotypic detection test for Ambler class A and B and OXA-48-like carbapenemases 
was performed with discs (Rosco Diagnostica A/S, Taastrup, Denmark) containing meropenem 
(10 µg), temocillin (30 µg), meropenem + phenyl boronic acid (PBA), meropenem + dipicolinic 
acid (DPA), meropenem + PBA + DPA, and meropenem + cloxacillin (CL), using a 0.5 McFarland 
suspension of the isolates on Mueller Hinton II agar plates. Zone diameters were measured after 
overnight incubation at 37°C. The temocillin zone diameter was only interpreted if no synergy 
was observed with DPA and/or PBA. Isolates without synergy with the PBA or DPA test and a temocillin zone diameter ≤10 mm (i.e. the absence of an inhibition zone around the temocillin 
disc) were considered OXA carbapenemase positive. The interpretation of the PBA and DPA 
synergy tests and the temocillin disc diffusion were as described previously.(17) 
DNA extraction and PCR for carbapenemase genes 
DNA from the isolates was extracted by a cell lysis step and boiling using the InstaGene 
Matrix (Bio-Rad Laboratories, USA) according to the manufacturer’s instructions. PCR-based 
detection of Ambler class A carbapenemases (blaKPC), Ambler class B metallo-β-lactamases 
(blaNDM), and class D β-lactamases (blaOXA-48-like) were carried out using T3000 Thermocycler 
(Biometra-Whatman, Goettingen). PCR primers and reaction conditions for PCR were as 
described previously.(18-20) Amplified PCR products were resolved by electrophoresis at 250 V 
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for 30 minutes on 1.5% agarose gels with 0.5 x Tris (89mM)-boric acid (89mM)-EDTA (2mM) 
buffer containing SyBr® Safe DNA Gel Stain and visualized under UV light and photographed. In 
each run, a positive and negative control was included.  
Clonal relatedness 
Raman spectroscopy (SpectraCell RA® Bacterial Strain Analyzer, RiverD International BV, 
Rotterdam, The Netherlands) was applied as a first typing method.(21, 22) All isolates were 
grown overnight on trypticase soy agar (TSA; BD). Samples were prepared and submitted to 
spectrometry as described previously.(22) Raman light scatterings were analyzed by 
SpectraCellRA software version 1.9.0.13444:24 (RiverD). The similarity between pairs of spectra 
was calculated using the squared Pearson correlation coefficient (R2-values), multiplied by 100 
and expressed as a percentage. The similarity threshold for this study was set at 91% so that two 
isolates with an R2 below this threshold were considered to be different and were designated 
different Raman types. Two isolates with an R2-value above 99.5% were considered 
indistinguishable and were considered to have the same Raman type. In case of an R2-value 
between of 91% and 99.5%, these isolates were considered highly related but not identical.(23) 
Correlation matrices displayed as 2D plots diagram were created using MATLAB version 7.1 (The 
MathWorks, Natick, MA, USA).  
Multiple-locus variable number tandem repeat analysis (MLVA) was used as a second 
typing method. The MLVA typing protocol was based on Brink et al.(24) with minor modifications 
(for details, see Supplement). DNA was quantitated using PicoGreen dsDNA reagent (Invitrogen, 
Bleiswijk, The Netherlands). Amplification reactions contained approximately 1 ng of DNA and 
primers according to Supplementary Table 2 in 1x Roche FastStart PCR Master Mix (Roche 
diagnostics, Almere, The Netherlands). The thermocycling protocol consisted of an initial 
denaturation for 5 min at 95°C followed by 30 amplification cycles of denaturation for 30s at 95°C, 
30s annealing at 58°C and 1 min extension at 72°C. A final extension step of 30 min at 72°C was 
applied before reactions were cooled to room temperature. Before loading, amplification 
products were diluted 100x, combined with the GeneScan 600 LIZ Dye Size Standard 
(ThermoFisher Scientific, Bleiswijk, The Netherlands) and run on an ABI 3130 capillary 
electrophoresis platform (ThermoFisher Scientific) using recommended conditions. 
Electropherograms were analyzed using the MLVA plugin in BioNumerics v7.6 software 
(Applied-Maths, Sint-Martens-Latem, Belgium). Assignment of repeat numbers was calibrated by 
comparing our results to those obtained with selected isolates that were genotyped by the 




Statistical analyses were performed using SPSS Version 24.0 (SPSS, Chicago, IL, USA). 
Baseline characteristics from patients admitted to the adult ICU were compared to those in the 
ER-ICU using Chi square and Mann-Whitney as appropriate. One-way ANOVA was used to 
compare patient characteristics according to their K. pneumoniae status. Univariate and 
multivariate analyses were performed to establish risk factors associated with in-ICU mortality 
using a multivariate logistic regression model with backward selection and inclusion of variables 
with a p value <0.1 in the univariate analysis. Cox proportional regression was used to analyze 
risk factors for length of stay. Kaplan-Meier method was performed to construct survival 
curves.The R-code (R-3.6.2.pkg binary for OS X 10.11  software can be obtained via CRAN, the 
Comprehensive R Archive Network, http://cran.R-project.org) was used to calculate the 
competing risks estimates (competing risk analysis is available in an add-on package called 
cmprsk) of the cumulative incidence function and conditional probability function for ICU 
discharge and in-ICU mortality.(25, 26) P values less than 0.01 were considered significant.(27)  
RESULTS 
Patient characteristics and outcomes 
During the 11-month study period, 1,211 patients were hospitalized in the ICUs (Adult 
ICU: 863, ER-ICU: 348). Of the 412 included patients, 188 were admitted to the adult ICU and 224 
to the ER-ICU. Supplementary Table 3 shows baseline characteristics of included patients in each 
ICU. There were no significant differences in characteristics between patients in both ICUs, except 
that in the adult ICU most of the patients had been referred from another ward in the same 
hospital and the proportion of patients with malignancies was higher. Therefore, we analyzed the 
data from the ICUs both separately and pooled.  
Overall, 192/412 (46.6%) patients had at least one positive culture with K. pneumoniae, 
the remaining 220 patients were free from K. pneumoniae on admission and remained so during 
their ICU stay. One hundred (24.3%) patients already carried K. pneumoniae on the day of 
admission, of whom 78 carried a carbapenem–susceptible K. pneumoniae and 22 (5.3%) carried 
a carbapenem-non-susceptible K. pneumoniae strain (Supplementary Figure 1). One hundred 
patients (32.1%) acquired K. pneumoniae during ICU stay, a carbapenem-non-susceptible K. 
pneumoniae strain in 37 cases and a carbapenem-susceptible strain of K. pneumoniae by 63 
patients. Thus, a total of 59 patients (14.3%) carried a carbapenem-non-susceptible K. 
pneumoniae at a certain moment during their ICU stay. In 44 patients, this K. pneumoniae was 
only found in a screening culture, in five patients only from a clinical specimen, and in ten patients 
from both screening and clinical samples. 
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The dynamics of acquisition of K. pneumoniae in the ICUs is shown in Figure 1. Patients 
that acquired a carbapenem-susceptible K. pneumoniae had their first positive culture 
approximately four days sooner than patients that acquired a carbapenem-non-susceptible strain 
of K. pneumoniae (p<0.001). However, the acquisition rate of carbapenem-susceptible K. 
pneumoniae was higher with 41.0 per 1,000 patient-days at risk (adult ICU: 46.1; ER-ICU: 35.9) 
compared to the acquisition rate of carbapenem-non-susceptible K. pneumoniae that was 24.7 per 
1,000 patient-days at risk (adult ICU: 22.2; ER-ICU: 27.0). 
Patient outcomes were clearly associated with K. pneumoniae status. Patients who 
acquired carbapenem-non-susceptible K. pneumoniae during ICU stay had a significantly longer 
length of stay (median [interquartile range (IQR)]: 11 [8-20] days, adjusted hazard ratio [aHR]: 
2.32 [99% confidence interval (CI): 1.35-3.68], p<0.001, Figure 2 and Supplementary Table 4) 
compared to the other groups of patients, of whom ≥80% were discharged from the ICU within 
2-13 days. Interestingly, these latter groups included the patients that were always free from K.
pneumoniae, and patients that already carried K. pneumoniae (either carbapenem-susceptible or
carbapenem-non-susceptible) at the time of admission to the ICU and patients who became
positive for carbapenem-susceptible K. pneumoniae during their stay in ICU (Figure 2).
A longer length of stay was also associated with mechanical ventilation ≥5 days (median 
[IQR]: 10 [7-15], aHR: 2.79 [CI99]: 1.80-4.34], p<0.001, Supplementary Table 4) and use of a 
urinary catheter ≥5 days (median [IQR]: 8 [5-12], aHR: 3.88 [CI99: 2.14-7.04], p<0.001, 
Supplementary Table 4) during ICU stay. 
However, the acquisition of K. pneumoniae was not associated with in-ICU mortality, 
30.5% of patients that remained free of K. pneumoniae died versus 17.5% and 43.2% of patients 
that acquired a carbapenem-susceptible or non-susceptible K. pneumoniae strain, respectively, 
during their ICU stay (Supplementary Table 5, adjusted Odds Ratio [aOR]: 0.40 [99% CI: 0.14-
1.13], p=0.023 and 1.03 [0.36-2.97], p=0.937). Interestingly, the group of patients that carried a 
carbapenem-susceptible strain of K. pneumoniae, either on admission or acquired during ICU 
stay, had the lowest observed mortality rates (24.3% and 17.5%, respectively), even lower than 
the 30.5% mortality observed among those patients that were always negative for this species, 
but this difference did not reach statistical significance. However, when compared to patients that 
had a carbapenem-non-susceptible isolate of K. pneumoniae, either on admission or during their 
ICU stay, the ICU survival of patients with carbapenem-susceptible strains was significantly 
higher (aHR: 2.57 [99% CI: 1.07-6.17], p=0.005, Figure 3). Importantly, the admission SIRS and 
qSOFA scores of patients with or without K. pneumoniae acquisition did not differ (Table 1), 
indicating that a difference in the risk of dying was not present at the time of ICU admission but 








Figure 1. Rate of acquisition of carbapenem-susceptible and -non-susceptible K. pneumoniae in ICUs. 
Acquisition dynamics of carbapenem-susceptible and –non-susceptible K. pneumoniae during ICU stay. The 
blue line represents the cumulative percentage of patients by first day of culture being positive for 
carbapenem-susceptible K. pneumoniae during ICU stay. The red line represents the cumulative percentage 
of patients by first day of culture being positive for carbapenem-non-susceptible K. pneumoniae during ICU 
stay. P value was calculated using independent samples-Mann Whitney U test. In total, data from 100 
patients are included in this figure. 
 
 
crude Odds Ratio [cOR]: 1.69 [99% CI: 0.55-5.22], p=0.230; qSOFA: cOR: 1.45 [99% CI: 
0.68-3.08], p=0.211, Supplementary Table 5). 
The competing risk estimates analysis also revealed that the incidence of death was 
higher in patients with a carbapenem-non-susceptible isolate of K. pneumoniae (p=0.006), and 
the incidence of being discharged alive from ICU was higher for patients with a carbapenem-
susceptible K. pneumoniae (p=0.0005) (Supplementary Figure 2). Patients that acquired a 
carbapenem-non-susceptible K. pneumoniae during ICU stay were more likely to have had prior 
exposure to antibiotics, especially carbapenems, and they were more likely to have had a medical 
indication for their admission to the ICU (Table 1).  
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Figure 2. Cumulative percentage of length of stay according to K. pneumoniae status. Cumulative length of ICU stay of 
patients based on their K. pneumoniae status. Length of stay (days) represent total days patients were hospitalized in 
the ICU. The blue line represents patients that were always K. pneumoniae negative during their ICU stay. The red line 
represents patients already positive for carbapenem-susceptible K. pneumoniae on the day of admission. The green 
line represents patients already positive for carbapenem-non-susceptible K. pneumoniae on the day of admission. The 
orange line represents patients that acquired carbapenem-susceptible K. pneumoniae during ICU stay and the black 
line represents patients that acquired carbapenem-non-susceptible K. pneumoniae during ICU stay. The length of stay 
of patients that became positive with carbapenem-non-susceptible K. pneumoniae during ICU stay was longer than that 
of the other groups (Cox regression, P < 0.001). 
Figure 3. Survival of patients according to their K. pneumoniae status. Survival of patients with carbapenem-non-
susceptible K. pneumoniae (on admission or acquired during ICU stay) (red line) compared with the survival of patients 
that had carbapenem-susceptible K. pneumoniae (on admission or acquired during ICU stay) (blue line) in their 
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Phenotypic and molecular characterization of carbapenem-non-susceptible K. pneumoniae 
Overall, 99/370 (26.8%) isolates from 59/192 (30.7%) patients were found to be non-
susceptible to carbapenems. In addition, one (water from suction connector) out of 31 K. 
pneumoniae isolates cultured from the environment (400 samples taken) was carbapenem-non-
susceptible. None of 24 K. pneumoniae isolates cultured from HCWs (out of 167 screened) were 
found to be carbapenem-non-susceptible. Thus, a total of 100 carbapenem-non-susceptible 
isolates was further subjected to phenotypic and molecular analyses. The phenotypic detection 
test indicated that 96/100 (96%) isolates produced a MBL. PCRs of carbapenemase genes 
demonstrated the presence of the blaNDM gene in these 96 carbapenem-non-susceptible isolates, 
including isolates from patients and the one from the environment. None of the 100 isolates was 
positive for either the blaKPC or blaOXA-48 gene. Four carbapenem-non-susceptible strains 
apparently contained another resistance mechanism, which was not further investigated, they 
remained relatively susceptible to carbapenems (MIC meropenem 2-4 mg/L).  The string test was 
positive for only four isolates from three patients, one of whom deceased in ICU.  
 
Clonal relatedness 
Raman spectroscopy analysis performed for 100 isolates revealed the presence of 
multiple types within this collection of K. pneumoniae. In total, 48 Raman types were identified. 
There were three major clusters (Supplementary Figure 3), the largest cluster (CIPTOKPN24) 
consisted of 20 isolates obtained from 13 patients (screening and clinical specimens). Strains 
belonging to the dominant cluster CIPTOKPN24 were present in both ICUs throughout the study 
period, whereas other clones seemed to wax and wane with time (Figure 4). 
A total of 97 clinical (two isolates were lost during storage) and 1 environmental isolate 
were further analyzed using MLVA genotyping, identifying 30 different genotypes (Figure 5). The 
most dominant clone accounted for 26.5% (n=26) of all isolates, whereas 19 isolates (19.4%) 
were of a unique genotype, the remaining 53 isolates belonged to 20 other genotypes. Clustering 
of strains by Raman spectroscopy into three dominant groups was concordant with clustering by 
MLVA, e.g. the 20 Raman CIPTOKPN 24 strains all belonged to a single MLVA clonal complex. 
Likewise, the four Raman CIPTOKPN 30 strains belonged to a single MLVA clonal complex as did 
8/10 CIPTOKPN 27 isolates. 
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Figure 4. Persistence of prevalent clones of carbapenem-non-susceptible K. pneumoniae in ICUs, as 
determined by Raman spectroscopy typing. Endemicity of the three largest clusters, as determined by 
Raman spectroscopy, of carbapenem-non-susceptible K. pneumoniae in ICUs, April–October 2013 and 
April–August 2014. The orange bars represent cluster CIPTOKPN24. The blue bars represent CIPTOKPN27. 
The green bars represent CIPTOKPN30. The x-axis indicates time periods of the study (by week, April 2013-
Oktober 2013 and April 2014–August 2014). The y-axis indicates number of isolates. 
DISCUSSION 
This is the first report of a study on the clinical and molecular epidemiology of 
carbapenemase-producing K. pneumoniae in ICUs in Indonesia. These two ICUs can be considered 
to have endemic carbapenem-non-susceptible K. pneumoniae whose acquisition by patients is 
associated with prolonged ICU stay and, possibly, an increased risk of dying.  
The dissemination of K. pneumoniae isolates harboring carbapenemase genes, continues 
unabated, and reports describing these isolates are emerging from different parts of the world, 
including Southeast Asia. (1, 4, 28). Colonization and infection with carbapenem-resistant K. 
pneumoniae has been reported in Singapore (29). In Malaysia, the National Surveillance of 
Antimicrobial resistance found carbapenem resistance rates among K. pneumoniae to increase 
from 0.5% (11,935 isolates tested) in 2010 to 1.6% (27,911 isolates tested) in 2014 (30). The 
Philippines Department of Health’s Research Institute reported a rate of 11.9% in 2015 (30). 
Morocco (31), Italy (32), and India have likewise shown dramatic increases over time (30). 







carbapenem-non-susceptible K. pneumoniae. By screening on ICU admission 5.3% of patients 
were already colonized with carbapenem-non-susceptible K. pneumoniae prior to their admission 
to the ICU.  
This suggests that patients may become colonized with such strains elsewhere in the 
same hospital or in another hospital from which they are referred, or may come with such strain 
directly from the community, possibly having acquired their strain during a previous healthcare 
contact or indirectly from exposure to reservoirs or relatives carrying such strains (33) 
Screening cultures can, therefore, be considered helpful for early detection and infection 
control. It may also be useful to guide rational antibiotic use, since previous studies have shown 
that colonization with a carbapenem-resistant K. pneumoniae is a risk factor for subsequent 
infection. (34) (35) However, during our study, carbapenem-non-susceptible K. pneumoniae 
strains were not isolated from blood cultures (data not shown). 
Our data also show that patients may acquire carbapenem-non-susceptible K. 
pneumoniae during ICU stay in the setting of our study and that these acquisitions are associated 
with significantly longer ICU stay. At the level of significance chosen, the acquisition of K. 
pneumoniae strains, whether carbapenem susceptible or not, was not associated with mortality 
when compared to patients who remained free of K. pneumoniae. In contrast, the study from 
Dautzenberg et al. (2015) showed patients colonized with carbapenemase-producing 
Enterobacteriaceae to have on average a 1.79 times higher hazard of dying in ICU than non-
colonized patients, primarily because of an increased length of stay (36). A study in Singapore 
reported that cases with carbapenem-resistant strains of Enterobacteriaceae had ~3.5 times 
increased odds of fatality adjusted for length of hospital stay. (29)  
Interestingly, our study shows that the risk of dying among ICU patients who were 
culture-positive for carbapenem-non-susceptible K. pneumoniae on admission or during ICU stay 
was significantly, 2.57 times, higher than among patients who were culture-positive for a 
carbapenem-susceptible K. pneumoniae. The observed ICU fatality rates were indeed highest 
(44.4%) among those acquiring carbapenem-non-susceptible K. pneumoniae and lowest (17.5%) 
amongst the patients acquiring carbapenem-susceptible strains of K. pneumoniae during their 
ICU stay. Since risk of mortality during ICU stay is influenced by many factors, as reported by 
other international findings (32, 37, 38), we cannot readily explain why susceptible K. 
pneumoniae acquisitions seem to be a proxy for protection whereas non-susceptible K. 
pneumoniae acquisitions may be predictive of a fatal outcome. Probably, exposure to carbapenem 
antibiotics, and the underlying reasons for this, may be important determinants in this respect.  
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The blaNDM gene was the most prevalent carbapenemase gene as it was detected in 96 
isolates, including one from the environment. Carbapenem resistance due to blaKPC-like and 
blaOXA-48-like genes was not detected. In South Asia (India and Pakistan) the NDM-1 gene was 
initially found and currently, this enzyme is by far the most prevalent and widely distributed 
carbapenem degrading enzyme in the world, including in Southeast Asia. (1, 3-6, 8-10, 18, 28-31) 
Walsh et al. (2011) have also found the presence of NDM-1 β-lactamase-producing 
bacteria, including K. pneumoniae, from waste seepages samples in Indian community. (33) 
Taking our study and the recent report on NDM-1 in carbapenem-non-susceptible 
Enterobacteriaceae from urinay tract samples of hospitalized patients in Surabaya, Indonesia, 
into account, we suspect that this carbapenemase gene is widespread in hospitals in 
Indonesia.(39) 
Carbapenem-susceptible and -non-susceptible K. pneumoniae that colonize or infect ICU 
patients may originate from the patient her/himself, but may also come from contaminated 
hospital equipment and environment, staff and other patients. In this study K. pneumoniae was 
found in the ICU environment, including one endemic strain that was carbapenem-non-
susceptible. Predictably, K. pneumoniae was also cultured from throat and rectal swabs of ICU 
personnel, although none of those isolates was carbapenem-non-susceptible. However, we 
cannot exclude personnel as a source or vector of K. pneumoniae since personnel was only 
screened once during this study and other body parts (e.g. hands) or clothes were not sampled, 
limiting the sensitivity of this part of the survey. A recent study in China found that almost 9% of 
medical personnel in ICU carried multidrug-resistant Gram-negative bacteria on their hands.(40) 
Transmission of the bacteria may occur with many risk factors involved. (1, 3, 41) Multiple 
studies reported outbreaks of carbapenem-resistant K. pneumoniae that were associated with 
environmental contamination.(42-44)  We performed Raman spectroscopy and MLVA to assess 
clonal relatedness. These analyses revealed three major clusters by Raman typing, with the 
largest one (CIPTOKPN24), persisting in both ICUs throughout the whole study period. However, 
many carbapenem-non-susceptible strains of K. pneumoniae cultured in this study were of a 
unique Raman type or belonged to small clusters that waxed and waned quickly, indicating both 
endemicity of certain clones in the ICUs but also regular new introductions and rapid loss of many 
clones over time. This epidemiologic information can and should be applied when designing 
interventions to reduce the acquisition of carbapenen-resistant K. pneumoniae in ICUs in 
Indonesia and in similar settings elsewhere. 
Although not used routinely, Raman spectroscopy typing can be valuable for 
discriminating types of strains within a species (21,22,23). Here we showed typing by Raman 
spectroscopy to yield K. pneumoniae strain clustering compatible with clustering based on MLVA 
genotyping. However, Raman typing results at a given site cannot be directly compared with 
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results generated or published elsewhere, and are, thus, not easily shared or pooled. Considering 
the modification that we made to MLVA marker VNTR58, the genotype of the most dominant 
clone in our study was of genotype “4-2.4-3-4-4.3-1-12-19”. This genotype would translate into 
“4-3-3-4-5-1-12-19” based on the original MLVA typing method for K. pneumoniae [24],  but this 
genotype was not observed by Brink et al.(24). On the other hand, the second and third most 
dominant genotype “5-3-3-4-6-1-9-12” and “5-3-3-5-6-1-9-12” match genotype “5-3-3-4-6-1-9-
1” and a single locus variant thereof from Brink et al. that involves isolates with MLST sequence 
type ST147. K. pneumoniae ST147 strains belong to a relatively common NDM-positive K. 
pneumoniae lineage and have been found in multiple countries across several continents, almost 
all of which were isolated from humans. (45, 46) Unlike in the original paper, in our approach the 
non-integer alleles were considered as separate alleles. As a result, the total number of alleles per 
marker will increase for several markers and as a result this may benefit the overall 
discriminatory power of the MLVA method. Indeed, in our study (exceeding the ones reported 
here), we observed several different genotypes that would have been assigned identical when the 
non-integer alleles would have been ignored by ‘rounding off’ their values using adjusted and 
broadened binsets (results not shown). 
There were some limitations in this study. First, as no colometric agar plate was used for 
the screening cultures, overgrowth of carbapenem-susceptible but cefotaxime-resistant isolates 
could have led to overlooking CNKP. However, all morphologically different colonies were 
checked, and this was done by trained and experienced microbiology technicians. Colometric 
media are expensive, therefore, could not be used in this study. Also, cefotaxime-susceptible OXA-
48-producing isolates could have been missed with our screening method. Nevertheless, based
on the isolates found in the clinical cultures, it is unlikely that these were playing a major role in
the epidemiology. Of note, the OXA-48 PCR was not able to detect OXA-54 and OXA-436, but given
the results of the phenotypic detection method, and epidemiology in countries nearby, these are
also not suspected. Second, only two ICUs in one tertiary care academic hospital participated,
which does not permit results to be called representative for all ICUs in Indonesia. Third, the
study was performed more than 5 years ago, hence the epidemiology of CNKP in Indonesia may
be different now. Finally, the limited rate of sampling of the environment and of personnel (as
opposed to patients) may have undervalued their role in the chain of transmission and acquisition
of carbapenem-non-susceptible K. pneumoniae.
CONCLUSIONS 
In summary, this study is the largest to date that describes the characteristics and 
epidemiology of, and outcome associated with carbapenem-non-susceptible K. pneumoniae in 
ICUs in Indonesia. Colonization or infection with carbapenem-non-susceptible K. pneumoniae 
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during hospitalization was independently associated with prolonged LOS in the ICU, and may 
affect survival during ICU stay. Prevention of colonization by and infection from these multidrug-
resistant strains requires interventions directed to source control and limiting the introduction 
and transmission of such strains to and between patients. 
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Supplementary Table 1. List of environmental samples 
Sample site  Number of samples 
Adult ICU ER-ICU 
Wash basin on ICUs ward 10 5 
Monitor 14 10 
Ventilator 15 5 
Ambu bag 8 
 
Stethoscope 10 9 
Drawer handle bedside cabinet  21 
 
Plastic multi-purpose container next to 
each bed 
18 8 
Stainless steel container 8 15 
Flowmeter  15 
 
Infusion stand   11 8 
Infusion pump  9 6 
Bed rails 20 14 
Tap water (wash basin on ICU ward) 10 8 
Chart paper on bedside cabinet 11 6 
Bedside cabinet table 15 11 
Cleaning room: wash basin 9 
 
Cleaning room: sink countertop 3 
 
Cleaning room: mug 2 
 
Cleaning room: dish rack 3 
 
Mattress 5 4 
Comb 3 
 
Water from siphon of wash basin  10 5 
Water from mug next to each bed 10 6 
Massage oil 5 
 
Chlorine solution after use  3 
 
Cleaning wipes 3 4 
Wall  3 2 
Drawer of bedside cabinet 3 
 
Water from suction  7 
 
Suction connector/container 3 
 
Water from humidifier 1 
 




Nurse station 1 1 
Abbreviations: ER-ICU. Emergency room Intensive Care Unit; ICU, Intensive Care Unit 
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Supplementary Table 3. Baseline characteristics of 412 patients admitted to the adult or 
emergency Room (ER) ICUs , and enrolled in this study. 
Adult ICU ER-ICU p value 
Number of patients enrolled 188 224 
Age (years). median (IQR) 49 (38-58) 43 (30-58) 0.041 
Gender 
Male (%) 91 (48.4) 123 (54.9) 0.188 
Female (%) 97 (51.6) 101 (45.1) 
Underlying diseases 126 (54.8) 104 (45.2) 0.000** 
Cardiovascular (%) 12 (6.4) 13 (5.8) 0.806 
Cerebrovascular (%) 10 (5.3) 19 (8.5) 0.211 
Chronic kidney disease (%) 9 (4.8) 16 (17.1) 0.319 
Diabetes mellitus (%) 15 (8) 18 (8) 0.983 
Malignancy (%) 80 (42.6) 38 (17) 0.000** 
Indication for ICU admission 0.039 
Medical (%) 54 (28.7) 86 (38.4) 
Surgical (%) 134 (71.3) 138 (61.6) 
Referral from 0.000** 
Other ward this hospital (%) 144 (76.6) 78 (34.8) 
Other hospital (%) 20 (10.6) 57 (25.4) 
Directly from Emergency Unit (%) 24 (12.8) 89 (39.8) 
Antibiotic exposure (before admission to ICU) 
Any antibiotic (%) 146 (77.7) 165 (73.7) 0.349 
Carbapenem (%) 40 (21.3) 39 (17.4) 0.321 
SIRS Score. (%) 0.992 
Score >2 172 (91.5) 205 (91.5) 
Score <2 16 (8.5) 19 (8.5) 
qSOFA Score. (%) 0.158 
Score >2 158 (84.0) 176 (78.6) 
Score <2 30 (16.0) 48 (21.4) 
Procedures (during ICU admission) 
Mechanical ventilation (%) 170 (90.4) 201 (89.7) 0.815 
Mechanical ventilation (days), median (IQR) 4 (1.5-9) 3 (2-7) 0.591 
>5 days (%) 87 (26.3) 95 (42.4) 0.431 
<5 days (%) 101 (53.7) 129 (57.6) 
Central venous catheter (%) 166 (88.3) 197 (87.9) 0.913 
Central venous catheter (days). median (IQR) 5.5 (3-10) 5 (3-8.5) 0.150 
>5 days (%) 106 (56.4) 117 (52.2) 0.400 
<5 days (%) 82 (43.6) 107 (47.8) 
Urinary catheter (%) 188 (100) 224 (100) N/A 
Urinary catheter (days), median (IQR) 6 (3-11) 5 (3-9) 0.181 







  Adult ICU  ER-ICU p value 
     <5 days (%) 70 (37.2) 91 (40.6)   
Antibiotic therapy (during ICU admission)    
Any antibiotic (%)  188 (100) 218 (97.3) 0.034 
Carbapenem (%) 99 (52.7) 100 (44.6) 0.105 
Outcomes       
    Length of stay (days). median (IQR) 5 (3-10.75) 5 (3-8) 0.024 
    Death (%) 52 (27.7) 67 (29.9) 0.616 
Abbreviations: ER-ICU. Emergency room Intensive Care Unit; ICU, Intensive Care Unit; IQR, 
Interquartile range; qSOFA, quick Sepsis-related Organ Failure Assessment; SIRS, Systemic 
Inflammatory Response Syndrome. 
**p<0.01
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Supplementary Figure 1. Klebsiella pneumoniae carriage of included patients admitted to the ICUs 
(adult- and ER-ICU) of Dr. Cipto Mangukusomo General Hospital, Jakarta, Indonesia 
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Supplementary  Figure 2. Plot of the cumulative incidence for ICUs discharge alive and death 
by carbapenem-susceptible and -non-susceptible K. pneumoniae. 
Legend:  Abbreviation: ICU, Intensive Care Unit; KP,  Klebsiella pneumoniae  
The probability of being discharged alive (solid lines) and in-ICUs mortality (dashed lines) among 
patients harboring carbapenem-susceptible K. pneumoniae (black lines) versus patients harboring 
carbapenem-non-susceptible K. pneumoniae (red lines) during their ICU stay. The probability of death 
in ICUs is significantly higher (p=0.006) among patients with carbapenem-non-susceptible K. 
pneumoniae, conversely the probability of being discharged alive from ICUs is significantly higher for 
patients with carbapenem- susceptible K. pneumoniae (p=0.0005)  
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Supplementary Figure 3. Raman spectroscopy-based cluster analysis of Klebsiella pneumoniae 
isolates from adult and ER-ICUs 
Legend: Raman spectra correlation matrix of carbapenem-non-susceptible K. pneumoniae isolates. 
The similarity between pairs of spectra was calculated using the squared Pearson correlation 
coefficient (R2-values), multiplied by 100 and expressed as a percentage. The similarity threshold for 
this study was set at 91% (yellow area) so that two isolates with an R2 below this threshold were 
considered to be different and were designated different Raman types. Two isolates with an R2-value 
above 99.5% (red area) were considered indistinguishable and were considered to have the same 
Raman type. In case of an R2-value between of 91% and 99.5% (orange area), these isolates were 
considered highly related but not identical. There were three dominant cluster CIPTOKPN24, 
CIPTOKPN27, and CIPTOKPN30.  
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A prospective observational study was performed to assess the epidemiology of carbapenem-
non-susceptible Pseudomonas aeruginosa (CNPA) in intensive care units (ICUs) of the national 
referral hospital in Jakarta, Indonesia. 
Materials/methods:  
Adult patients consecutively hospitalized for >48 hours in two ICUs of the national referral 
hospital were included. P. aeruginosa from clinical cultures and systematic screening were 
included. Environmental niches and healthcare workers (HCWs) were also screened. 
Susceptibility was determined phenotypically and the presence of carbapenemase genes by PCR. 
Multiple-locus variable number tandem repeat analysis (MLVA) and multilocus sequence typing 
(MLST) were used for genotyping.  
Results: Seventeen out of 412 (4.1%) patients carried CNPA on admission and 34/395 (8.6%) 
became positive during ICU stay. The acquisition rate was 18/1,000 patient-days at risk. Twelve 
out of 16 (75.0%) environmental isolates were CNPA. HCWs screened negative. Acquisition of 
CNPA was associated with longer ICU stay (adjusted hazard ratio: 1.89 [CI99: 1.12-3.13]). 
Mortality was >40% among patients with CNPA versus <30% among those without CNPA 
(p=0.019). Of the 119 CNPA isolates, 83 (69.7%) carried a carbapenemase gene, blaVIM (n=36), 
blaIMP (n=23), and blaGES-5 (n=24). Four sequence types (ST) dominated (ST235, ST823, ST446, 
ST357). Five major MLVA clusters were distinguished, two belonging to ST235, the others to 
ST823, ST446, and ST357. 
Conclusions:  
CNPA are introduced into these ICUs and some strains expand clonally among patients and the 
environment, creating endemic CNPA. VIM-, IMP-, and GES-5 genes are often involved. CNPA 
acquisition was associated with prolonged ICU stay and may affect ICU survival.  
Keywords:  
Pseudomonas aeruginosa, microbial drug resistance, carbapenemase, metallo-beta-lactamase, 
intensive care unit, Indonesia. 
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INTRODUCTION 
Beta-lactam antibiotics are the drugs of choice for treatment of severe infections due to 
Pseudomonas aeruginosa. However, worldwide emergence of carbapenem-non-susceptible P. 
aeruginosa (CNPA) compromises treatment of these infections [1]. Non-susceptibility to 
carbapenem antibiotics in P. aeruginosa is usually due to a combination of mechanisms, including 
beta-lactamase production, increased efflux pump activity, outer membrane modifications, and 
production of a carbapenemase as a single potent resistance mechanism; VIM, IMP, and GES-5 are 
most commonly found around the world [2-4].  
Little information exists on the epidemiology of CNPA from Indonesia, the fourth most 
populous country in the world. In 2011, 21.9% of P. aeruginosa strains from the ICU of the Dr. 
Cipto Mangunkusumo General Hospital, Jakarta, were carbapenem-resistant, and four P. 
aeruginosa isolates contained the blaIMP gene [5] . 
The aim of our study was to delineate the clinical and molecular epidemiology of CNPA in two 
ICUs of the Dr. Cipto Mangunkusumo General Hospital, the national referral teaching hospital. 
MATERIALS AND METHODS 
Study design 
A prospective observational study was performed at the Dr. Cipto Mangunkusumo 
General Hospital, in Jakarta, Indonesia, from April–October 2013 and from April–August 2014. 
We conducted this study in the 12-bedded adult ICU and the 8-bedded Emergency Room (ER)-
ICU with an average of 1,010 and 415 admissions per year, respectively. Both ICUs are open-plan 
wards [6].  
All adult patients (≥18 years old) admitted to those ICUs and hospitalized for more than 
48 hours were eligible for enrolment. The first screening cultures were taken on the day of 
admission. Informed consent was obtained from the patient or their relatives. Demographic and 
clinical characteristics (age, gender, medical or surgical indication, underlying diseases, 
hospitalization history, previous use of antibiotics) were recorded on admission. The systemic 
inflammatory response syndrome (SIRS) and quick Sequential Organ Failure Assessment 
(qSOFA) score on admission were calculated [7].  
The primary outcome measure was acquisition of a CNPA during ICU stay 48 hours after 
admission. Acquisition of CNPA was defined by a screening culture or clinical culture positive 
with CNPA. Secondary outcome measures were length of ICU stay, and in-ICU mortality. 
Environmental samples were taken twice (in October 2013 and December 2014), in both 
ICUs. Screening of healthcare workers (HCWs) was performed once (September 2013). HCWs 
were defined as all personnel (doctors, nurses, cleaning staff, administration staff, porters, 
nutritionist) working in the ICUs during the study. 
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Screening cultures were obtained from throat and rectum or stools on the day of 
admission, at the time of discharge from the ICU, and weekly if the patient’s stay exceeded seven 
days. Sampling was performed using sterile cotton-tipped swabs which were transported in 
Amies transport medium (Oxoid, UK) at ambient temperature to the laboratory on the same day. 
All swabs were processed within 24 hours. 
Clinical samples were collected on indication under aseptic precautions from the lower 
respiratory tract, blood, urine, tissue, or wounds.  
Environmental samples were taken from various sites (Supplementary Table 1) with swabs and 
placed in Amies transport medium [6]. From HCWs, throat and rectal swabs were collected. 
Microbiological methods 
Isolation and identification 
In the Clinical Microbiology Laboratory (Faculty of Medicine, Universitas Indonesia, 
Jakarta) swabs were placed in 5 ml trypticase soy broth (TSB) with cefotaxime 2 mg/L, 
vancomycin 50 mg/L and incubated overnight. A loop of broth (10 µl) was aerobically sub-
cultured onto MacConkey agar (Oxoid, UK) for 16-24 hours, following identification and 
susceptibility testing of colonies suggestive of P. aeruginosa using the VITEK2® (bioMérieux, 
France).  
Blood cultures were collected in BACTEC® (BD, Franklin Lakes, NJ, USA) bottles as per 
manufacturer’s instructions. Other clinical specimens were inoculated onto blood and 
MacConkey agar plates and incubated as above. All colonies were examined by Gram stain and 
identified using the VITEK2®. 
Strains were stored at -80°C in TSB with 10% v/v glycerol. The identity of strains was confirmed 
in Erasmus MC, Rotterdam, the Netherlands, by using matrix-assisted laser desorption/ionisation 
mass spectrometry (Maldi Biotyper, Bruker, UK). 
Antimicrobial susceptibility testing 
Susceptibility of the screening isolates to imipenem and meropenem was investigated by 
Kirby-Bauer disk diffusion using Mueller-Hinton plates (BD, USA). For the isolates from clinical 
cultures, minimum inhibitory concentrations (MICs) were determined by VITEK2®. Carbapenem 
zone sizes and MICs were interpreted according to EUCAST (2013, breakpoints for non-
susceptibility: meropenem <24 mm and MIC >2 mg/L, imipenem <20 mm and MIC >4 mg/L) [8]. 
Phenotypic detection of carbapenemases 
For detection of metallo-beta-lactamase (MBL), the imipenem and doripenem combo disk 
test with EDTA was performed [9].  
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DNA extraction and carbapenemase gene detection 
DNA was extracted using the InstaGene Matrix (Bio-Rad Laboratories, Hercules, CA, USA). PCRs 
for Ambler class B MBLs (blaNDM, blaVIM, blaIMP) were carried out using a T3000 Thermocycler 
(Biometra-Whatman, Germany)[10, 11].  
Clonal relatedness 
Multiple-locus variable number tandem repeat analysis (MLVA) and in silico multilocus 
sequence typing (MLST) were used for typing with primers according to Supplementary Table 
2.[12] Two µL of 100x diluted PCR products were analyzed on an ABI3130xl Genetic Analyzer 
(Thermo Fisher Scientific, USA). Electropherograms were analyzed using the MLVA plugin in 
BioNumerics v7.6 (Applied Maths, Belgium). Typing data were analyzed categorically. 
MLST types as well as carbapenemase gene subtypes were inferred from whole genome 
sequencing (WGS) using the MLST plug-in and sequence extraction tool from BioNumerics® v7.6 
(Applied Maths, Belgium). The classical 7-digit in silico MLST profiles were obtained through 
BLAST using the pubMLST database hosted at https://pubmlst.org. Sequencing was performed 
using a HiSeq 2500 instrument (Illumina Inc., USA). 
Statistical analysis 
Statistical analyses were done using SPSS Version 24.0 (SPSS, USA). Patients admitted to 
adult ICU were compared to ER-ICU using Chi-square or Fishers’ exact and Mann-Whitney as 
appropriate. One-way ANOVA was used to compare patient characteristics according to their P. 
aeruginosa status. Univariate and multivariate analyses were performed to establish risk factors 
associated with mortality using a multivariate logistic regression model with backward selection 
and inclusion of variables with a p-value <0.1 in the univariate analysis. Cox proportional 
regression was used to analyse risk factors for length of stay. Kaplan-Meier method was 
performed to construct survival curves. P-values of less than 0.01 were considered significant 
[13].  
RESULTS 
Patient characteristics and outcomes 
During the study, 1,211 patients were hospitalized in the ICUs (Adult ICU: 863, ER-ICU: 
348). Of 412 included patients, 188 were admitted to the adult ICU and 224 to the ER-ICU. Most 
of the non-eligible patients were excluded due to short length of stay. Comparison of patients’ 
baseline characteristics showed that there were no significant differences between patients in 
both ICUs, except that in the adult ICU most of the patients had been referred from another ward 
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and more patients had malignancies (Supplementary Table 3). Therefore, we analysed the data 
from the ICUs both separately and pooled.  
Overall, 145/412 (35.2%) patients had at least one positive culture with P. aeruginosa, 
the remaining 267 patients were free from P. aeruginosa on admission and remained so during 
their ICU stay. Eigthty-three patients (20.2%) already carried P. aeruginosa as revealed by 
cultures taken on the day of admission, of whom 66 patients carried a carbapenem–susceptible 
P. aeruginosa (CSPA) and 17 patients carried a CNPA (Supplementary Figure 1). Thirty-four
patients acquired a CSPA, 34 patients acquired a CNPA. For the 51 patients with CNPA, 35 CNPA
were obtained from screening specimens, 6 from clinical specimens and 10 from both screening
and clinical samples; there were no CNPA-positive blood cultures.
The dynamics of acquisition of P. aeruginosa in the ICUs is shown in Figure 1A. Patients 
who acquired a CSPA had their first positive culture approximately two days earlier than patients 
that acquired a CNPA (p=0.065). The acquisition rate of CSPA was 19 per 1,000 patient-days at 
risk (adult ICU: 22; ER-ICU: 14) compared to 18 per 1,000 patient-days at risk for CNPA (adult 
ICU: 15; ER-ICU: 21). 
Patient outcomes were associated with P. aeruginosa status. Patients who acquired CNPA 
had a significantly longer length of stay (median [interquartile range (IQR)]: 16 [6-27] days, 
adjusted hazard ratio [aHR]: 1.89 [99% confidence interval (CI99): 1.12-3.13], p=0.002, 
Supplementary Table 4, Figure 1B) compared to the other groups of patients, of whom ≥80% 
were discharged from the ICU within 7-12 days. These latter groups included the patients that 
were always free from P. aeruginosa, and patients that already carried P. aeruginosa (either CSPA 
or CNPA) at time of ICU admission and patients who became positive for CSPA during their stay 
in ICUs (Figure 1B). 
A longer length of stay was also independently associated with mechanical ventilation ≥5 
days (median [IQR]: 10 [7-15], aHR: 3.09 [CI99]: 1.98-4.83], p<0.001, Supplementary Table 4) and 
use of urine catheters ≥5 days (median [IQR]: 8 [5-12], aHR: 3.03 [CI99: 1.73-5.30], p<0.001, 
Supplementary Table 4). 
Acquisition of P. aeruginosa was not associated with in-ICU mortality, 27.7% of patients 
that remained free of P. aeruginosa died versus 14.7% and 41.2% of patients that acquired a CSPA 
or CNPA, respectively, during (Supplementary Table 5, adjusted Odds Ratio [aOR]: 0.41 [CI99: 
0.10-1.71], p=0.109 and 1.08 [CI99: 0.34-3.46], p=0.867). The group of patients that acquired CSPA 
had the lowest mortality rate, and when compared to those that acquired a CNPA, the probability 
of ICU survival was higher for patients who acquired a CSPA compared to patients who acquired 
CNPA (aHR: 4.06 [CI99: 0.87-18.88], p=0.019, Figure 1C). Likewise, the ICU mortality among all 
patients with CNPA was 22/51 (43.1%) versus 97/361 (26.9%) among patients without CNPA 
(p=0.016). 
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The admission SIRS and qSOFA scores of patients with or without P. aeruginosa 
acquisition did not differ, indicating that a significant difference in the risk of dying was not 
present at the time of ICU admission but rather emerged later during their ICU stay (SIRS: crude 
Odds Ratio [cOR]: 1.69 [CI99: 0.55-5.22], p=0.230; qSOFA: cOR: 1.45 [CI99: 0.68-3.08], p=0.211, 
Supplementary Table 5). In multivariate comparison, patients that acquired a CNPA during ICU 
stay were more likely to have had prior exposure to antibiotics, especially carbapenems (aOR: 
2.67 [CI99: 0.94-7.62], p=0.015). 
Phenotypic and molecular characterization of CNPA 
Overall, 107/281 (38.1%) isolates from 51/145 patients were found to be non-
susceptible to either imipenem and/or meropenem. Additionally, 12/16 (75.0%) P. aeruginosa 
isolates cultured from the environment (tap water, dish dryer, table top, water from siphon and 
water from suction connector) were CNPA (Supplementary Table 6). None of 25 P. aeruginosa 
isolates from HCWs were found to be CNPA. A total of 119 CNPA were subjected to phenotypic 
and molecular analyses. The phenotypic detection test indicated that 68/119 (57.1%) isolates 
produced an MBL. PCR demonstrated the presence of blaVIM in 36 of these isolates and blaIMP in 
23, including isolates from patients and one from the environment. None of the 119 isolates were 
positive for blaNDM. Presence of blaGES-5 (non-MBL) was deduced from WGS and detected in 24 
isolates. 
Clonal relatedness 
MLST revealed four major clusters (ST235, ST823, ST446, ST357) as well as several new 
sequence types (STs). By MLVA, five major clusters were distinguished, two belonging to ST235; 
the other MLVA clusters corresponded with ST823, ST446 and ST357 (Figure 2A). These four 
major genetic clusters included 97/107 (90.7%) CNPAs from patients (ICU-imported and ICU-
acquired) as well as 11/12 (91.7%) environmental isolates (ST235, ST823, ST446) (Figure 2B). 
Most isolates belonged to ST235 (10 imported and 32 acquired patient isolates, and 4 
environmental isolates) and 22 isolates harboured blaIMP, twenty-four isolates harboured blaGES-
5 but no isolates contained blaVIM. All ST823 isolates (36 isolates) harboured blaVIM 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The epidemiology and characterization of CNPA in ICUs in Jakarta
139
Figure 1. Acquisition of carbapenem-susceptible and –non-susceptible  P. aeruginosa and its effect on ICU 
stay and survival. A, Acquistion of carbapenem-susceptible P. aeruginosa (orange) and carbapenem-non-
susceptible P. aeruginosa (blue) (P value by independent Mann-Whitney U test). B, Length of ICU stay by P. 
aeruginosa status: patients that were always P. aeruginosa negative (blue), patients already positive for 
carbapenem-susceptible P. aeruginosa on admission (green), patients already positive for carbapenem-
non-susceptible P. aeruginosa on admission (yellow), patients that acquired carbapenem-susceptible P. 
aeruginosa during ICU stay (red) and patients that acquired carbapenem-non-susceptible P. aeruginosa 
during ICU stay (black) (P value by Cox regression), and C, survival of patients acquiring a carbapenem-
susceptible P. aeruginosa (blue) compared with patients acquiring a carbapenem-non-susceptible P. 




The dissemination of P. aeruginosa isolates harbouring carbapenemase genes, continues 
unabated, and reports describing these isolates are emerging from different parts of the world, 
including Southeast Asia [14]. We found that 12.4% of the patients in our ICUs carried CNPA and 
4.1% of patients were already colonized prior to admission. Patients may become colonized 
elsewhere in the same hospital, or in another hospital from which they are referred, or may come 
with such strain directly from the community, possibly having acquired their strain during a 
previous healthcare contact or indirectly from exposure to relatives carrying such strains or 
unknown environmental niches. 
Hence, screening cultures must be performed for early detection and infection control. 
This will guide rational antibiotic use, since it has been shown that colonization with CNPA is a 
risk factor for infection [15].  
Our data show that patients acquire CNPA during ICU stay and that this is associated with 
significantly longer ICU stay. At the level of significance chosen, the acquisition of CSPA or CNPA 
was not associated with mortality when compared to patients free of P. aeruginosa. Still, the 
observed mortality rate was higher among patients with CNPA versus those without. A study in 
Taiwan (2016) did not find carbapenem resistance as a significant factor associated with 
mortality either [16]. Other study revealed a relationship between CNPA carriage and mortality 
[17].  
Among the 107 CNPA from 51 patients and 12 environmental niches, blaVIM, blaIMP, and 
blaGES-5 were the most prevalent carbapenemase genes, detected in 83 isolates, including six from 
the environment. These genes are widely distributed in the world. The first MBL found in P. 
aeruginosa was IMP-1, originally identified in Japan in 1988. VIM was first identified in Italy in 
1997, but reached Southeast Asia [3], [14]. GES-5-producing P. aeruginosa was first detected in 
China in 2004 and was since then isolated on a global scale [18], [19]. 
In a review by Voor In 't Holt et al., it was shown that carbapenem use and use of medical 
devices are the leading risk factors for carriage of CNPA [20]. They identified environmental 
sources and reservoirs with sinks being the most frequently reported reservoirs [21]. More 
recent reports of outbreaks of CNPA also demonstrate an association with environmental 
contamination [22-24]. This phenomenon was observed in our setting as well. The four 
environmental blaIMP -positive ST235 isolates were all cultured from wet sources in the common 
cleaning room. In this room, located adjacent to the adult ICU, all items that are reused in patients, 
are manually cleaned and stored. These types of ‘wet’ rooms may serve as a persistent source of 
resistant bacteria and should be targeted by infection control.    
5




































































































































































































































































































































































































MLST revealed four major clusters (ST235, ST823, ST446, ST357) and a few new clones, 
MLVA revealed five major clusters. ST235 is the most prevalent of these so-called ‘international’ 
clones associated with poor clinical outcomes in part due to multi- and high-level antibiotic 
resistance [25]. The Indonesian offspring of this clone, identified in this study, always harboured 
blaIMP or blaGES-5, but not blaVIM. All ST823 isolates consistently harboured only blaVIM and no MBL 
genes were found in the other prevalent clones (ST446, ST357). Three dominant clusters 
included isolates from the ICU environment (ST235, ST823, ST446). This epidemiologic 
information should be used when designing interventions to reduce the acquisition of CNPA in 
ICUs in Indonesia and similar settings elsewhere. 
Our study has limitations. First, it was a single-centre study during a situation of endemic CNPA 
colonization and infection, so our data are not representative for the whole country. Second, we 
were unable to evaluate the effect of other possible confounders of CNPA acquisition (e.g. long-
term kidney dialysis, need for inotropes, surgery, previous hospital admission).  
 
CONCLUSIONS 
This study is the largest describing characteristics, epidemiology, and outcome of CNPA in ICUs 
in Indonesia. Colonization or infection with CNPA during ICU hospitalization was independently 
associated with prolonged length of stay, and possibly survival. ST235 was the dominant clone, 
as were IMP and VIM MBLs and GES-carbapenemase. Prevention of colonization and infection by 
these strains would require active screening for carriers among newly admitted patients and for 
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Supplementary Table 1.  List of environmental samples 
Sample site  Number of samples 
Adult ICU ER-ICU 
Washbasin on ICUs ward 10 5 
Monitor 14 10 
Ventilator 15 5 
Ambu bag 8 
 
Stethoscope 10 9 
Drawer handle bedside cabinet  21 
 
Plastic multi-purpose container next to 
each bed 
18 8 
Stainless steel container 8 15 
Flowmeter  15 
 
Infusion stand   11 8 
Infusion pump  9 6 
Bed rails 20 14 
Tap water (washbasin on ICU ward) 10 8 
Chart paper on bedside cabinet 11 6 
Bedside cabinet table 15 11 
Cleaning room: washbasin 9 
 
Cleaning room: sink countertop 3 
 
Cleaning room: mug 2 
 
Cleaning room: dish rack 3 
 
Mattress 5 4 
Comb 3 
 
Water from siphon of washbasin  10 5 
Water from mug next to each bed 10 6 
Massage oil 5 
 
Chlorine solution after use  3 
 
Cleaning wipes 3 4 
Wall  3 2 
Drawer of bedside cabinet 3 
 
Water from suction  7 
 
Suction connector/container 3 
 
Water from humidifier 1 
 




Nurse station 1 1 
Abbreviations: ICU.Intensive Care Unit.  
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Supplementary Table 3. Baseline characteristics of patients admitted to the adult and 
emergency Room (ER) ICUs 
Adult ICU ER-ICU p value 
Number of patients enrolled 188 224 
Age (years). median (IQR) 49 (38-58) 43 (30-58) 0.041 
Gender 
Male (%) 91 (48.4) 123 (54.9) 0.188 
Female (%) 97 (51.6) 101 (45.1) 
Underlying diseases 126 (54.8) 104 (45.2) 0.000** 
Cardiovascular (%) 12 (6.4) 13 (5.8) 0.806 
Cerebrovascular (%) 10 (5.3) 19 (8.5) 0.211 
Chronic kidney disease (%) 9 (4.8) 16 (17.1) 0.319 
Diabetes mellitus (%) 15 (8) 18 (8) 0.983 
Malignancy (%) 80 (42.6) 38 (17) 0.000** 
Indication for ICU admission 0.039 
Medical (%) 54 (28.7) 86 (38.4) 
Surgical (%) 134 (71.3) 138 (61.6) 
Referral from 0.000** 
Other ward this hospital (%) 144 (76.6) 78 (34.8) 
Other hospital (%) 20 (10.6) 57 (25.4) 
Directly from Emergency Unit (%) 24 (12.8) 89 (39.8) 
Antibiotic exposure (before admission to ICU) 
Any antibiotic (%) 146 (77.7) 165 (73.7) 0.349 
Carbapenem (%) 40 (21.3) 39 (17.4) 0.321 
SIRS Score. (%) 0.992 
Score >2 172 (91.5) 205 (91.5) 
Score <2 16 (8.5) 19 (8.5) 
qSOFA Score. (%) 0.158 
Score >2 158 (84.0) 176 (78.6) 
Score <2 30 (16.0) 48 (21.4) 
Procedures (during ICU admission) 
Mechanical ventilation (%) 170 (90.4) 201 (89.7) 0.815 
Mechanical ventilation (days). median (IQR) 4 (1.5-9) 3 (2-7) 0.591 
>5 days (%) 87 (26.3) 95 (42.4) 0.431 
<5 days (%) 101 (53.7) 129 (57.6) 
Central venous catheter (%) 166 (88.3) 197 (87.9) 0.913 
Central venous catheter (days). median (IQR) 5.5 (3-10) 5 (3-8.5) 0.150 
>5 days (%) 106 (56.4) 117 (52.2) 0.400 
<5 days (%) 82 (43.6) 107 (47.8) 
Urine catheter (%) 188 (100) 224 (100) N/A 
Urine catheter (days). median (IQR) 6 (3-11) 5 (3-9) 0.181 
>5 days (%) 118 (62.8) 133 (59.4) 0.486 
5
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Adult ICU ER-ICU p value 
     <5 days (%) 70 (37.2) 91 (40.6) 
Antibiotic therapy (during ICU admission) 
Any antibiotic (%)  188 (100) 218 (97.3) 0.034 
Carbapenem (%) 99 (52.7) 100 (44.6) 0.105 
Outcomes 
  Length of stay (days). median (IQR) 5 (3-10.75) 5 (3-8) 0.024 
  Death (%) 52 (27.7) 67 (29.9) 0.616 
Abbreviations: ER-ICU. Emergency room Intensive Care Unit; ICU. Intensive Care Unit; IQR. 
Interquartile range; qSOFA. quick Sepsis-related Organ Failure Assessment; SIRS. Systemic 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Figure 1. Pseudomonas aeruginosa carriage of included patients admitted to the 
ICUs (adult and emergency room) of Dr. Cipto Mangunkusomo General Hospital, Jakarta, Indonesia 
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Hand hygiene (HH) is considered to be the single most effective measure in preventing healthcare-
associated infections. However, HH compliance rates among nurses and doctors in hospitals are 
often very low. Few studies have addressed HH compliance in Indonesia, performed interventions 
to increase HH compliance, and none have had long-term follow-up. We, therefore, addressed this 
issue by performing long-term follow-up after a multifaceted intervention in the intensive care unit 
(ICU) setting. 
Methods:  
This was an observational, prospective, before-and-after intervention study (May-September 2014, 
February-April 2017). We measured HH knowledge and HH compliance before (at baseline) and 
directly after a multifaceted improvement program (post-intervention) and performed a re-
evaluation three years later. The multifaceted improvement program included education, feedback, 
reminders, interviews and the use of role models. The study involved nurses and physicians working 
in two ICUs of the Dr. Cipto Mangunkusumo Hospital in Jakarta. 
Results:  
A total of 97 at baseline, and 72 at post-intervention HH knowledge questionnaires were completed. 
There was a statistically significant improvement in the mean overall HH knowledge score at post-
intervention (from 14.3 to 20.8, p<0.001). There was no significant difference between the two ICUs. 
The overall HH compliance was 27% at baseline and significantly improved to 77% post-
intervention (p<0.001). For all five HH moments, the compliance of nurses and physicians separately 
improved significantly from the baseline phase to the post-intervention phase (p<0.0001), except 
for ‘moment 3’ (after body fluid exposure), for which baseline rates were already high. Most of the 
compliance rates were significantly lower in both groups of healthcare workers upon follow-up three 
years later. Overall, the HH compliance of the nurses was significantly better than the physicians’ 
compliance (p=0.005). 
Conclusions:  
Our multifaceted improvement program, for nurses and physicians of the ICUs in the largest hospital 
of Indonesia, resulted in a significant improvement of the HH knowledge and HH compliance, but HH 
compliance levels waned over time after the intervention, indicating a need for continued monitoring 
and repeated interventions. 
Trial registration:  
The study was registered at www.trialregister.nl (No: 5541). 
Candidate number: 23527, NTR number: NTR5541, Date registered NTR: 22-DECEMBER-2015 
Keywords:  
hand hygiene, multifaceted improvement program, compliance, Intensive Care Unit, Indonesia 
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INTRODUCTION 
In both developed and resource-poor countries, healthcare-associated infections (HCAIs) 
have a large impact, especially those with multidrug-resistant (MDR) bacteria.[1, 2] One fourth of 
HCAIs involve patients in intensive care units (ICUs) and among them, the burden of infections by 
MDR microorganisms is the highest.[3, 4] 
The World Health Organization (WHO) identified the risk of acquiring a HCAI as being universal. The 
importance of hands in the transmission of infectious agents has been demonstrated. HH is 
considered to be the single most effective measure not only reducing the spread of microorganisms, 
but also preventing HCAIs.[3] Despite this fact, studies in developed countries, especially with a mid-
level sociodemographic profile, have reported very low compliance rates, including, India: 3-50.2% 
[5]. Vietnam: 43.6% [6], and other cities in Indonesia: Semarang (22.0% and 46.0%) [7], Malang 
(5.2%, 10.1% and 24.1%) [8]. In a recent systematic review of the global HH literature, Erasmus et 
al. found a median HH compliance rate of 40% with a range of 4 -100%.[9] 
A recent study on potential determinants of HH compliance showed that, besides the 
perception of the healthcare workers (HCWs) that there is a lack of evidence that HH is effective in 
preventing HCAIs, a lack of positive role models and social norms may hinder compliance.[10]  
Another study which took place on the island of Java, Indonesia, found that questionnaires in 
conjunction with site visits and interviews was a valuable strategy to identify trouble spots in the 
hospitals and to determine barriers of change that should be taken into account when planning 
interventions.[11]  
The complexity of the process of behavioural change suggests that the application of 
multimodal, multifaceted strategies is necessary. Multifaceted strategies seem to result in a larger 
improvement of HH compliance (27-83%) as compared with using a single strategy (4-18%). [12] 
Education with written material, reminders, and continued feedback of performance can have an 
important effect on HH compliance.[12] 
Using this information on HH improvement strategies, we developed a multifaceted 
improvement program to apply on the ICUs in the largest hospital of Indonesia, a country currently 
considered to have a mid-level sociodemographic index. This multifaceted improvement program 
was based on WHO tools and included education, feedback, reminders, interviews and the use of role 
models.[13] The aim was to improve the HH knowledge and HH compliance of the nurses and 
physicians working on the ICUs of the Dr. Cipto Mangunkusumo Hospital in Jakarta. The study was 





We performed an observational, prospective, before-and-after study in two ICUs of the 
largest hospital of Indonesia. Dr. Cipto Mangunkusumo Hospital is a 1200-bed university hospital 
located in Jakarta. At the time of this study up to 86% of patients did not have health insurance and 
had to pay for their hospital stay, medicines and laboratory tests. To improve HH knowledge and HH 
compliance among physicians and nurses we performed a multifaceted improvement program. This 
program was applied to the general ICU as well as to the ICU of the Emergency Department (ER-ICU), 
which is housed in a different part of the hospital but is managed by the same staff of Intensive Care 
Medicine. 
The study consisted of four study phases (Table 1). In phase I, also referred to as baseline, 
which lasted from May 22nd – June 29th,2014, we measured HH compliance by means of anonymous 
observations after which we performed HH knowledge tests through questionnaires completed 
between June 30th - July 7th, 2014. Phase II was the intervention that lasted from July 10th – August 
29th, 2014, and which consisted of the implementation of a multifaceted improvement program that 
included education, feedback, reminders, interviews and the use of role models. Phase III was the 
post-intervention period from September 2nd – 30th, 2014, during which period HH knowledge was 
again measured through the same questionnaires as in phase I (from 1st-4th of September, 2014) and 
in which HH compliance was again measured through unobtrusive observations. Long-term 
evaluation of HH compliance was evaluated in phase IV (which lasted from February 20th – April 10th, 
2017) by using the same protocols. 
Table 1. Study phases and activities performed 
Study phase  Activity Date 
Phase I: baseline Hand hygiene compliance observations: 
healthcare workers 
22 May- 29 June 2014 
Hand hygiene knowledge questionnaire: nurses 
and physicians 
30 June-7 July 2014 
Phase II: intervention Multifaceted hand hygiene improvement 
program* 
10 July – 29 August 2014 
Phase III: post-intervention Hand hygiene compliance observations: 
healthcare workers 
2- 30 September 2014 
Hand hygiene knowledge questionnaire: nurses 
and physicians 
1-4 September 2014
Phase IV: long-term 
evaluation  
Hand hygiene compliance observations: 
physicians and nurses 
20 February – 10 April 
2017 
* Interventions are specified in Table 2. 
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Study setting and population 
HCWs who participated in this study included all physicians on rounds in the ICUs, 
intensivists, all residents, nurses, students (medical students and nursing students), involved in 
patient care in these ICUs. HCWs were categorized into two categories, “physicians” and “nurses”, for 
the sake of simplicity. At the individual level, the mix of participants differed somewhat in each phase. 
In the general ICU, 43 nurses and 8 physicians were employed. This ICU has fifteen beds. In 
the ER-ICU, 34 nurses, 6 student nurses and 6 physicians were employed. The ER-ICU has six beds. 
Two nurses and one physician were involved in the HH improvement strategies and were, therefore, 
not subjected to observations, interviews and questionnaires. At the start of the study, each patient 
bed had one wall-fixed, alcohol-based liquid hand disinfectant dispenser with alcohol-based hand 
rub based on the WHO formula.[13] Per two patient beds there was one sink with a medicated soap 
dispenser (Cutisoft(@)), containing 4% chlorhexidine, and one wall-fixed paper towel dispenser. 
There was no possibility of improving these basic facilities owing to the financial circumstances.  
Hand hygiene improvement strategies 
Based on the study by M. Tromp et al., we developed an improvement program which 
included education, feedback and reminders.[12] Education was given in the form of interactive 
lessons developed by the WHO, including formal lectures, practical demonstrations and written 
material.[13] In each lesson, we emphasized that alcohol-based hand rub is superior to traditional 
handwashing as it requires less time, acts faster, irritates skin less often, and proved to be 
contributing significantly to sustainable improvement in compliance, which was associated with 
decreased infection rates.[14] Only when hands are visibly dirty or are visibly soiled with blood or 
other body fluids, hand washing with either non-antimicrobial soap and water or an antimicrobial 
soap and water was indicated.[15] 
Behavioural theories suggest that performance can by changed by feedback. In phase II and 
phase III personalized and non-personalized performance feedback was given to nurses and 
physicians of both wards. In several studies reminders were shown to have a sustainable effect on 
HH compliance. We gave reminders in the form of posters with handwashing messages placed on 
prominent sites in both ICUs.[16]
In addition, we conducted interviews to determine the importance of social influence. The 
seven group interviews took 40-60 minutes. Each group interview consisted of 5-10 participants, 
both nurses and physicians. The interviews were led by a moderator. At the start of the interview, it 
was emphasized that there were no good or bad answers. All group interviews were recorded with 
a voice recorder. To ensure that all topics of interest were discussed an interview guide was 
developed and used in each interview. All performed strategies are summarized in Table 2 and 






Table 2. Hand hygiene improvement strategies used during the study 
Improvement strategy Date 
Education July 2014 
Educational training  
Practical demonstration  
Written material  
Reminders July 2014 
Posters with hand hygiene reminders  
Interviews August 2014 
7 group interviews   
Performance feedback July 2014-September 2014 
Bar charts: hand hygiene compliance rates at baseline  
Individual feedback during observations  
Role models September 2014 




Hand hygiene knowledge questionnaire 
Based on the WHO’s ‘Hand Hygiene knowledge questionnaire’ a local questionnaire was 
developed (Supplemental data 1). The questionnaire was designed by the researchers and consisted 
of eight questions (including 17 sub-questions) about knowledge and five about attitude, perceived 
obstacles and self-reported behaviour. Two of the questions about perceived obstacles were 
developed by a Dutch clinical microbiologist. The questionnaire was translated into Indonesian after 
a pilot was tested by an Indonesian infection control nurse and physician. The questionnaire survey 
was carried out anonymously. 
Participants completed the questionnaire during sessions at which the researchers were 
present to supervise. The ward was written on the form directly after a participant completed the 
questionnaire.  
 
Hand hygiene compliance observation 
The gold standard to monitor compliance of HH is direct observation.[17]  
There were four observers who worked in parallel in phase I, two observers had received 
training about the correct method of HH at the Unit Infection Prevention of the Erasmus MC 
University Medical Center that is accredited to do so. In phase I, two local fellows of clinical 
microbiology were enlisted as additional observers, who were trained and supervised by the 
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principal investigator and the Erasmus MC trained observers. Prior to their scoring in the study these 
two fellows did a comparative trial run on observing compliance together with the trained observers 
from Erasmus MC and their results were compared using a kappa statistic to determine the 
interrater reliability. The two Erasmus MC trained observers scored HH compliance during phases I 
and III. The observers of the HH compliance in the phase IV, three years later, were local medical 
doctors recruited, trained and supervised in HH observations by one of the principal investigators 
(YRS). 
Individual HCWs were observed during routine patient care by the observers with respect to 
potential HH opportunities available. The HCWs were not made aware that they were being 
observed. The nurses and physicians were unaware of the true reason for the presence of the 
observers at baseline, since we mentioned a participation to a different study as a reason for having 
observers on the wards. In addition, to avoid a Hawthorne effect we elected, when designing the 
study, not to include the week in which questionnaires on hand hygiene were completed as part of 
the baseline observation period.  
An observation list was developed based on the five moments for HH, and based on the WHO 
tools. The observations were carried out several times a week during differing time slots, but not 
during the weekend. Every episode of observation lasted about 30 to 60 minutes, but sometimes 
longer, also to reduce the Hawthorne effect. 
The observation list contained 5 indications for HH: (1) before touching a patient, (2) before 
a clean/aseptic procedure, (3) after body fluid exposure risk, (4) after touching a patient (regardless 
of the use of sterile or nonsterile gloves), (5) after touching patient’s surroundings. 
HH compliance was defined as hand disinfection using alcohol-based hand rub or washing 
hands with soap and water following one of the above-mentioned indications. The applied HH 
indication(s) and the performed HH action were marked on the observation list by the 
observers.[12] The outcomes of these observations were presented as percentages of compliance 
representing the fraction of the number of times when hand hygiene should have taken place 
correctly, and the number of times it had actually taken place correctly. The researchers, who were 
also the observers, recorded possible opportunities for HH over a period, which included 
observations at baseline (phase I), observations in the post-intervention phase (phase III), and long-
term evaluation (observation by RK and M) (Phase IV), on both wards.  
The targeted minimum number of observations for the baseline and post-intervention 
phases of the study was 1,100 moments, as derived from a recent systematic review of previous HH 
compliance studies [9]. The WHO [13] points out that low numbers of observation are associated 
with wide ranges of the confidence intervals. When designing the study, we, therefore, elected to 
have at least 1,100 observations in each of the pre- and post-intervention phases of the study to keep 




For analysis of the questions regarding knowledge, correct answers were analysed as 
‘correct’; incorrect answers, missing values (including ‘no answer’ and ‘do not know’) were all 
categorized as ‘incorrect’. The results of HH knowledge questionnaires were analysed in two ways: 
a) at the level of the individual HCW, i.e. number of correct answers per person, and b) at the level of
individual questions asked, i.e. the percentage of correct answers given per question. For the first
analysis each question was given the same value of one, such that each HCW received a score ranging
from 0 - 25. To compare the scores of individual HCWs before and after the intervention (phase I and
III, respectively), the scores were graphically plotted, and mean and median scores were calculated
and compared using the Mann Whitney test for independent samples. Because no data were stored
on the identity of each HCW per phase, the scores in different phases could not be linked to each
other, and a paired statistical analysis was thus not possible.
The performance of each of the 25 questions was analysed by scoring the percentage of 
participants providing the correct answer, thus these question-level scores ranged from 0 to 100%. 
The effect of the intervention on the percentage correct answers of each question was analysed using 
Fisher’s exact testing (two-tailed), and Mann Whitney testing was used to compare the medians 
across all 25 questions before and after the intervention.  
For the questions about attitude, perceived obstacles and self-reported behaviour, the 
answers were used for the development of the improvement program. To determine the effects of 
the improvement strategy on compliance over time, we used linear mixed models for the repeated 
measurements of the compliance rates. The independent variables in this model were type of HCW 
(nurse or physician), phase (phase I, III, or IV), moment (a categorical variable for the 5 indications), 
and ward (general ICU or ER-ICU). All independent variables were coded as categorical variables. 
Two-way interaction effects between type of HCW, phase and moment were included in the model. 
Because the HCWs were not identified during data collection, the responses could not be linked 
between phases at the individual level. Instead we estimated the model for aggregated data, i.e. the 
outcome consisted of the average compliance rate (expressed as a percentage) for each combination 
of the variables type of HCW, phase, moment, and ward. This aggregation approach uses the fact that 
we can link outcomes over time at the level of a ward and allowed us to account for correlations 
between repeated measurements. The correlations were modelled by including a random intercept 
for each combination of type of HCW, ward, and moment in the model. We accounted for the 
substantial variation in the number of observations between different phases and moments by 
modelling the variance of the compliance rate as a function of the binomial variance (i.e. the observed 
compliance rate times (1-observed compliance rate) divided by the number of observations). The 
results of the linear mixed model analysis were summarized using the estimated marginal means, 
i.e. the predicted compliance rates adjusted for the effects of covariates, and presented graphically.
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These estimated marginal means were compared between the phases for each combination of 
moment and type of HCW. The comparisons were adjusted for the effects of multiple testing using 
Tukey’s method. 
Concordance between the observers was analysed using a kappa statistic. A kappa value of 
>0.60 was considered good. For the linear mixed model, we used ‘R’, version 3.5.2 with packages
nlme and emmeans. For other analyses, we used SPSS version 22.0 (SPSS, Inc, Chicago, IL.). In all
analyses, a two-sided p-value <0.01 was considered statistically significant.
RESULTS 
Interviews 
Prevention of cross-infections was named by the participants as the main advantage of HH. 
Dryness and soreness of hands after performing HH were the main disadvantages brought up by the 
participants. 
A lack of social control with regard to HH compliance was mentioned by nurses as well as 
physicians. Nurses had no difficulties in approaching other HCWs, even physicians, about their HH 
behaviour. However, physicians reported to have difficulties in approaching for example senior staff 
members, because of ‘the culture’ in the hospital. In addition, they mentioned that noncompliance 
among physicians could arise from lack of strong evidence supporting the effectiveness of HH for 
prevention of HCAIs. Participants, nurses in particularly, mentioned the need for positive role 
models. The presence of negative role models, nurses or physicians noncompliant with HH, was 
reported as reason for their own noncompliance.  
Furthermore, participants noted that strategically placed reminders (posters, labels with 
messages) would help increase and maintain compliance with HH. Also, participants advised to 
regularly change the reminders into different ones in order to be sure that the reminders remain 
effective. 
Hand hygiene knowledge 
At baseline we measured the HH knowledge of 43 nurses and 8 physicians of the general ICU. 
At the ER-ICU 34 nurses, 6 physicians and 6 nurse students participated. The overall score of 
correctly answered HH knowledge questions for all HCWs and both wards combined ranged from 1 
to 22, with a mean overall score of 14.3 (median 15; interquartile range (IQR) 13-16). Post-
intervention we measured the HH knowledge of 32 nurses and 5 physicians of the general ICU. At 
the ER-ICU these were 31 nurses and 4 physicians. Of this group, the mean overall score of correctly 
answered knowledge questions for all HCWs and both wards combined was 20.8 (median 22; IQR 
18-23), with a range from 13 to 25 (Figure 1). Compared with baseline, there was a significant
improvement in the overall mean HH knowledge score post-intervention (p<0.001). There was no
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significant difference observed in the overall mean score between the general ICU and the ER-ICU 
(p=0.692 by Mann-Whitney test, data not shown).  
The multifaceted intervention resulted in significant improvement in HCW knowledge 
(median percent correct answer across all questions pre-intervention, 71% versus post-intervention 
phase, 89%; p=0.002). Supplementary Table 1 displays the results for the 25 individual HH 
knowledge questions separately, at baseline as well as post-intervention. For 15 questions, 
significantly more correct answers were given in the post-intervention phase compared to baseline. 
Interestingly, the question (5c) with the 2nd lowest number of correct answers in the pre-
intervention phase (14.4%) significantly improved its score but had the lowest score in the post-
intervention phase (52.8%); this question addressed the effectiveness of hand rubbing compared to 
handwashing. Thus, even after education and hand-written evidence almost half of the respondents 
remained convinced that handwashing with water and soap is more effective than hand rubbing with 
alcohol. In contrast, the rate of correct answers to question 2 improved from a very low 4.0% to 
75.0%, this question dealt with the most prevalence source of pathogens causing nosocomial 
infections. 
Figure 1. Effect of an educational intervention on hand hygiene knowledge of healthcare workers.  
Legend: Bars indicate the number of persons achieving indicated overall score derived from 
questionnaires taken during the baseline (blue bar) and post-intervention (orange bar) phases of the 
study. 
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Hand hygiene compliance 
In the general ICU and the ER-ICU combined, a total of 7187 HH opportunities was observed 
(Table 3). The observations between researchers and the clinical microbiology fellows were 
concordant (kappa 0.72) when tested in a pilot run in the general ICU.  
The most frequently observed indications for HH were ‘after touching patient’s 
surroundings’ 3126/7187 (44%) and ‘after touching a patient’ (24%) (Table 3). 
Table 3. Number of opportunities for hand hygiene observed at baseline, in the post-intervention 
phase, and at long-term follow-up.  
Baseline Post-intervention Long-term evaluation Total 
Before touching a patient 386 218 705 1309 
Before a clean/aseptic procedure 212 171 241 624 
After body fluid exposure risk 108 59 267 434 
After touching a patient 692 299 703 1694 
After touching patient’s surroundings 920 642 1564 3126 
Total 2318 1389 3480 7187 
The number of HH opportunities at baseline, both wards combined, was 2318 with an overall 
compliance rate of 27%. In the post-intervention phase, the number of HH opportunities was 1389 
with an overall compliance of 77%. Thus, the overall HH compliance improved significantly from 
baseline phase I to the post-intervention phase III, but had regressed to the baseline level again when 
evaluated at long-term follow-up (33% in phase IV, Figure 2, Table 4). For all moments, the HH 
compliance of nurses and physicians separately improved significantly from phase I to phase III 
(p<0.0001), except for moment 3 (Figure 3, Table 4). Over the whole observation period, however, 
the HH compliance rates were higher among the nurses than among the physicians (44% versus 
27%, p=0.005 in linear mixed model). There was no significant difference in compliance rate found 
between the two wards (p=0.463, data not shown). 
We also analysed the sustainable effect of this intervention program by a long-term follow-
up evaluation (phase IV), most of the compliance rates were significantly lower in both groups of 
HCWs (phase III versus phase IV), except for moment 3 (after body fluid exposure risk), for which 
both physicians and nurses had high compliance rates at baseline and remained so in phase III and 
IV, albeit that these values were statistically not significantly higher. 
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Figure 2. Time series of compliance rates per observation day. 
Legend: Dots indicate the compliance rates per observation day. The observations used to calculate the 
compliance rates per day were conducted in the baseline phase and the post-intervention phase in 2014, and 
in the long-term evaluation phase in 2017. The horizontal lines represent the average of compliance rate in 
each phase. 
DISCUSSION 
This was an observational, prospective, before-and-after intervention study. The overall HH 
compliance rates at baseline phase were low in both ICUs (27%). The HH compliance level observed 
before intervention was similar to those reported from other countries that have a mid-level 
sociodemographic index  [18] [5] [19] [20] [6], and other cities in Indonesia[7] [8]. 
Our study showed that overall a significant increase in the HH compliance of HCWs could be 
achieved using a multifaceted improvement program (compliance in post-intervention phase: 77%). 
In line with the report by Tromp et al. [12], we developed a multifaceted improvement program. 
Since this is a multifaceted approach, it is not possible to determine the contribution of each 
component to the observed improvement.  
Duerink et al. introduced a multifaceted intervention study to improve compliance in a 
tertiary care hospital in the city of Semarang, Indonesia, and found this strategy increased HH 
compliance from 46.0% to 77.0% in the internal medicine ward and from 22.0% to 62.0% in the 
paediatric ward.[7] Santosaningsih et al. also performed interventions in a similar hospital in 
Malang, and improved HH compliance significantly in paediatric (24.0% to 44.0%) and internal 
medicine wards (5.0% to 19.0%), but also in the control ward, obstetrics-gynaecology, where no  
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Figure 3. Predicted compliance rates by WHO moment of hand hygiene and by healthcare worker in 
the baseline phase (I) and post-intervention phases (III and IV). 
Legend: HCW, healthcare worker; HCW: N: nurse; HCW: P: physician. 
Moment 1 is before touching a patient. Moment 2 is before a clean/aseptic procedure. Moment 3 is after body 
fluid exposure risk. Moment 4 is after touching a patient. Moment 5 is after touching patient’s surroundings. 
Black dots indicate the estimated marginal means of compliance rate. The red arrows give information on the 
significance of the difference between phases. Overlapping red arrows within a block (i.e. a block of phase I, III, 
and IV) means a nonsignificant difference between phases, nonoverlapping arrows imply a significant 
difference. The arrows are adjusted for multiple testing using Tukey’s method. The blue bars are 95% 
confidence intervals, not adjusted for multiple testing. 
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no intervention had been performed (10.0% to 21.0%).[8] They concluded that role model training 
had the most impact.[8] 
Our strategy was highly effective for the nurses as well as the physicians. Similar to previous 
studies [21], the overall level of HH compliance in our study was significantly higher among nurses 
(44%) than among physicians (27%). In the setting of our study, we noticed a clear difference in 
activities of nurses and physicians. Nurses play an important role in the daily care of the patients. 
Physicians have much fewer patient contacts. Therefore, the nurses have far more HH opportunities 
in their daily routine. This could explain why the nurses had a more pro-active attitude towards the 
improvement program with a higher HH compliance as result. This difference in HH compliance 
between nurses and physicians may also be due to the fact that not all physicians were convinced 
about the effectiveness of HH. Physicians mentioned that their noncompliance was associated with 
a perceived lack of evidence that hand hygiene is effective in the prevention of hospital-acquired 
infection, which could be an explanation for the inverse correlation found between the level of 
education and the rate of handwashing compliance. Better information about the available evidence 
might well promote better compliance.[16, 21]  
In the analysis of the compliance rates per HH moment, there is a notable difference between 
‘moment 3’ and the other four HH moments. The HH compliance rates for ‘moment 3’ at baseline 
(physicians: 80%, nurse: 69%), were already very high, compared to the HH compliance rates of the 
other HH moments. Moment 3 is defined as a HH indication after body fluid exposure risk. Other 
studies have shown that the HH behaviour of healthcare workers appears to be motivated by self-
protection and a desire to clean oneself after a task that is perceived to be dirty, rather than protect 
their patients by proper HH before approaching the patients. This may explain the high HH 
compliance rate at baseline in our study.[21]  
HH knowledge was indeed low at baseline, but showed a large increase in the post-
intervention phase. Therefore, we hypothesize that education was an important component of the 
intervention.  
Dryness and soreness of hands after performing HH were the main obstacles reported by 
participants of the interviews and in the HH knowledge questionnaire before the multifaceted 
intervention. The medicated soap and the hand alcohol suspensions did not contain moisturizers and 
emollients. Hand washing with 4% chlorhexidine medicated soap dries out the skin and results in 
pre-irritated skin. Applying alcohol-based hand rub to pre-irritated skin may cause a burning 
sensation. Because of the burning sensation the HCWs tend to reduce the use of alcohol-based hand 
rub and prefer hand washing with medicated soap, which is the underlying reason for the burning 
sensation. However, this fact was not stressed during the educational part of the intervention. Due 
to financial constraints, additional moisturizing hand creams were not available. Replacement of the 
medicated soap to plain mild soap would have been more in line with the WHO strategy. 
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The long-term effect of our multifaceted improvement program was assessed after three 
years. This follow-up showed that the intervention by and large did not have a sustainable effect on 
HH compliance, except ‘moment 3’ (after body fluid exposure risk) in both groups of HCWs. In Khatib 
et al.[22] the use of reminders showed a modest positive effect on HH compliance rates, but they 
were able to maintain higher compliance rates for a longer period of time. Other studies also showed 
that reminders have a modest sustaining effect on HH compliance rates.[16, 23] With the use of 
reminders and positive role models in our multifaceted improvement program, we strived to have a 
long-term effect on HH compliance rates. 
Human behaviour is a complex process determined among others by knowledge about and 
attitude towards the behaviour, perceived social standards and self-efficacy.[11] Behavioural change 
is often viewed as a difficult process, also in the hospital. HCWs continue to fail in adherence to the 
guidelines for HH which hampers the reduction of HCAIs.[4] In several studies, the effectiveness of 
different HH improvement strategies have been described.[17] Erasmus et al. found that personal 
beliefs about the efficacy of HH and examples and norms provided by senior hospital staff are of 
major importance for HH compliance. They further reported that HH is most often performed after 
tasks that they perceive to be dirty, and personal protection appeared to be more important for 
compliance than patient safety. Physicians mentioned that their noncompliance arose from their 
belief that the evidence supporting the effectiveness of HH for prevention of HCAIs is not strong.[21] 
Some possible limitations of our study must be considered. For measuring the HH 
compliance, we used direct observations using the standard observation form as defined by the 
WHO.[3] Direct observations have limitations; they are time-consuming, manpower intensive and 
continuous monitoring is currently not feasible in this setting. The information provided probably 
represents a low percentage of all HH opportunities. By mentioning our participation to a different 
study as reason for the presence of the observers, the nurses and physicians were unaware of the 
true reason for the observations at baseline. Despite of our long periods of observations, observation 
bias and the Hawthorne effect cannot be fully excluded. Also, the effectiveness of HH on the 
prevention of HCAIs depends on HH technique in addition to HH compliance.[24] HH technique 
training was a part of our program, however, this was not evaluated. A full system change was not 
achieved by the intervention. State of the art is to increase the use of alcohol-based hand rub and 
decrease hand washing. 4% Chlorhexidine medicated soap should have been removed from all 
wards. A mild liquid soap should have been provided instead of medicated soap. The observed 
decrease in HH compliance rates after the initial post-intervention phase could be, at least in part, 
the result of an incomplete system change. 
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CONCLUSIONS 
In conclusion, our multifaceted improvement program, for nurses and physicians of the ICUs 
in the largest hospital of Indonesia, resulted in a highly significant improvement in the HH knowledge 
and HH compliance, but maintaining high levels of HH compliance requires continuous monitoring 
and regular interventions. 
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SUPPLEMENTAL MATERIALS 
Supplementary Table 1. Survey results regarding hand hygiene knowledge questions. 
Baseline (%) 
correct answer 




Overall median 15 (71) 22(89) <0.0001 
Question 1 79 (81.4) 50 (69.4) 0.099 
Question 2 4 (4.1) 54 (75.0) <0.0001 
Question 3a 92 (94.8) 72 (100) 0.072 
Question 3b 17 (17.5) 50 (69.4) <0.0001 
Question 3c 83 (85.6) 69 (95.8) 0.037 
Question 3d 17 (17.5) 49 (68.1) <0.0001 
Question 4a 23 (23.7) 55 (76.4) <0.0001 
Question 4b 86 (88.7) 67 (93.1) 0.430 
Question 4c 20 (20.6) 56 (77.8) <0.0001 
Question 4d 83 (85.7) 66 (91.7) 0.336 
Question 5a 74 (76.3) 69 (95.8) <0.0001 
Question 5b 15 (15.5) 50 (69.4) <0.0001 
Question 5c 14 (14.4) 38 (52.8) <0.0001 
Question 5d 26 (26.8) 45 (62.5) <0.0001 
Question 6 69 (71.1) 69 (95.8) <0.0001 
Question 7a 80 (82.5) 70 (97.2) 0.003 
Question 7b 69 (71.1) 69 (95.8) <0.0001 
Question 7c 90 (92.8) 72 (100.0) 0.021 
Question 7d 29 (29.9) 48 (66.7) <0.0001 
Question 7e 45 (46.4) 64 (88.9) <0.0001 
Question 7f 89 (91.8) 71 (98.6) 0.080 
Question 8a 84 (86.6) 70 (97.2) 0.026 
Question 8b 61 (62.9) 43 (59.7) 0.750 
Question 8c 78 (80.4) 65 (90.3) 0.088 
Question 8d 58 (59.8) 63 (87.5) <0.0001 
Differences between baseline and post-intervention data were assessed using Fisher’s exact test 
and Mann Whitney test. The written text of each question can be retrieved from the supplementary 
dataset. 
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Infection control effectiveness evaluations requires detailed epidemiological and 
microbiological data. We analyzed the genomic profiles of Carbapenem Non-susceptible 
Pseudomonas aeruginosa (CNPA) strains collected from two intensive care units (ICUs) in the 
national referral hospital in Jakarta, Indonesia, where a multifaceted infection control 
intervention was applied. We used clinical data combined with whole-genome sequencing (WGS) 
of systematically collected CNPA to infer CNPA strain’s transmission dynamics and characterize 
their resistome. We found that the number of CNPA transmissions and acquisitions by patients 
was highly variable over time but that overall the rates were not significantly reduced by the 
intervention. Environmental sources were involved in these transmissions and acquisitions. Four 
high-risk international CNPA clones (ST235, ST823, ST357 and ST446) dominated, but the 
distribution of these clones changed significantly after the intervention was implemented. 
Carbapenem resistance was explained from resistome analysis by the presence of various 
carbapenemase-encoding genes (blaGES-5, blaVIM-2-8, blaIMP-1-7-43) and by mutations within the porin 
OprD. Our results describe for the first time the dynamics of P. aeruginosa AMR profiles in 
Indonesia, and additionally shows the utility of WGS in combination with clinical data to evaluate 
the impact of an infection control intervention.  
IMPORTANCE: 
In low-to-middle income countries such as Indonesia, the work in intensive care units (ICUs) can 
be hampered by lack of resources. Conducting large epidemiological studies in such settings using 
genomic tools is rather challenging. Still, we were able to systematically study the within and 
between ICU transmissions of carbapenem non-susceptible strains of  P. aeruginosa (CNPA), 
before and after an infection control intervention. Our data show the importance of the broad 
dissemination of the internationally recognized CNPA clones, the relevance of environmental 
reservoirs, and mixed effects of the implemented intervention: it led to a profound change in the 
clonal make-up of CNPA, but it did not reduce the patients’ risk of CNPA acquisitions. Thus, CNPA 
epidemiology in Indonesian ICUs is part of a global expansion of multiple CNPA clones that 
remains difficult to control by infection prevention measures. 
KEYWORDS:  
Microbial drug resistance, Pseudomonas aeruginosa, Intensive Care Units, infection control, Single 
Nucleotide Polymorphism, Indonesia. 




Pseudomonas aeruginosa is especially dreaded as one of the leading species to cause 
healthcare-associated infections [1,2]. P. aeruginosa is an opportunistic human pathogen with a 
remarkably versatile genome, which allows it to adapt to a wide range of environments and 
conditions and, consequently, survive in a variety of niches. This is mainly due to traits encoded 
in its accessory genome, which includes genes coding for antimicrobial resistance (AMR), a great 
diversity of metabolic pathways, and virulence factors [3]. AMR is a major concern in clinical P. 
aeruginosa isolates, as almost 31% of all invasive isolates are resistant to at least one of the main 
antimicrobial groups tested, according to the most recent AMR surveillance report by the 
European Centre for Disease Prevention and Control (ECDC) [4]. Additionally, a limited number 
of P. aeruginosa clones with multi-drug resistance (MDR) profiles are particularly worrisome 
since they have been shown to have achieved nearly global expansion [5,6]). Especially in low- to 
middle-income countries, MDR P. aeruginosa contributes to in-hospital mortality [7,8]. Gathering 
as much clinical and microbiological information as possible with respect to these isolates is 
essential to inform nosocomial infection control and surveillance procedures. 
During recent years, whole-genome sequencing (WGS) has developed rapidly into a 
reference tool for outbreak management [9–12]. However, there is not a common standardized 
and accepted methodology to infer bacterial transmissions during outbreak investigations from 
WGS data. This is troublesome, especially when the WGS approach is implemented in regions of 
the world where MDR and XDR microorganisms are already endemic.  
The aim of this study was to assess nosocomial transmission of carbapenem non-
susceptible P. aeruginosa (CNPA) using WGS in combination with detailed clinical data, from ICU 
patients of the national referral hospital of Indonesia. CNPA were systematically collected before 
and after an infection control intervention, such that we could study its effect on the dynamics of 
transmission of CNPA in this setting in detail. Additionally, we highlight the main P. aeruginosa 
clones found as well as their resistomes. Risk factors for the carriage and acquisition of CNPA and 
its effect on patients’ outcomes have been analyzed and published separately [13]. 
Study design – sample collection 
We performed a prospective, quasi-experimental before-and-after study in two ICUs of 
the national referral hospital of Indonesia. Dr. Cipto Mangunkusumo Hospital is a 1200-bed 
university hospital located in Jakarta. We conducted this study in two ICUs for adult patients: the 
12-bedded adult ICU and the 8-bedded Emergency Room (ER)-ICU with an average of 1,010 and
415 admissions per year, respectively. Both ICUs have an open ward design. The populations
served by these two ICUs were very similar, and there was also no difference in the care provided
[8]. The study consisted of three study phases, pre-intervention phase (April-October 2013 and
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April-August 2014), intervention phase (December 2014- January 2015) and post-intervention 
phase (February-December 2015) [8,14]. 
CNPA strains were collected from clinical cultures and by targeted screening in the pre- 
and post-intervention phases. Healthcare personnel and the ICU environment were screened for 
CNPA as well, once in both pre- and post-intervention phases of the study. A list of the isolates 
together with clinical data, can be found in Table S5. All isolates were stored in 10% glycerol 
containing media and frozen at -80°C until further use. The study was registered at 
http://www.trialregister.nl (Trial NL5424 (NTR5541)). Further details on the wards for the 
period 2013-2014, the sampling process and microbiological methods such as the CNPA selection 
criteria, have been previously described in detail [8]. Replicate collections of all these isolates 
were archived in Jakarta (Indonesia), Rotterdam (The Netherlands) and La Balme Les Grottes 
(France). 
Intervention 
Between the two collection periods mentioned above, an infection control bundle aimed 
at reducing transmission of carbapenem-non-susceptible P. aeruginosa, Klebsiella pneumoniae 
and Acinetobacter baumannii-calcoaceticus complex was implemented in both ICUs. The measures 
adopted with this intervention included enhanced environmental cleaning, enforced antibiotic 
stewardship which included a daily revision of all antibiotics on weekdays, and a targeted hand 
hygiene education for healthcare workers of the ICUs [14]. Once-daily bathing with chlorhexidine 
2% was introduced and for intubated patients, oral hygiene was performed four times per day by 
rinsing with 2% chlorhexidine solutions. Patients colonized or infected with carbapenem non-
susceptible Gram-negative bacteria were grouped together in a dedicated area of the ward, with 
contact isolation precautions as recommended by the CDC. 
 (https://www.cdc.gov/infectioncontrol/basics/transmission-based-precautions.html). 
Bacterial identification, antibiotic susceptibility testing and DNA extraction 
Stored strains were regrown from the -80°C stocks using Columbia agar + 5% sheep blood 
(COS plates; bioMérieux, Marcy-l’Étoile, France) and colonies confirmed to be Pseudomonas 
aeruginosa using Vitek® MS with standard acquisition parameters according to the 
manufacturers’ instructions (bioMérieux). Antibiotic susceptibility testing (AST) was performed 
with Vitek® 2 (bioMérieux) using EUCAST 2019 breakpoints [15]. The antibiotics tested were 
ticarcillin, piperacillin, ticarcillin/clavulanic acid, piperacillin/tazobactam, ceftazidime, cefepime, 
imipenem, meropenem, aztreonam, ciprofloxacin, levofloxacin, amikacin, gentamicin and 
tobramycin. Susceptibility to colistin was not reported, since a validated automated test to do so 
was lacking.    
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Whole Genome Sequencing and Bioinformatics 
DNA was extracted from pure cultures using the UltraClean® microbial DNA isolation kit 
(Qiagen N.V., Venlo, Netherlands) and quantity and quality were assessed using the Qubit dsDNA 
BR assay kit (ThermoFisher Scientific, Waltham, MA USA). 
(i) Whole-genome sequencing methods and quality control.
Samples from the pre-intervention phase were sequenced using either a HiSeq 2500 
instrument (Illumina Inc., Cambridge, United Kingdom) with 150-bp paired-end reads or the 
MiSeq instrument (Illumina Inc.) with 200-bp paired-end reads. Samples from the post-
intervention phase were sequenced using a NextSeq 500 (Illumina Inc), with 150-bp paired-end 
reads. Nextera XT DNA library prep kit (Illumina Inc.) was used in all cases. Paired-ended reads 
were assembled into contigs and scaffolds using the A5-MiSeq pipeline (v20160825) [16]. Correct 
identity of assemblies was confirmed by an Average Nucleotide Identity (ANI) analysis using 
FastANI (v1.2) [17], using P. aeruginosa PAO1 as reference (NC_002516.2). QUAST (v5.0.2) was 
run to assess the assemblies quality, using standard parameters and including the “–scaffold” 
parameter when scaffolds were obtained from the assembly [18]. Reads and assemblies from all 
sequenced samples are available at the European Nucleotide Archive website under the project 
name PRJEB30625 and PRJEB32907, for the clinical and environmental samples, respectively. 
(ii) Antimicrobial resistance and MLST typing.
Antimicrobial resistance determinants were identified from assemblies using the 
Resistance Gene Identifier (RGI) command line tool associated with the Comprehensive 
Antimicrobial Resistance Database [19–21] (updated in 2018, analysis date: December 2018), 
using the “Strict algorithm”, which allows the detection of previously unknown AMR genes. To 
display the results of the RGI tool, we used a cluster map created with a custom Python 3 script. 
Additionally, we screened the literature for genes belonging to the mutational resistome of P. 
aeruginosa, and analyzed them using Snippy (v1.4.1) (Seemann T [2015] snippy: fast bacterial 
variant calling from NGS reads. https://github.com/tseemann/snippy) by aligning the contigs to 
the P. aeruginosa PAO1 reference genome (NC_002516.2), and selecting missense variants with a 
minimum coverage of X50. BioNumerics® 7.6 (Applied Maths, St-Martens-Latem, Belgium) was 
used for in silico Multi Locus Sequence Typing (MLST) using the pubMLST database site (hosted 
at https://pubmlst.org by the University of Oxford). goeBURST was used to infer the relatedness 
of the MLST profiles [22]. 
(iii) Genomic epidemiology of the bacterial strains. 
We used the assemblies to perform a k-mer based SNP analysis using kSNP3 (v3.01) [23]. 
kSNP3 was executed with the parameters “–k 21 –core”, setting the k-mer nucleotide length to 21-
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bp and allowing the calculation of the “core SNPs”. The “core SNPs” are those identified from k-
mers present in all input samples. The goal was to use SNPs data and the available clinical 
information to infer transmission patterns of individual CNPA strains between patients during the 
whole study period. To do so, the first step was to set up a similarity SNP cut-off, below which all 
isolates were considered genetically identical, i.e. isogenic. From all kSNP3 output files, we used 
the file containing the k-mer core SNPs detected (“core_SNP_matrix.fasta”), and used it as input 
file for snp-dists (v0.6; https://github.com/tseemann/snp-dists). snp-dists was executed with the 
“–a –b” parameters. We used the pairwise SNP matrix to evaluate different SNP thresholds. To 
calculate the optimal SNP threshold value, we assumed that truly identical strains could only be 
cultured from the same patient, and that different patients never shared the same strain. Thus, we 
considered a true positive (TP) match when two isolates from the same patient had a number of 
SNP differences below or equal to the tested threshold, a true negative (TN) when two isolates 
from different patients had a number of SNP differences above the tested threshold, a false 
positive (FP) when two isolates from different patients had a number of SNP differences below or 
equal to the tested threshold, and a false negative (FN) when two isolates from the same patient 
had a number of SNP differences above the tested threshold. Using a custom Python script we 
counted the number of true positives (TP), true negatives (TN), false positives (FP) and, false 
negatives (FN), and then calculated sensitivity and specificity values for a large range of 
thresholds (0 - 20000). Sensitivity and Specificity values for these different SNP thresholds were 
used to calculate and plot a cumulative distribution analysis figure and Receiver Operating 
Characteristic (ROC) curves to finally select the optimal similarity SNP cut-off using Youden’s 
Index. Isolates that had SNP profile differences below this cut-off were considered to be isogenic, 
i.e. represent the same strain circulating in this ICU setting at the time of the study. We also
evaluated the effect of varying the genotype distribution of the CNPA collection on the optimal
SNP cut-off value by similarly calculating optimal SNP cut-off values for different sub-collections
of our initial panel of P. aeruginosa isolates.
(iv) Possible transmission events vs acquisition events.
In order to highlight the importance of clinical metadata in the outcome and interpretation 
of the genomic epidemiology analysis, we differentiated between two approaches to account for 
transmissions of CNPA strains in the ICU setting: the first one takes into account only the genetic 
concordance between isolates based on SNP differences generated by WGS, yielding what we 
called Possible Transmission Events (PTEs). We defined a PTE as two isolates cultured from two 
different patients - or a patient and an environmental sample - who were genetically considered 
to be the same (isogenic) because the SNP profiles of their core genomes differed less than the 
SNP cut-off value (see above). In the second approach, we incorporated both the genetic 
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concordance and the clinical and other laboratory information, such as patient ID, date of the 
culture and patients admission and discharge dates, to generate what we called Acquisition Events 
(AEVs). A patient was considered to have acquired a CNPA in the ICU only when screening at 
admission was negative and when the first CNPA was isolated from a sample taken at least 48 
hours after admission to the ICU. A patient could have an AEV from either a known or an unknown 
source. An AEV from a known source was defined when a patient acquired a CNPA strain that was 
genetically the same (as defined above) as an isolate cultured earlier from another patient or from 
an environmental site, and the clinical and microbiological data (e.g. sampling date) could not 
exclude that a transmission had occurred between them. If the origin of a CNPA strain cultured 
from a given patient could not be traced back to a previously identified source, we labelled this 
AEV as “from an unknown source”. To calculate either PTE or AEV, we considered only the 
first/earliest CNPA strain isolated, subsequent isogenic isolates from the same patient were 
ignored in enumerating the number of PTEs and AEVs. To compare transmissions before and after 
the intervention, the occurrence of PTEs and AEVs was expressed as an attack rate, using the total 
number of patients at risk of CNPA transmission for each period as denominator. Chi-square test 
was used to report significance. 
Finally, as measures of diversity we also calculated the first three Hill Numbers (0D, 1D, 2D) 
[24] for the CNPA collections cultured in each of the pre- and post-intervention phases. These Hill
numbers are mathematically converted classic diversity indexes 0D = richness, 1D (exponential of
Shannon-Wiener’s diversity index), and 2D (the reciprocal of Gini-Simpson’s index).
RESULTS 
A total of 412 patients were included in the study during the pre-intervention phase (188 
were admitted to the adult ICU and 224 to the Emergency Room-ICU) and from 51 (12.4%) 
patients at least one CNPA was isolated. During the post-intervention phase 363 patients were 
included (Adult ICU:133 and ER-ICU: 230), and from 52 (14.3%) patients at least one CNPA was 
isolated [8]. Risk factors, including antibiotic usage, and patient outcomes of CNPA carriage and 
acquisition during ICU stay are reported elsewhere [13]. A total of 119 CNPA strains were isolated 
during the pre-intervention phase, hereby defined as the “pre-intervention phase” set, which 
included 12 environmental isolates. 118 CNPA strains were isolated during the post-intervention 
phase, hereby named the “post-intervention phase” set, including 3 environmental isolates. Note 
that the two strain collections contained multiple CNPA isolates per patient. This was the case for 
51 patients. In order to avoid overrepresentation of specific genotypes, in indicated calculations 
we used only the first isolate per unique genotype per patient (see below).  
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Phenotypic identification and antibiotic susceptibility testing of the P. aeruginosa strains 
Vitek® MS confirmed the correct identification of all P. aeruginosa isolates, (data not 
shown). A total of 130/237 (54.9%) isolates were resistant to all antibiotics tested. Detailed 
susceptibility results at the isolate level are presented in Table S1. 
Sequencing statistics and assembly quality 
The median N50 value was 225,489 bp (IQR 195,941 – 269,325 bp), and the median 
contigs number was 114 (IQR 72 – 148) . Genomes sizes ranged from 6,3Mb to 7,3Mb. FastANI 
identity values for all assemblies were over 98.5%, confirming the correct species nature of all 
isolates. Detailed sequencing statistics and QUAST [18] results are summarized in Table S2. The 
quality criteria were met for all sequences. 
in silico MLST 
We identified four major CNPA sequence types (ST235, ST357, ST823, ST446), and three 
new sequence types (ST3275, ST3277, ST3278), along with 12 minor STs (Figure 1). A goeBURST 
analysis showed that 17/19 of the sequence types found belong to an already existing P. 
aeruginosa clonal complex, while ST1189 and ST3277 were singletons (Figure 1S). Between the 
two phases of the study we observed a clear shift in the sequence type distribution: while in the 
pre-intervention phase ST235 was the dominant sequence type, in the post-intervention phase 
ST357 had emerged as the dominant ST. Only the main sequence types and ST244 were present 
in both phases of the study, the remainder were detected only in the pre-intervention phase 
(ST2951, ST620, ST274, ST1189, ST253, ST3277 and ST1182) or only in the post-intervention 
phase (ST3278, ST455, ST1076, ST555, ST312, ST260 and ST3275). Detailed results regarding the 
MLST profiles of all isolates are filed in Table S3. 
Analysis of AMR determinants 
We found 102 different AMR-related genes, from which at least 32 were acquired 
resistance genes according to literature. Additionally, 70 genes were analyzed with snippy, which 
brought to light a considerable amount of mutations directly related to antibiotic resistance (such 
as the ampC cephalosporinase or penicillin-binding proteins), and mutations in intrinsic genes 
such as RND efflux pumps and regulators. The mutational resistome obtained with snippy can be 
found in Table S4. Figure 2A presents a heat map of the AMR determinants found by RGI-CARD 
in each genotypically unique strain in the CNPA collection. Eighteen beta-lactam resistance genes 
were detected, among them genes encoding the carbapenem degrading enzymes blaGES-5 (16/130, 
12.3%), blaIMP-1 (1/130, 0.8%), blaIMP-7 (42/130, 32.3%), blaIMP-43 (1/130, 0.8%), blaVIM-2 (26/130, 
20.0%) and, blaVIM-8 (1/130, 0.8%). Interestingly, some of these genes were restricted to certain 
High-risk international clones of CNPA endemic in Indonesian ICUs
243
9
CNPA clones, including blaGES-5, blaIMP-1, blaIMP-43, blaOXA-10 and blaVIM-8 genes that were found only 
in ST235, while ST823 was the only sequence type harbouring blaVIM-2. As expected, strains 
carrying these carbapenemase genes had high imipenem and meropenem MIC values (Figure 2B, 
subplots 1 and 2).  
Figure 1. Multilocus sequence type of genotype-corrected CNPA. Sequence types are displayed in the abscissa axis. The 
ordinate axis indicates the number of genotype-corrected isolates. 
The mutational analysis of the oprD revealed 32 different missense mutations, including 
insertions leading to frameshifts. Only one isolate had an OprD sequence identical to that of the 
type strain PAO1, the rest accumulated a pattern of point mutations that led to amino acid changes 
in the primary protein structure of the OprD porin. Eight out of the 32 amino acid substitutions 
were present in more than 50% of the analyzed isolates: T103S (83/130, 63.9%), K115T (83/130, 
63.9%), F170L (82/130, 63.0%), E185Q (118/130, 90.8%), P186G (116/130, 89.2%), V189T (118/130, 
90.8%), R310E (92/130, 70.8%) and, A315G (88/130, 67.7%). Detailed results of the amino acid 
substitutions patterns can be found in Table S4. We observed that in carbapenemase non-
producing strains, certain OprD types were prone to have higher imipenem and meropenem MIC 
values (Figure 2B), but we could not establish a conclusive correlation between these porin gene 
mutations and the phenotypic susceptibility patterns of the CNPA strains. 
Four different AMR determinants known to confer reduced susceptibility to quinolones 
were found. The gyrA modification that confers resistance to quinolones in P. aeruginosa (through 
the T83I amino acid substitution) was present in 105/130 (80.8%) strains, all of them belonged 
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to the prevalent clones ST235, ST357, ST823 and to minor clone ST244. The T83I amino acid 
substitution in gyrA was present in all strains that had MICs >= 4 mg/L for ciprofloxacin (Figure 
2B, subplot 3). Two additional amino acid substitutions were found in this gene (H148N and 
D682E). Additional mutations were found in the genes gyrB, parC and parE (see Table S4). The 
aminoglycoside resistome of the collection constituted 21 different aminoglycoside-modifying 
enzymes and their variants, but the most prevalent aminoglycoside resistant determinant was the 
chromosomally encoded APH(3')-IIb which was present in all strains. Additionally, we also 
detected mutations in mexZ and fusA1, both genes previously linked to aminoglycoside resistance 
[25] (see Table S4). We observed that all these genes were associated to variable levels of
susceptibility to amikacin (Figure 2B, subplot 4). Regarding polymyxin resistance, we did not find
any of the plasmid-mediated mcr genes. With RGI-CARD we only found three AMR determinants
(arnA, basR and basS). arnA is a component of the arnT operon, but was the only gene of the operon
present. The response regulator gene (basR) of the two-component regulatory system BasRS was 
absent in all strains belonging to the prevalent clones ST357 and ST823, and the minor clones
ST1076, ST312 and ST3277. We expanded this analysis with the mutational resistome, including
other genes related to polymyxin resistance. Finally, genes related to bycyclomycin, fosfomycin
and chloramphenicol resistance (bcr-1, fosA, and catB, respectively) were present in all isolates
of the collection.
Genomic epidemiology 
The optimal threshold for distinguishing isogenic CNPA strains from other strains 
circulating in this clinical setting was found to be ≤ 5 SNPs difference. Thus, isolates that had core 
genome SNP profile differences below this threshold were considered to belong to the same, i.e. 
isogenic, strain present in this clinical setting. This cut-off value had an à priori sensitivity and 
specificity of 0.76 and 0.95, respectively (Figure 3). This 5 SNPs cut-off was compatible with the 
median SNPs differences found between isolates belonging to the dominant multi-locus sequence 
types, these median [range] SNP differences were 59 [0-82] for strains belonging to ST235, 17 [0-
32] for ST357 strains, 5 [0-54] for ST446 strains, and 5 [0-54] for ST823 strains. We observed
several cases where multiple CNPA isolates, cultured from the same patient, had the same multi
locus sequence type, but differed by more than the 5 SNPs threshold, indicating that those were
different strains circulating independently from each other in this clinical setting at the time of
the study. Such finding included cases with isolates that were acquired and those that were
imported into the ICU. Also, we observed that excluding prevalent sequence types from the
calculations had some impact on the optimal cut-off (Table S6), indicating that the genotypic
composition of a collection of CNPA isolates may generate (slightly) different optimal cut-off
values.





Figure 2. (A) Antimicrobial resistance heat map of 130 isolates of carbapenem-nonsusceptible P. aeruginosa 
(CNPA). The x axis contains only AMR determinants that were variably present in the CNPA collection. The following AMR determinants are not displayed because they were present in all isolates: APH(3′)-IIb 
(aminoglycoside resistance); blaOXA-50 (β-lactam resistance); fosA (fosfomycin resistance); bcr-1 
(bicyclomycin resistance); arnA and basS (polymyxin resistance); catB (chloramphenicol resistance); 
pmpM (multidrug and toxic compound extrusion [MATE] transporter); emrE (small multidrug resistance 
efflux pump); crpP (quinolone resistance); mexA-mexB-oprM plus mexR, nalC, and nalD plus cpxR plus 
ArmR (resistance-nodulation-cell division [RND] efflux pump plus mexAB repressors plus mexAB activator 
plus mexR inhibitor); mexC-mexD-oprJ plus NfxB (RND efflux pump plus mexCD-oprJ repressor); mexE-
mexF-oprN plus mexT plus mexS (RND efflux pump plus mexEF activator plus mexT suppressor); mexG-
mexH-mexI-opmD plus soxR (RND efflux pump plus transcriptional activator); mexJ-mexK-opmH plus 
mexL (RND efflux pump plus mexJK repressor); mexM-mexN-oprM (RND efflux pump); mexP-mexQ-opmE 
(RND efflux pump); mexV-mexW-oprM (RND efflux pump); muxA-muxB-muxC-opmB (RND efflux pump); 
triA-triB-triC-opmH (RND efflux pump); mexY plus mexZ (RND efflux pump component plus mexXY 
transcriptional regulator). (B) Bar plots showing the relation between the MIC of imipenem, meropenem, 
ciprofloxacin, and amikacin (subplots 1 to 4) and their related resistance genes found among the CNPA 
according to the literature. Vertical red dashed lines mark the EUCAST 2019 resistance breakpoints. 
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Figure 3. (Top image) Receiving operator characteristics curve. The area under the curve value is 
represented at the right corner of the image. (Bottom image) Cumulative distribution analysis 
showing the effects of variations in the cutoff SNP values on sensitivity (blue line), specificity (red 
line), and the positive likelihood ratio (green line). A vertical dashed black line shows the 




Figure 4. (A) Potential transmission events (PTEs) and (B) acquisition events (AEVs) 
from known sources during the study period. The boxes consisting of dashed lines 
represent the two intensive care units, during the preintervention and postintervention 
phases (panels on the left and right, respectively). Environmental sources of CNPA are 
depicted by green-colored sinks. Dashed lines represent transmissions (both PTEs and 
AEVs) between the two study phases; note that such transmissions have been registered 
as belonging to the postintervention phase. 
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Using the 5 SNP threshold, the PTEs occurred in the ICU setting at a rate of 27.7/100 
admissions and 38.0/100 admissions during the Pre- and Post-intervention phases, respectively. 
However, the rate of AEVs was much lower, at 9.2/100 admissions in the Pre-intervention phase 
and 11.8/100 admissions in the Post-intervention phase. The majority of AEVs were from known 
sources. However, a sizable minority of AEVs (38% and 42% in the respective phases of the study) 
were from an unknown source. 
Figure 4 displays the number of PTEs and AEVs from known sources during the study 
period. Most transmission events (PTEs and AEVs) occurred between patients within each of the 
two ICU’s, but such transmissions were also noted to occur between the two ICU wards. 
Environmental sources were mostly linked to transmissions in the ER-ICU, although we registered 
four PTEs linking Adult-ICU patients admitted during the pre-intervention phase to CNPA positive 
environmental samples cultured during the post-intervention phase, indicating long term 
circulation of these strains in the ICU. Using either of the two approaches, we did not find a 
statistically significant difference between the PTE or AEV rates in the pre- versus the post-
intervention period (p-values > 0.05). However, the observed number of AEVs in the Adult ICU 
dropped from six to zero in the pre- versus the post-intervention periods. In contrast, AEVs 
increased from eight to 17 in the ER-ICU at the same time. Similar contrary trends were observed 
while tracing PTEs.  
Finally, the calculated Hill Numbers for the collections of CPNA isolated in the pre- and 
post-intervention phases, increased (0D = 20 and 29, 1D = ≈10 and ≈20, 2D = ≈7 and ≈17), indicating 
that the genotypic diversity among the CNPA isolates cultured during the post-intervention phase 
had increased compared to the genotypic diversity of the collection before the intervention. 
DISCUSSION 
In this study, carbapenem non-susceptible Pseudomonas aeruginosa (CNPA) strains were 
found to be endemic in the ICUs of the Dr. Cipto Mangunkusumo General Hospital in Jakarta, 
Indonesia. CNPA clones are present in the ICU environment and are regularly being transmitted 
to and from patients and their immediate environment. We detected four dominant P. aeruginosa 
clones (ST235, ST357, ST446 and ST823), which have previously been shown to have spread 
worldwide and carry a repertoire of antimicrobial resistance related genes, from carbapenemases 
(such as blaIMP or blaVIM) to defective outer membrane porins (see below). We also traced CNPA 
transmissions using whole-genome sequencing (WGS). To do so we distinguished isogenic CNPA 
strains using a new methodology based on the differences in the SNP profiles of their core 
genomes and on patients from whom they were cultured. An optimal SNP threshold – below which 
strains are considered isogenic -, was calculated and then applied to trace transmissions of CNPA 






strains being cultured from different sites. In another approach we additionally used clinical data 
to infer CNPA acquisitions by patients during their ICU stay. The latter approach helped us focus 
on CNPA transmission routes relevant for nosocomial infection control. 
We also assessed the impact of an infection control intervention that was implemented in 
both ICUs to reduce transmissions of multidrug resistant pathogens. We did observe a large shift 
in the distribution of CNPA clones, together with an increase in the genotypic diversity of the CNPA 
population. However, overall the rates of acquisition of CNPA strains by patients during their ICU 
stay did not change significantly. Interestingly and inexplicably, a reduced transmission rate in 
one ICU was accompanied by an increased transmission rate of CNPA in the other ICU. Since the 
study did not include comparator ICU’s that were not intervened with, the observed changes 
might well be a reflection of the natural variation in the epidemiological dynamics of CNPA in such 
settings. Although both ICUs were under same management, the ICUs are in different buildings, 
have dedicated nursing staffs, and also differ in turnover of patients, which all might have 
confounded the effects of the intervention. Either prospective comparative study designs or quasi-
experimental designs such as interrupted time series analysis would be needed to come to more 
definitive evaluations of the effect of hygienic interventions on the epidemiology of CNPA in 
intensive care units. 
The four main sequence types described in the ICUs of this hospital in Jakarta belong to 
the so called P. aeruginosa high-risk international clones reported around the globe that are 
associated with MDR profiles: ST235 and ST357 have been extensively reported in several 
countries [26–29], while the other two main STs, ST823 and ST446, have more recently emerged. 
A recent study of MDR P. aeruginosa from Malaysia also found ST235, ST357 and ST446 in a 
hospital setting [30]. ST823 has already been described as a minor sequence type found in a 
multicentre study undertaken in the Gulf Cooperation Council states; more specifically, this clone 
was found among isolates from Qatar and the United Arab Emirates [31]. ST823 has also been 
found in India and was shown to contain an atypically long genomic island harbouring blaVIM-2 
[32]. ST446 has been isolated in small clusters or singletons in Spain, The Netherlands, Eastern-
France and Belgium, showing MDR or carbapenemase-producing profiles [33–36]. None of the 
minor sequence types of CNPA in this study harbored genes coding for carbapenemases, including 
the ST244 strains, which in a previous study from West and Central Africa have been linked to the 
production of blaVIM-2 carbapenemase [37]. One of the possible consequences of the intervention 
we cannot readily explain is the substitution of ST235 by the ST357 as the dominant clone. We 
argue that this substitution may have been the consequence of the intervention, cleaning up 
environmental sites and limiting transmission initially but not being able to maintain hygienic 
vigilance over time [14]. Alternatively, the waxing and waning of different CNPA sequence types 
over time may be the rule rather than the exception in ICUs, and this natural trend may not have 
High-risk international clones of CNPA endemic in Indonesian ICUs
251
9
been much influenced by the infection control intervention applied in our ICU setting. In addition, 
we did not observe significant changes in the number and composition of AMR determinants in 
both sequence types, which augurs against changes in antibiotic pressure as a direct cause of the 
replacement of the CNPA strains. Other hypotheses we contemplated are changes in the virulence 
patterns, as in the study of Bricio-Moreno et al. (2017) [38], or a different susceptibility to certain 
disinfectants such as chlorhexidine, as chlorhexidine bathing and mouth wash was part of the 
intervention.  
We wanted to see the full repertoire of AMR genes present in our collection, because P. 
aeruginosa is well known for its capacity to expand its resistome, especially in hospital settings, 
with the ICU as an important hotspot [39]. In a recent study determining the resistomes of 672 P. 
aeruginosa strains, Jaillard et al. identified 147 loci associated with antimicrobial resistance, 
including associations between AMR-markers and antibiotics not described before [40]. Around 
40% of the AMR determinants described in our collection overlapped with those described by 
Jaillard  et al. These differences might be explained by the huge diversity in the P. aeruginosa 
genome, i.e.: over 30 different aminoglyoside-resistance markers were present, plus mutations in 
other AMR determinants such as mexZ or fusA1 could contribute to the global aminoglycoside 
resistance of the strains [25]. Predictably, over two thirds of the genotypically unique strains 
(87/130, 66.9%) in our CNPA collection carried a carbapenem-degrading enzyme. Back in 2015, 
Potron et al. [41], published a review focusing on the AMR mechanisms and epidemiology of 
mutltidrug resistant Acinetobacter baumannii and P. aeruginosa which featured several tables 
including all known carbapenemases, including those found in our study. Interestingly, while 
blaGES-5, blaIMP1-7-43, and blaVIM-2 had been previoulsy reported in Asian countries, including Japan, 
China, India and Malysia, blaVIM-8 had only been previoulsy reported in Colombia, South America 
[42]. To our knowledge, this study is the first one to report this specific blaVIM-8 type outside of 
South America. 
Another well known mechanism of non-susceptibility to carbapenems is a defective OprD, 
an outer membrane porin in P. aeruginosa [43]. We found several amino acid substitutions and 
insertion and/or deletion events in the tertiary structure of the porin protein OprD, but we could 
not associate them to specific resistance phenotypes. All these point mutations, have been 
previously described [44–46]. Specific point mutations (i.e.: early stop codons) and frame shifts 
may be involved in the loss of the OprD porin, and, therefore, affect carbapenem susceptibility 
[47,48]. 
The spread of MDR Gram-negative bacteria carrying carbapenem resistance genes, such 
as those described above, has been largely influenced by several factors in a local and global scale, 
including pathogen and host characteristics, antibiotic prescription practices, and public health 
policies [49]. Furthermore, there is increasing evidence relating antibiotic consumption to the rise 
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of AMR. A recent retrospective study in 153 tertiary hospitals in China significantly correlated the 
use of carbapenems to the rate of carbapenem-resistant Gram-negative bacteria including P. 
aeruginosa [50]. To address this issue, antimicrobial stewardship programs (ASP) aimed to 
optimize the use of broad-spectrum antibiotics, have been set up in different forms and contexts 
[51]. According to a recent meta-analysis, ASP outcomes translate to less broad-spectrum 
antibiotics consumed and less infections by MDR microorganisms, among others benefits [52]. As 
an example, an ASP to restrict the use of carbapenems was implemented in the ICU of a Saudi 
Arabian hospital, effectively reducing the prevalence of MDR strains among the P. aeruginosa 
isolates [53]. 
Until a few years ago hospitals from high-income countries relied on techniques, such as 
PFGE, to classify nosocomial pathogens into genetically closely related groups called genotypes, 
such that their epidemiology could be ascertained. However, WGS provides maximum 
discriminatory power and is deemed able to unequivocally assign identity to them [54]. Two WGS-
typing approaches have emerged: Multi locus sequence type based on whole/core-genomes 
(wg/cgMLST) or analysis of Single Nucleotide Polymorphisms across the whole/core-genome 
(wg/cgSNP)[55,56]. Our typing method, based on cgSNPs and clinical data, depends on the quality 
of each of these data sources. The calculated optimal SNPs threshold value depends to some 
degree on the genotypic composition of the collection of isolates under analysis. We have shown 
that the diversity of bacterial population may influence this cut-off value, although it remains 
fairly similar to the 4 SNPs threshold established in other studies [11,57]. Thus, there may not be 
a single optimal SNP cut-off value to distinguish isogenic strains across different collections of P. 
aeruginosa. However, an optimal SNP cutoff value can be derived for each collection using the new 
method we describe in this report. 
We would like to point out some other limitations in our study design, the main being the 
relatively small number of environmental isolates included. Environmental samples were only 
taken once during each of the two phases of the study. Thus, much more frequent environmental 
sampling is needed, as was done for the patients themselves, to better detect the niches and 
transmission routes of CNPA in the innate environment of the ICUs. Similarly, healthcare 
personnel was sampled only twice, which may not be a sufficiently sensitive method to exclude 
their potential role as (intermediate) reservoirs, sources or vectors of CNPA. Another issue is that 
we did not target carbapenem-susceptible P. aeruginosa (CSPA) which would have allowed a 
deeper understanding of the role of resistance genes in the epidemiology of P. aeruginosa in this 
healthcare setting and would have further clarified the development of the resistome of this 
important nosocomial pathogen. Finally, all our calculations were made with a couple of custom 
Python scripts, and some manual counting. This makes the process not fully automated and, as it 
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is now, not fully scalable. Further steps to improve the scalability and reproducibility of this 
methodology are necessary.  
CONCLUSIONS 
Using whole genome sequencing in combination with clinical data, we were able to closely 
track and trace the endemic spread of isogenic carbapenem non-susceptible strains of 
Pseudomonas aeruginosa over a three year period in ICUs of a single tertiary care hospital in 
Indonesia, a large tropical middle-income country. We observed significant changes in the clonal 
composition of CNPA and provide insight into the dynamics of transmission of these strains over 
time, but could not directly ascribe these changes to the infection control interventions applied. 
Additionally, we detected the presence of high-risk international clones of multidrug resistant P. 
aeruginosa in Indonesia and present their resistomes.  
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Table S1:  
Detailed antibiotic susceptibility testing performed by Vitek 2 of the 237 isolates. Categories of 
isolates are indicated as follows: Y (yes), isolates that appear in Results in the article; N (no), 
isolates excluded from description because of genotype overrepresentation. Download Table S1, 
XLSX file, 0.02 MB. 
Table S2:  
Whole-genome sequencing quality control parameters. *, average nucleotide identity analysis: 
reference Pseudomonas aeruginosa PAO1 (GenBank accession no. NC_002516.2). 
Download Table S2, XLSX file, 0.04 MB. 
Table S3:  
Detailed results of multilocus sequence typing of the 237 isolates. Download Table S3,DOC file, 
0.05 MB. 
Table S4:  
Direct and intrinsic mutational resistomes associated with antimicrobial resistance. “Direct mut. 
Resistome” indicates missense variations leading to amino acid point mutations in genes directly associated with antimicrobial resistance to β-lactams, aminoglycosides, quinolones, and/or 
polymyxins. “Intrinsic mut. resistome” indicates intrinsic genes (mainly RND efflux pumps 
determinants and regulators) with amino acid point mutations. Blank boxes signify that no 
missense variation was found. Download Table S4, XLSX file, 0.10 MB. 
Table S5:  
Detailed information regarding the clinical data of the samples and patients included in the 
study. Download Table S5, XLSX file, 0.1 MB. 
Table S6:  
Table showing the effect of the genotypic composition of the input samples in the cutoff 
calculation. “original” indicates the current composition of the collection of carbapenem-
nonsusceptible P. aeruginosa isolates. Each “NOT” row represents removal of all isolates of one 
of the main sequence types described. Download Table S6, DOCX file, 0.01 MB. 
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Figure S1: goeBURST of the 3321 sequence types listed in the Pseudomonas aeruginosa PubMLST database 
(August 2019). Blue points represent sequence types (STs); lines connect single-locus variants (SLVs). Red 
boxes within the circles are the STs found in this study, light green boxes represent the clonal complex group 
founder, while dark green boxes the sub-group founder. ST1189 and ST3277 are singletons. 
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Figure S2: OprD types among the carbapenemase non-producing strains. Three main OprD types and 11 
other sub-types were observed. The point mutation pattern is described below, note that sub-types I.a, I.a2, 
and I.a3 additionally carried the 372(VDSSSS-YAGL-)383 indel in the C-terminal part of OprD, firstly described 
by Epp, et al. [40].I.a (S57E,  S59R, V127L,  E185Q,  P186G,  V189T,  E202Q,  I210A,  E230K,  S240T,  N262T,  T276A,  A281G,  
K296Q,  Q301E,  R310E,  A315G,  L347M,  S403A, Q424E); 
• I.a2 (V127L,  E185Q,  P186G,  V189T,  E202Q,  I210A,  E230K,  S240T,  N262T,  T276A,  A281G,  K296Q, 
Q301E,  R310E,  A315G,  L347M,  S403A, Q424E); 
• I.a3 (S57E,  S59R, V127L,  E185Q,  P186G,  V189T,  E202Q,  I210A,  E230K,  S240T,  N262T,  T276A,  A281G, 
K296Q,  Q301E,  R310E,  A315G, V352L, S403A, Q424E). 
• I.b (D43N, S57E,  S59R, V127L,  E185Q,  P186G,  V189T,  E202Q,  I210A,  E230K,  S240T,  N262T, A267S, 
A281G, K296Q, Q301E, R310G, V359L);
• I.c (S57E,  S59R, V127L); 
• II.a T103S, K115T, F170L, E185Q, P186G, V189T, R310E, A315G, G425A 
• II.a2 T103S, K115T, F170L, E185Q, P186G, V189T, R310E, G425A 
• II.a3 T103S, K115T, F170L, E185Q, P186G, V189T, R310E, A315G, C420R 
• II.a4 T103S, K115T, F170L, E185Q, P186G, V189T, R310E, A315G 
• II.b T103S, K115T, F170L 
• II.b2 D43N, T103S, K115T, F170L 
• II.c T103S, K115T, F170L, E185Q, P186G, V189T, R310E, A315G, Y350STOP 
• III W417STOP 
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Carbapenem-non-susceptible Gram-negative bacteria constitute one of the biggest threats 
to global health, especially to lower-middle income countries and one of these countries is 
Indonesia. Indonesia is the fourth populous country in the world, but at the time this study started 
only few data on such resistant strains were reported from Indonesia. Intensive care units (ICUs) 
are high-risk areas for transmission of antimicrobial-resistant bacteria. Carbapenem use is 
particularly high in this setting. However, in many cases, patients are treated with antimicrobial 
agents without proper clinical microbiological diagnosis (1), thus, the attending doctors tend not 
to really know what the causes of the patients’ illnesses are, and habitually prescribe broad 
spectrum antibiotics. To improve this situation, first we need proper local microbiological data 
and surveillance, they are key to any infection control program. 
In this thesis, we have studied the molecular epidemiology and resistance mechanisms of 
carbapenem-non-susceptible Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas 
aeruginosa in two ICUs in the National Referral Hospital in Jakarta, Indonesia. After an initial 
baseline epidemiological survey, an intervention was designed using a set of inexpensive 
measures that were deemed feasible to implement in a low-resource ICU. In this chapter, the main 
findings are summarized and discussed on the basis of objectives of the study. Furthermore, 
suggestions for further research on the different topics are presented. 
Objective 1 of the study:  To obtain a baseline insight into the epidemiology and the phenotypic 
and genetic characteristics of carbapenem-non-susceptible strains of Acinetobacter baumannii, 
Pseudomonas aeruginosa and Klebsiella pneumoniae in a low-resource ICU setting. 
In total, we included 412 patients in this baseline period, 188 were admitted to the adult 
ICU and 224 to the emergency room (ER-)ICU. Overall, 38% patients had a positive culture with 
carbapenem-non-susceptible A. baumannii-calcoaceticus complex (CNAB), and 14% patients 
carried a carbapenem-non-susceptible K. pneumoniae (CNKP) at a certain moment during their 
ICU stay.  Carbapenem-non-susceptible P. aeruginosa (CNPA) were isolated from 12% patients. 
(2-4) 
Screening cultures taken on the day of ICU admission revealed that 17% patients already 
carried CNAB, 5% carried a CNKP strain, and 4% patients carried a CNPA strain.(2-4) With this 
data, we can conclude that some patients already carry carbapenem-non-susceptible strains when 
entering the ICU. Such patients may carry more than one species of carbapenem-non-susceptible 
bacteria. (see Figure 1) This should increase our awareness that patients who are admitted into 




Figure 1. Venn Diagram of carbapenem-non-susceptible A. baumannii-calcoaceticus 
complex, K. pneumoniae and P. aeruginosa on admission 
During ICU stay 26% patients who were initially culture-negative acquired carbapenem-
non-susceptible A. baumannii-calcoaceticus complex, 9% a carbapenem-non-susceptible K. 
pneumoniae and 8% patients acquired a carbapenem-non-susceptible P. aeruginosa. The 
acquisition rate was, thus, the highest for carbapenem-non-susceptible A. baumanni-calcoaceticus 
complex (43 per 1000 patient-days at risk), followed by carbapenem-non-susceptible K. 
pneumoniae (25 per 1000 patient-days at risk) and carbapenem-non-susceptible P. aeruginosa 
(18/1000 patient- days at risk).(2-4) Again, quite a few patients acquired more than one species 
of carbapenem-non-susceptible strains.(see Figure 2) 
Figure 2. Venn Diagram of carbapenem-non-susceptible A. baumannii-calcoaceticus 
complex, K. pneumoniae and P. aeruginosa during ICU stay. 
Chapter 10
268
Acquisition of carbapenem-non-susceptible strains occurred quite rapidly after admission 
to the ICU, within one-week half of the patients that acquired such strain had already done so, and 
by day 12-14 more than 80% of patients had acquired their resistant strain. This indicates that 
the acquisition risk was always present and was always high in these ICUs. Indeed, the most 
consistent risk factor for the acquisition of the strains was the use of carbapenem antibiotics. 
Acquisition of carbapenem-non-susceptible strains of these three species was associated 
with poor outcomes, patients’ lengths of stay were much longer and the observed mortality rates 
were higher (>40%) among those with carbapenem-non-susceptible strains compared to patients 
not acquiring such strains (< 30%). Patients that acquired multiple carbapenem-non-susceptible 
strains belonging to two or more species had an even higher mortality rate (50%), where as those 
patients that acquired only a single such strain had a lower mortality rate (39.4%). In contrast, 
patients that acquired carbapenem-susceptible strains of K. pneumoniae or of P. aeruginosa had 
low mortality rates (<20%), compatible with the lower severity of their illnesses and with less 
exposure to mechanical ventilation and to carbapenem antibiotics. Thus, patients can also acquire 
susceptible strains of K. pneumoniae and of P. aeruginosa during their ICU stay. To the contrary, 
virtually all strains of A. baumannii circulating in the ICU were carbapenem-non-susceptible. 
The innate environment may contain niches where antibiotic resistant strains survive and, 
even multiply.(5, 6) Environmental screening was done twice in the baseline phase of this study; 
from a total of 400 samples we uncovered six carbapenem-non-susceptible A. baumannii-
calcoaceticus complex isolates (cultured from table, bed rails, sinks, and tap water).(2) In addition, 
one water sample (taken from a suction connector) yielded a K. pneumoniae strain that was 
carbapenem-non-susceptible. Remarkably, 16 strains of carbapenem-non-susceptible P. 
aeruginosa were isolated from the environment (3, 4) This finding was very important, since it 
clearly implicated the environment as a potentially significant source of carbapenem-non-
susceptible strains, clearly it should be a target for interventions that aim to reduce the acquisition 
rate of resistant species, especially of resistant P. aeruginosa and A. baumannii. 
Health care workers were also screened as a potential source of transmission. Only a 
single isolate from a healthcare worker (throat) was CNAB,(2) none of 24 K. pneumoniae isolates 
cultured from HCWs (out of 167 screened) were found to be carbapenem-non-susceptible,(4) and 
none of 25 P. aeruginosa strains isolated from HCWs was carbapenem-non-susceptible, suggesting 
that HCW do not play a significant role in the epidemiology of such strains in the ICU setting.(3) 
However, a clear limitation of this study was that HCW screening was done only one time, and 
only throat and rectal samples were cultured (not hands). We could, therefore, not properly assess 
the contribution of HCWs to the acquisition of such strains by ICU patients. Future studies 
entailing large scale and repeated sampling of HCWs are needed to properly define their role in 




High-level resistance of carbapenem is primarily mediated by carbapenemases. These 
enzymes occur mainly among Gram-negative pathogens such as Klebsiella pneumoniae, 
Pseudomonas aeruginosa and Acinetobacter baumannii, and may be intrinsic or mediated by 
transferable carbapenemase-encoding genes.(7)   
A. baumannii has a native chromosomal oxacillinase (OXA-51 and its variants) that usually
undergoes low-level expression, but it can potentially confer carbapenem resistance when 
upregulated following upstream insertion of the insertion element ISAba1 or ISAba9. However, it 
is A. baumannii‘s ability to acquire carbapenemases, specifically the Ambler class B metallo-β-
lactamases and class D oxacillinases and recently class A carbapenemases as well, that has 
resulted in the widespread development of carbapenem-resistant A. baumannii.(7, 8) In our study, 
we found the blaOXA-23-like gene in 92% isolates including isolates from patients, the environment 
and from the healthcare worker. The blaOXA-24-like gene was detected in a single isolate. Coexistence 
of OXA-23 with other oxacillinases and carbapenemases was found: OXA-23/OXA-58 (1 isolate), 
and OXA-23/NDM-1 (4 isolates). The blaOXA-23-like gene was always demonstrated in combination 
with the ISAba1 insertion element upstream to the OXA-23 β-lactamase. The intrinsic A. 
baumannii-calcoaceticus complex gene blaOXA-51-like was demonstrated in all isolates. In the subset 
of isolates that were subjected to whole-genome sequencing (WGS), the blaOXA-51- like gene involved 
was blaOXA-66 in 13 isolates and blaOXA-68 in one isolate.(2)  
Carbapenem-non-susceptibility among K. pneumoniae may be due to production of Ambler class A β-lactamases (e.g. KPC), class B metallo- β-lactamases (MBLs, e.g. VIM, IMP, NDM) 
or class D oxacillinases (e.g. OXA-48 like enzymes).(4, 8) The phenotypic detection test of CNKP 
indicated that 96% isolates produced an MBL. PCRs of carbapenemase genes demonstrated the 
presence of the blaNDM gene in all carbapenem-non-susceptible isolates, including isolates from 
patients and the one from the environment. None of isolates was positive for either the blaKPC or 
blaOXA-48 gene.  
Non-susceptibility to carbapenem antibiotics in P. aeruginosa is usually due to a combination of mechanisms, including β-lactamase production, increased efflux pump activity 
and outer membrane modifications or to production of a carbapenemase as a single potent 
resistance mechanism; VIM, IMP and GES-5 carbapenemases are most commonly found around 
the world.(3, 9) Using resistome analysis, CNPA was explained by the presence of various 
carbapenemase-encoding genes (blaGES-5, blaVIM-2-8, and blaIMP-1-7-43) and by mutations within the 
porin OprD.(6) Phenotypic testing showed that 57% isolates in our study produced a MBL. PCR 
demonstrated the presence of blaVIM in 30% and blaIMP in 19%, including isolates from patients 
and the environment. None of the isolates were positive for blaNDM. The presence of non-MBL 






In summary, we found that carbapenem-non-susceptibility of these three species was largely based on the production of β-lactamases, but these three species did not share the same 
genes coding for the carbapenemases. 
Hospital-associated infections (HAI) outbreaks caused by pathogenic strains have 
dramatic repercussions. In order to tackle this problem, infection-control teams use a broad range 
of typing techniques to help trace bacterial sources, to define the mode of dissemination of 
pathogenic clones and, ultimately, to hinder or preferably stop microbial spread. Most routine 
medical microbiology laboratories across the world currently use molecular biological techniques 
for this purpose. For the last decades Pulsed-Field Gel Electrophoresis (PFGE; based on the 
fragmentation of the bacterial genome by a specific enzyme) has been one of the most commonly 
used techniques in diagnostic laboratories across the world. In addition, Multi-locus variable 
number of tandem repeats (VNTR) analysis (MLVA), multi-locus sequence typing (MLST, based 
on polymorphisms in a limited number of housekeeping genes) are employed. During the last few 
years, whole-genome sequencing (WGS) has become a preferred tool for the molecular 
epidemiological surveillance of infectious diseases.(6) In the beginning of the study, we also used 
Raman spectroscopy as a rapid phenotypic bacterial typing method.(10) We were able to apply 
this technique to differentiate strains of Klebsiella pneumoniae and Acinetobacter baumannii, but 
the technique could not be applied to P. aeruginosa due to interference by pyocins that are 
intrinsic to this species. 
Typing with Raman spectroscopy revealed five major clusters of CNAB, the largest cluster 
(designated CIPTO-31) consisted of isolates obtained from patients (screening and clinical 
specimens) and isolates from the environment throughout the study period. MLST, performed for 
a subset of 14 isolates, revealed the presence of multiple sequence types (STs), which 
corresponded closely to the Raman spectroscopy clustering. Four previously identified STs 
(ST195, ST208, ST218, and ST642) as well as several new STs, and a new allele for the gpi gene 
were found in this study.(2) 
  Raman spectroscopy analysis also revealed the presence of multiple types of CNKP. There 
were three major clusters, the largest cluster (CIPTOKPN24) consisted of isolates obtained from 
patients (screening and clinical specimens) and were present in both ICUs throughout the study 
period, whereas other clones seemed to wax and wane with time.(4) A total of 97 clinical and 1 
environmental isolate were further analyzed using MLVA genotyping, identifying 30 different 
genotypes. Clustering of strains by Raman spectroscopy into three dominant groups was 
concordant with clustering by MLVA, e.g. the 20 Raman CIPTOKPN24 strains all belonged to a 
single MLVA clonal complex. Likewise, the four Raman CIPTOKPN30 strains belonged to a single 
MLVA clonal complex as did CIPTOKPN27 isolates.(4) 
MLST revealed four major clusters of CNPA (ST235, ST823, ST446 and ST357) as well as several 




and the others corresponding to ST823, ST446 and ST357. Most isolates belonged to ST235 
(patient and environmental isolates), of which 22 isolates harbored blaIMP, 24 isolates harbored 
blaGES-5 but no isolates contained blaVIM. All ST823 isolates harbored blaVIM.  
We further evaluated five molecular typing techniques using an epidemiologically well-
characterized set of CNPA. They were Multi-Locus Variable Number of Tandem Repeat (VNTR) 
Analysis (MLVA), in-silico seven-loci multi-locus sequence typing (MLST), core and whole genome 
MLST (cg/wgMLST), and core Single Nucleotide Polymorphism (SNP) analysis (cgSNP). Our 
findings show that the three latter techniques (cgMLST, wgMLST and cgSNP) provide the highest 
level of resolution allowing detailed epidemiological analysis of local outbreaks and international 
dissemination. MLVA is a suitable alternative for accurate typing of P. aeruginosa, useful in 
settings where the transition towards WGS is currently not feasible. 
Thus, the overall impression is that carbapenem-non-susceptible strains of the three species 
targeted by our studies show endemicity of a few clones that are circulating among ICU patients 
and the ICU environment. 
Objective 2 of the study:  To develop an intervention - feasible to be applied in a low-resource 
ICU setting - that may significantly reduce the risk of acquisition and infection by carbapenem-non-
susceptible A. baumannii, P. aeruginosa and K. pneumoniae. 
A large percentage of HAI are preventable through effective infection prevention and 
control (IPC) measures.(11) After phase 1, we introduced a multimodal bundle of IPC 
interventions that initially consisted of the following measures (12) and see chapter 8: 
1. A multifaceted hand hygiene improvement program.
We based the hand hygiene programs on the WHO’s Five Moments for Hand Hygiene
guidelines and tools. The hand hygiene improvement program included education with
pre- and post-questionnaires testing of knowledge and attitudes, performance feedback
and reminders, interviews, and role models as described before.(12)
2. A single round of an environmental disinfection campaign involving the whole
environment of both ICUs using 1:100 sodium hypochlorite solution. This disinfectant
solution was applied to walls, floors, doors, beds (mattresses and bed rails), sinks, overbed
tables, infusion and suction pumps and stands, monitors and ventilators including
connecting lines, surrounding counter tops including the adjacent cleaning service room.
In addition, all curtains between beds were exchanged for clean ones.
3. Routine environmental disinfection was introduced with 1:100 sodium hypochlorite
solution that included the floors, beds, and immediate surrounding of the patients. This
was done twice daily. In case of visible dirt, this was first removed with a brush and water, 
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before the application of the sodium hypochlorite solution. The intensive procedure as 
described above was repeated every two weeks in this phase. The curtains between beds 
were refreshed every 1-2 months or immediately after visible soiling.  
4. Enforced antibiotic stewardship (including daily evaluation of all antibiotic prescriptions
on weekdays).
5. All patients found positive for one or more carbapenem-non-susceptible A. baumannii-
calcoaceticus complex, K. pneumoniae, or P. aeruginosa were cohorted in one dedicated
corner of the ICU. HCWs donned mask, gown, and gloves when approaching and providing
care for cohorted patients.
6. Daily total body-washing with cloths soaked in a chlorhexidine gluconate 2% solution.
These cloths were prepared and pre-packaged individually in sealed plastic bags by the
hospital pharmacy.
7. Introduced a 2% chlorhexidine gluconate solution for decontamination of the oropharynx.
Bottles containing this solution were also prepared and provided by the hospital and used
per patient. Oral decontamination was performed 4 time daily.
Objective 3 of the study: To apply and determine the efficacy of the intervention (developed as 
specified above/ under 2) in a low-resource ICU setting. 
We measured HH knowledge and HH compliance before (at baseline) and directly after a 
multifaceted improvement program (post-intervention) and performed a re-evaluation three 
years later. The multifaceted improvement program included education, feedback, reminders, 
interviews and the use of role models. There was a statistically significant improvement in the 
median overall HH knowledge score at post-intervention. 
The overall HH compliance was 27% at baseline and significantly improved to 77% post-
intervention. For all five HH moments, the compliance of nurses and physicians separately 
improved significantly from the baseline phase to the post intervention phase, except for 
‘moment 3’ (after body fluid exposure), for which baseline rates were already high. Most of the 
compliance rates were significantly lower in both groups of healthcare workers upon follow-up 
three years later, they essentially had fallen back to pre-intervention levels. Overall, the HH 
compliance of the nurses was significantly better than the physicians’ compliance.(12) Thus, 
maintaining high levels of HH compliance requires continuous monitoring and regular 
interventions. 
We evaluated the effect on the acquisition of carbapenem-non-susceptible Acinetobacter 
baumannii-calcoaceticus complex (CNAB), Klebsiella pneumoniae (CNKP), and Pseudomonas 




species taken together there was a significant step change, from phase 1 to phase 3 in the rate of 
acquisition of carbapenem-non-susceptible strains. This significant decrease in the overall 
acquisition rate of carbapenem-non-susceptible strains of the three species was mainly caused 
by a decrease in the acquisition of carbapenem-non-susceptible A. baumannii-calcoaceticus 
complex and, to a lesser extent, K. pneumoniae. Interestingly, the acquisition rate of P. aeruginosa 
was little affected by the multimodal intervention. Within each of the two phases there was no 
major downward or upward trend observed in the rate of acquisition of resistant strains for any 
of the three species separately nor for the three species taken together, although the risk of 
acquisition was increasing slightly in phase 1.(see chapter 8) 
Using WGS in combination with clinical data, we were able to closely track and trace the 
endemic spread of isogenic carbapenem-non-susceptible strains of Pseudomonas aeruginosa 
over a 3-year period in the ICUs. We found that the number of CNPA transmissions and 
acquisitions by patients was highly variable over time but that, overall, the rates were indeed 
not significantly reduced by the intervention. Environmental sources were involved in these 
transmissions and acquisitions. Four high-risk international CNPA clones (ST235, ST823, ST357, 
and ST446) dominated, but the distribution of these clones changed significantly after the 
intervention was implemented.(6) Thus, the multimodal intervention may have altered the 
clonal composition of endemic carbapenem-non-susceptible P. aeruginosa but it did not 
eradicate the sources or niches nor affected the transmission of such strains in the ICU 
environment. 
We conclude that a multimodal intervention aiming to prevent acquisition of resistant 
strains of important ICU pathogens is essentially feasible and may be quite effective in ICUs in 
lower-middle income countries. However, even multimodal interventions may not be equally 
effective for all species harbouring antibiotic-resistant strains. 
RECOMMENDATION FOR FURTHER RESEARCH 
Our study was conducted in two ICUs in a single center, the national reference hospital in 
Jakarta, Indonesia. Since Indonesia is a large country and the fourth most populous in the world, 
the data presented in this thesis do not represent the whole of Indonesia. 
In the future, a national surveillance program for carbapenem-non-susceptible Gram-negative 
bacilli should be established, including all provinces of Indonesia, with collection of 
epidemiological data, phenotypic and genotypic resistance mechanisms, and analysis of clonal 
relatedness. An alert system should be set up for the recognition of “high-risk” clones or 
unnoticed transmission routes. For example, our finding that some patients already carried 






transmission between hospitals when patients are transferred or referred, or even suggestive 
for the existence of reservoirs in the community. These possible sources and routes should be 
further explored. 
We found a limited variety of carbapenemase genes in each species, CNAB only had blaoxa-23 and 
blaoxa-51 genes, CNKP only carried blaNDM and CNPA carried blaVIM, blaGES-5 and blaIMP.. Do we also 
find the same carbapenemase-coding genes among ICU isolate of these three species in the other 
provinces in Indonesia? That still questionable. A surveillance system would generate data on 
this. 
We concluded that a multimodal intervention aiming to prevent acquisition of resistant 
strains of important ICU pathogens is feasible and may be quite effective in ICUs in lower-middle 
income countries, but not for CNPA. Environmental cleaning seemed to be a very important part 
of the intervention with CNPA. Pseudomonas aeruginosa is a unique pathogen, this organism can 
survive over a long-term period and live in moist niches. There are two likely transmission 
pathways for CNPA, i.e. via exposure to untreated (waste)water and via contaminated sinks/taps 
in the hospital. This hypothesis needs to be explored by multicentre collaborative research 
efforts. 
We found in our study, that the use of antibiotics, especially carbapenems, in ICUs is a 
major independent risk factor for the acquisition of carbapenem-non-susceptible strains. We, 
therefore, suggest that antimicrobial stewardship should be introduced in ICU daily practice and 
that its effects on the epidemiology of antimicrobial resistance be studied in this setting.  
Also, the application of the intervention was not monitored except for the hand hygiene 
compliance. Future studies should closely monitor environmental cleaning (by observation of 
cleaning practices, and by much more environmental culturing), monitor the use of 
chlorhexidine body and oral decontamination) and last, but not least, it should be monitored 
whether patients with positive cultures are actually cohorted in the designated space or room. 
This should all be registered in future studies, essentially providing accurate data on the 
implementation of multimodal interventions. 
Finally, when building new ICU facilities, even in low-resource settings, one should pay 
much more attention to avoid creating typical environmental niches for ICU pathogens and 
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Resistentie van bacteriën voor antimicrobiële middelen is wereldwijd een toenemend 
probleem. Met name de carbapenem-ongevoelige Gram-negatieve bacteriën vormen één van de 
grootste bedreigingen voor de wereldgezondheid, vooral in lage- en middeninkomenslanden. 
Indonesië is volgens de Wereldbank een land met een laag-midden inkomen, het is tevens het 
vierde dichtstbevolkte land ter wereld. Op het moment dat deze studie begon waren er zeer 
beperkt gegevens bekend over het voorkomen van dergelijke resistente stammen in Indonesië.  
In het algemeen is er een verhoogd risico op verspreiding van resistente bacteriën in 
ziekenhuizen, en dan vooral op intensieve zorgafdelingen (“intensive care units”, IC’s). Resistente 
bacteriën worden daar meer dan elders uitgeselecteerd door frequent gebruik van 
breedspectrum antibiotica, zoals de carbapenems;  in lager-middeninkomenslanden gebeurt dat 
vaak zonder een klinische microbiologische diagnose (1). Om deze situatie te verbeteren zijn 
goede lokale microbiologische data nodig. In hoofdstuk 2 van dit proefschrift wordt een overzicht 
van de literatuur gepresenteerd die gaat over op de IC verkregen infecties in dergelijke landen. 
Uit de beperkt beschikbare gegevens bleek dat het spectrum van pathogenen op IC’s in laag-
middeninkomenslanden anders is dan in hoge-inkomenslanden: resistente Acinetobacter 
baumannii, Pseudomonas aeruginosa en Klebsiella pneumoniae worden vaker gevonden.  
In dit proefschrift hebben we de moleculaire epidemiologie en resistentiemechanismen 
van de drie genoemde soorten bacteriën bestudeerd op twee IC's in het National Referral Hospital 
in Jakarta, Indonesië: carbapenem-ongevoelige A. baumannii, P. aeruginosa en K. pneumoniae. 
Allereerst werd de uitgangssituatie onderzocht. Daarna werd een pakket van haalbare 
maatregelen ontworpen om het vóórkomen en de verspreiding van deze bacteriën op ICs te  
verminderen en dit pakket werd geïmplementeerd als interventie. Hieronder worden de 
belangrijkste bevindingen samengevat en besproken aan de hand van de doelstellingen van het 
onderzoek. 
Doelstelling 1: Een inzicht verkrijgen in de epidemiologie en de fenotypische en genetische 
kenmerken van carbapenem-ongevoelige stammen van A. baumannii, P. aeruginosa en K. 
pneumoniae in twee IC’s in Jakarta voorafgaand aan de interventie. 
Er werden 412 patiënten geïncludeerd in deze eerste fase van het onderzoek, 188 
patiënten werden opgenomen op de IC voor volwassenen (IC-V) en 224 op de IC van de 
spoedeisende hulp afdeling (IC-SEH). In totaal had 38% van de patiënten een positieve kweek met 
een carbapenem-ongevoelige A. baumannii (CNAB), en 14% van de patiënten had op een bepaald 
moment tijdens hun IC-verblijf een carbapenem-ongevoelige K. pneumoniae (CNKP) bij zich.
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Carbapenem-ongevoelige P. aeruginosa (CNPA) werden geïsoleerd bij 12% van de patiënten 
(hoofdstuk 3, 4, 5) (2-4). 
Uit screeningskweken die op de dag van opname op de IC werden afgenomen, bleek dat 
17% van de patiënten al drager was van een CNAB, 5% van een CNKP en 4% van een CNPA (2-4). 
Patiënten bleken meer dan één soort carbapenem-ongevoelige bacteriën bij zich te kunnen dragen 
(Figuur 1). Deze bevinding zou ons bewustzijn moeten vergroten dat patiënten die op de IC in 
Jakarta worden opgenomen, bronnen van dergelijke resistente bacteriën kunnen zijn. 
Figuur 1. Venn Diagram van carbapenem-ongevoelige A. baumannii, K. pneumoniae en P. 
aeruginosa bij opname 
Tijdens hun IC-verblijf kreeg 26% van de patiënten die aanvankelijk bij opname negatieve 
screeningskweken hadden, een CNAB, 9% een CNKP en 8% een CNPA. De acquisitiefrequentie was 
dus het hoogst voor CNAB (43 per 1000 patiëntdagen), gevolgd door CNKP (25 per 1000 
patiëntdagen) en CNPA (18 per 1000 patiëntdagen) (2-4). Nogal wat patiënten werden met meer 
dan één soort carbapenem-ongevoelige bacteriën besmet (Figuur 2). 
Acquisitie van carbapenem-ongevoelige bacteriestammen trad vrij snel op na opname op 
de IC, binnen een week had de helft van de patiënten die een dergelijke stam kregen deze al 
opgedaan, en op dag 12-14 had meer dan 80% van de patiënten hun resistente stam. Dit geeft aan 
dat het acquisitierisico altijd aanwezig en altijd hoog was op deze IC's. De meest consistente 





Figuur 2. Venn Diagram van carbapenem-ongevoelige A. baumannii, K. pneumoniae en P. 
aeruginosa verkregen tijdens verblijf op de IC 
Het tijdens het IC verblijf verkrijgen van één van deze drie carbapenem-ongevoelige 
bacteriën was negatief geassocieerd met het resultaat van de IC-zorg. De verblijfsduur van de 
patiënten was veel langer en de waargenomen sterftecijfers waren hoger (> 40%) onder degenen 
met carbapenem-ongevoelige bacteriën in vergelijking met patiënten die dergelijke stammen niet 
verworven (<30%). Patiënten die twee of drie van de carbapenem-ongevoelige bestudeerde 
bacteriën verkregen hadden een nog hoger sterftecijfer (50%), terwijl patiënten die slechts met 
één zo’n resistente stam besmet werden een lager sterftecijfer hadden (39,4%). Patiënten die 
carbapenem-gevoelige stammen van K. pneumoniae of P. aeruginosa verkregen hadden juist een 
lage mortaliteit (<20%), een uitkomst dat paste bij de lagere ernst van hun ziekte en met minder 
blootstelling aan mechanische beademing en carbapenem antibiotica. Patiënten kunnen dus ook 
gevoelige stammen van K. pneumoniae en P. aeruginosa verkrijgen tijdens hun IC-verblijf. De A. 
baumannii stammen die op de IC circuleerden waren echter vrijwel allemaal ongevoelig voor 
carbapenem antibiotica.  
De ziekenhuisomgeving kan niches bevatten waar antibioticaresistente bacteriën 
overleven en zelfs vermenigvuldigen (5, 6). Het kweken van de omgeving werd tweemaal 
uitgevoerd in de eerste fase van deze studie; uit in totaal 400 kweken hebben we zes CNAB-
stammen geïsoleerd (uit monsters afgenomen van tafels, bedhekken, gootstenen en kraanwater) 
(2). Bovendien leverde één watermonster (genomen uit een afzuigaansluiting) een K. 
pneumoniae-stam op die niet gevoelig was voor de carbapenems. Opmerkelijk was dat 16 
carbapenem-ongevoelige stammen van P. aeruginosa uit de omgeving werden geïsoleerd (3, 4). 
Deze bevindingen zijn belangrijk, omdat het duidelijk maakt dat de IC-omgeving een potentieel 
belangrijke bron is voor carbapenem-ongevoelige stammen; de IC-omgeving zou dus een doel 
moeten zijn voor interventies die gericht zijn op het verminderen van de acquisitie van resistente 
bacteriën, met name van resistente P. aeruginosa en A. baumannii. 
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Gezondheidspersoneel werd ook gescreend als mogelijke bron.  Slechts één isolaat van 
een gezondheidsmedewerker (keel) bleek een CNAB (2), géén van de 24 K. pneumoniae-isolaten 
gekweekt uit 167 personeelsleden van de IC bleek ongevoelig voor carbapenems te zijn (4), en 
geen van de 25 gevonden P. aeruginosa stammen was ongevoelig voor carbapenem antibiotica, 
wat suggereert dat gezondheidsmedewerkers geen significante rol spelen in de epidemiologie van 
dergelijke stammen op de IC (3). Een beperking van deze studie was echter dat het kweken van 
personeel slechts één keer werd uitgevoerd en dat alleen keel- en rectumkweken werden 
geanalyseerd (geen handen). We konden daarom de bijdrage van personeel aan de epidemiologie 
van dergelijke stammen op de IC’s niet goed inschatten. Toekomstige studies met uitgebreidere 
en herhaalde bemonstering van gezondheidsmedewerkers zijn nodig om hun rol in de 
epidemiologie van CNAB, CNKP en CNPA in IC's beter te definiëren. 
Resistentie tegen carbapenem antibiotica wordt voornamelijk gemedieerd door 
carbapenemasen. Deze enzymen komen met name voor bij Gram-negatieve pathogenen zoals K. 
pneumoniae, P. aeruginosa en A. baumannii, en kunnen intrinsieke eigenschap van de bacterie zijn. 
Anderszins kunnen dergelijke enzymen worden verkregen door overdracht van carbapenemase-
coderende genen van resistente stammen naar gevoelige soortgenoten(7).   
A. baumannii heeft een chromosomaal oxacillinase (OXA-51 en zijn varianten) die
gewoonlijk een lage expressie heeft, c.q. niet leidt tot klinisch relevante resistentie;  maar deze 
genen kunnen carbapenem-resistentie leveren wanneer stroomopwaarts het insertie-element 
ISAba1 of ISAba9 aanwezig is. Het is echter het vermogen van A. baumannii om carbapenemasen 
te verwerven, met name de Ambler klasse B metallo-β-lactamasen (MBL, bijv. NDM, VIM, IMP) en 
klasse D oxacillinasen en recent ook klasse A carbapenemasen, dat heeft geresulteerd in het 
wijdverspreid opduiken van carbapenem-resistente A. baumannii (7, 8). In onze studie vonden we 
het blaOXA-23-like gen in 92% van de geïsoleerde stammen, dit is inclusief de isolaten van patiënten, 
de omgeving en van een gezondheidsmedewerker. Het blaOXA-24-like gen werd gedetecteerd in één 
stam. Het metallo-β-lactamase blaNDM-1 werd bij 4 blaOXA-23-like-positieve isolaten aangetoond. Het 
intrinsieke A. baumannii-calcoaceticus-complex gen blaOXA-51-like werd in alle isolaten aangetoond. 
In een subset van isolaten die werden geanalyseerd met “whole genome sequencing” (WGS) bleek 
het om het blaOXA-66 gen te gaan in 13 isolaten en blaOXA-68 in één isolaat (2).  
Ook bij K. pneumoniae kan carbapenem-ongevoeligheid veroorzaakt worden door de productie van Ambler klasse A β-lactamases (bijv. KPC), klasse B MBL of klasse D oxacillinases 
(bijv. OXA-48) (4, 8). De fenotypische detectietest van CNKP gaf aan dat 96% van de isolaten een 
MBL produceerden. PCR's van carbapenemase-genen toonden de aanwezigheid van blaNDM aan in 
alle carbapenem-ongevoelige isolaten, inclusief isolaten van patiënten en die uit de omgeving. 




De carbapenem-ongevoeligheid bij P. aeruginosa is meestal te wijten aan een combinatie van mechanismen, waaronder de productie van β-lactamase, een activiteit van hun 
effluxpompen, en aan veranderingen van het buitenmembraan van deze bacteriën, óf het is te 
wijten aan de productie van een carbapenemase als één enkel krachtig resistentiemechanisme: 
VIM-, IMP- en GES-5-carbapenemasen worden wereldwijd het meest aangetroffen (3, 9). Met 
behulp van resistoomanalyse kon de carbapenem-ongevoeligheid bij de CNPA verklaard worden 
door de aanwezigheid van verschillende carbapenemase-coderende genen (blaGES-5, blaVIM-2-8, en 
blaIMP-1-7-43) en door mutaties in de porine OprD (hoofdstuk 9) (6). blaVIM kwam het meest 
frequent voor (30% van de isolaten) (3). 
Samenvattend vonden we dat de ongevoeligheid voor carbapenems van deze drie bacteriën grotendeels gebaseerd was op de productie van β-lactamasen die carbapenem 
antibiotica kunnen afbreken, maar deze drie bacteriesoorten hadden niet dezelfde 
carbapenemase genen. 
Uitbraken van ziekenhuis- of zorg-gerelateerde infecties, zeker met resistente bacteriën, 
hebben dramatische gevolgen. Het is daarom belangrijk om bacteriële bronnen op te sporen en 
de verspreidingsroute van pathogene klonen te bepalen, zodat uiteindelijk de verspreiding van de 
pathogenen kan worden tegengegaan en bij voorkeur gestopt. Een breed scala aan 
typeringstechnieken is hiervoor beschikbaar. De meeste medische microbiologische laboratoria 
in de hele wereld gebruiken momenteel moleculair-biologische technieken voor dit doel. “Pulsed-
Field Gel Electrophoresis” (PFGE; gebaseerd op de fragmentatie van het bacteriële genoom door 
een specifiek enzym) is de laatste decennia en wereldwijd een van de meest gebruikte technieken. 
Deze techniek is lang beschouwd als “gouden standaard”, maar heeft ook diverse beperkingen. 
Naast PFGE worden tegenwoordig “Multi-locus Variable Number of Tandem Repeats” (VNTR) 
analyse (MLVA) en de multilocus sequentietypering (MLST, gebaseerd op polymorfismen in een 
beperkt aantal huishoudgenen) gebruikt. In de afgelopen jaren is “whole genomen sequencing” 
(WGS) opgekomen als instrument voor de moleculaire epidemiologische surveillance van 
pathogenen (6). In het begin van onze studie hebben we Raman-spectroscopie gebruikt, een snelle 
en goedkope fenotypische bacteriële typeringsmethode (10). We waren in staat om deze techniek 
toe te passen om stammen van K. pneumoniae en A. baumannii te analyseren, maar de techniek 
kon niet worden toegepast op P. aeruginosa vanwege de pyocyanines die deze bacteriësoort 
produceren. 
De analyse met Raman-spectroscopie bracht vijf grote clusters van CNAB aan het licht. Het 
grootste cluster (aangeduid als CIPTO-31) bestond uit isolaten verkregen van patiënten (van 
screeningskweken en klinische kweken) en isolaten uit de omgeving. MLST, uitgevoerd voor een 
subset van 14 isolaten, onthulde de aanwezigheid van meerdere sequentietypen (ST's), die nauw 
overeenkwamen met de Raman-spectroscopieclustering. Vier eerder geïdentificeerde ST's 
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(ST195, ST208, ST218 en ST642) evenals verschillende nieuwe ST's werden in deze studie 
gevonden (2). 
  Raman-spectroscopieanalyse onthulde ook de aanwezigheid van meerdere typen CNKP. 
Er waren drie grote clusters, het grootste cluster (CIPTOKPN24) bestond uit isolaten verkregen 
van patiënten (van screeningskweken en klinische kweken) en waren aanwezig op beide IC's 
gedurende de onderzoeksperiode, terwijl andere klonen leken te komen en gaan over de tijd (4). 
Een totaal van 97 klinische en 1 isolaat uit de IC-omgeving werden verder geanalyseerd met 
behulp van MLVA-genotypering, waarbij 30 verschillende genotypen werden geïdentificeerd. De 
clustering van isolaten door Raman-spectroscopie in drie dominante groepen kwam overeen met 
clustering door MLVA (4).  
Ook de CNPA isolaten werden op meerdere manieren geanalyseerd. Met MLST werden vier 
belangrijke clusters van CNPA geïdentificeerd (ST235, ST823, ST446 en ST357) evenals 
verschillende nieuwe sequentietypen. Met MLVA werden vijf grote clusters onderscheiden, twee 
behorend tot ST235 en de andere overeenkomend met ST823, ST446 en ST357. De meeste 
isolaten behoorden tot ST235 (patiënten- en omgevingsisolaten), waarvan 22 isolaten blaIMP 
bevatten en 24 isolaten blaGES-5. Er waren geen ST235 isolaten met een blaVIM gen. Daarentegen 
was een blaVIM gen wel aanwezig in alle ST823-isolaten.  
Vervolgens evalueerden we vijf moleculaire typeringstechnieken voor de CNPA: MLVA, 
MLST met zeven loci, “core genome” en “whole genome” MLST (cg / wgMLST) en “core genome 
Single Nucleotide Polymorphism” (cgSNP) analyse (hoofdstuk 6). Onze bevindingen tonen aan 
dat de drie laatste technieken (cgMLST, wgMLST en cgSNP) het hoogste resolutieniveau bieden, 
waardoor gedetailleerde epidemiologische analyse van lokale uitbraken en van eventuele 
internationale verspreiding mogelijk is. MLVA is een geschikt alternatief voor het typeren van P. 
aeruginosa daar waar de overgang naar WGS momenteel niet haalbaar is. 
De algemene conclusie van deze analyses is dat de drie carbapenem-ongevoelige 
bacteriësoorten waar ons onderzoek op gericht was, endemisch voorkomen op de twee IC’s in 
Jakarta, waarbij slechts enkele persisterende klonen meer frequent worden gevonden bij 
patiënten en in de omgeving. 
Doelstelling 2: Een interventie ontwikkelen - haalbaar voor toepassing op een IC met weinig 
middelen - die het risico op het verkrijgen van een carbapenem-ongevoelige A. baumannii, P. 
aeruginosa en K. pneumoniae aanzienlijk zou kunnen verminderen. 
Zorggerelateerde infecties en verspreiding van pathogenen die deze veroorzaken kan 
worden voorkomen door effectieve infectiepreventiemaatregelen (11). Na de studieperiode 




infectiepreventiemaatregelen die aanvankelijk bestond uit de volgende onderdelen (hoofdstuk 
8) (12):
8. Een verbeterprogramma voor handhygiëne.
Dit verbeterprogramma werd gebaseerd op de handhygiënerichtlijnen en -hulpmiddelen
van de Wereldgezondheidsorganisatie (“World Health Organization”, WHO). Het
programma omvatte onderwijs met vragenlijsten, het testen van kennis en attitudes,
prestatiefeedback, geheugensteuntjes, interviews en het trainen van rolmodellen (12).
9. Een enkele ronde van schoonmaak en desinfectie waarbij de hele omgeving van beide IC's
met een 1:100 natriumhypochlorietoplossing werd gedesinfecteerd. Deze
desinfecterende oplossing werd aangebracht op wanden, vloeren, deuren, bedden 
(matrassen en bedhekken), wasbakken, bedtafels, infuus- en afzuigpompen en palen,
beeldschermen en ventilatoren inclusief aansluitleidingen. Ook de aangrenzende
spoelruimte/bijkeuken werd hierin meegenomen. Bovendien werden alle gordijnen
tussen de bedden vervangen door schone.
10. Routinematige omgevingsdesinfectie met 1:100 natriumhypochlorietoplossing werd
geïntroduceerd voor de vloeren, bedden en directe omgeving van de patiënten. Dit werd 
tweemaal daags gedaan. Bij zichtbaar vuil werd dit eerst verwijderd met een borstel en
water, voordat de natriumhypochlorietoplossing werd aangebracht. De intensieve
procedure zoals beschreven bij 2. werd bovendien elke twee weken herhaald. De
gordijnen tussen de bedden werden elke 1-2 maanden verschoond of onmiddellijk na
zichtbare vervuiling.
11. Versterkt “antibiotic stewardship” (inclusief dagelijkse evaluatie van alle
antibioticavoorschriften van opgenomen patiënten op weekdagen).
12. Alle patiënten die positief werden bevonden voor één of meer carbapenem-ongevoelige
bacteriën (CNAB, CNKP, CNPA) werden in een daarvoor aangewezen hoek van de IC-
afdeling geplaatst, in een zogenaamd “cohort”. Bij het verlenen van zorg aan deze
patiënten trokken gezondheidsmedewerkers een isolatiejas, een mondneusmasker en
handschoenen aan.
13. Dagelijkse wassen van het lichaam van alle patiënten met doekjes gedrenkt in een
chloorhexidine gluconaatoplossing van 2%. Deze doekjes werden door de
ziekenhuisapotheek zelf bereid en per stuk verpakt.
14. Introductie van een 2% chloorhexidinegluconaatoplossing voor decontaminatie van de
orofarynx. Flessen met deze oplossing werden ook bereid en geleverd door de




Doelstelling 3: Het toepassen en bepalen van de effectiviteit van de interventie (ontwikkeld zoals 
hierboven bij doelstelling 2 gespecificeerd) op twee IC’s met beperkte middelen in een ziekenhuis in 
Jakarta. 
Het verbeterprogramma voor handhygiëne staat beschreven in hoofdstuk 7. We hebben 
de kennis en compliantie van handhygiëne gemeten vóór en direct na het verbeterprogramma 
(de interventie) en voerden drie jaar later opnieuw een meting van de compliantie uit. Direct na 
het verbeterprogramma was er een statistisch significante verbetering in de mediane algehele 
kennisscore. De algehele handhygiënecompliantie was 27% bij aanvang en verbeterde 
significant tot 77% na de interventie. Voor alle vijf momenten van handhygiëne verbeterde de 
compliantie van verpleegkundigen en artsen afzonderlijk significant van de baselinefase tot de 
post-interventiefase, behalve voor ‘moment 3’ (na blootstelling aan lichaamsvloeistof), waarvoor 
de baselinecijfers al hoog waren. Bij follow-up drie jaar later bleken meeste compliantie 
percentages weer significant lager in beide groepen gezondheidswerkers, ze waren 
teruggevallen tot het niveau van vóór de interventie. Over het algemeen was de compliantie van 
de verpleegkundigen significant beter dan die van de artsen (12). Het behouden van een hoog 
niveau van naleving van handhygiëne vereist dus continue monitoring en regelmatige 
interventies. 
In hoofdstuk 8 beschrijven we een analyse van het effect van het hele pakket aan 
maatregelen op de acquisitie van carbapenem-ongevoelig A. baumannii (CNAB), K. pneumoniae 
(CNKP) en P. aeruginosa (CNPA) door patiënten op de twee IC’s in Jakarta. De opzet was dus een 
quasi-experimentele voor-en-na-studie. De statistische analyse (met een regressiemodel) toonde 
aan dat er voor alle drie de bacteriën tezamen een significante stapsgewijze verandering, c.q. 
vermindering was in de kans op het verkrijgen van carbapenem-ongevoelige stammen, van fase 
1 (de fase voor de interventie) naar fase 3 (de fase na de interventie). Deze significante afname 
in de totale acquisitie van carbapenem-ongevoelige stammen van de drie soorten werd 
voornamelijk veroorzaakt door een afname in de acquisitie van CNAB, en in mindere mate CNKP. 
Interessant genoeg werd de acquisitiesnelheid van CNPA weinig beïnvloed door de multimodale 
interventie. Binnen elk van de twee fasen was er géén sprake van een belangrijke opwaartse of 
neerwaartse trend in de mate van verwerving van resistente stammen voor een van de drie 
soorten afzonderlijk noch voor de drie soorten samen, hoewel het risico van acquisitie licht 
toenam in fase 1. 
Een verdere analyse van het effect van de interventie op CNPA is beschreven in 
hoofdstuk 9. Met behulp van WGS in combinatie met klinische gegevens waren we in staat om 
de endemische verspreiding van isogene CNPA stammen gedurende de onderzoeksperiode van 




transmissies en acquisities door patiënten in de loop van de tijd zeer variabel was, maar dat de 
percentages over het algemeen inderdaad niet sterk werden verminderd door de interventie. Bij 
deze transmissies en acquisities waren bronnen in de omgeving betrokken. Vier CNPA-klonen, 
die bekend staan als intenationale hoog-risico klonen (ST235, ST823, ST357 en ST446) 
overheersten, maar de distributie van deze klonen veranderde aanzienlijk nadat de interventie 
was geïmplementeerd (6). De multimodale interventie kan dus de klonale samenstelling van 
endemische CNPA hebben veranderd, maar het heeft de omgevingsbronnen van CNPA niet 
gesaneerd, noch heeft het de overdracht van dergelijke stammen in de IC sterk belemmerd. 
We concluderen dat een multimodale interventie gericht op het voorkomen en acquisitie 
van resistente stammen van belangrijke pathogenen haalbaar is en behoorlijk effectief kan zijn 
op IC's in landen met een lager-middeninkomensniveau. Echter, zelfs multimodale interventies 
zijn mogelijk niet even effectief voor alle antibioticaresistente stammen. 
In hoofdstuk 10 worden de belangrijkste resultaten besproken en in bredere context 
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Diskusi Dan Ringkasan (Bahasa Indonesia) 
Bakteri gram negative yang resisten terhadap Karbapenem merupakan salah satu 
ancaman paling berbahaya pada kesehatan global, terutama di  negara yang memiliki penghasilan 
yang menengah ke bawah dan salah satunya adalah Indonesia. Indonesia merupakan negara 
dengan jumlah penduduk keempat terbesar di dunia, tetapi pada saat studi ini dimulai, data 
mengenai strain resisten ini sangat sedikit yang sudah dilaporkan di Indonesia. Unit perawatan 
intensif (ICU) adalah area yang beresiko tinggi terjadinya transmisi bakteri yang resisten 
terhadap antimikroba. Penggunaan karbapenem sangat tinggi di ICU. Namun, dalam banyak 
kasus, pasien diobati dengan antimikroba tanpa diagnosis mikrobiologi klinik (1) demikian, 
dokter penanggung jawab cenderung tidak benar-benar mengetahui apa penyebab infeksi pada 
pasien, dan biasanya meresepkan antibiotik spektrum luas. Untuk memperbaiki situasi ini, 
pertama-tama kita membutuhkan data surveilans mikrobiologi lokal yang tepat, karena data ini 
merupakan kunci untuk setiap program pengendalian infeksi. 
Dalam tesis ini, kami meneliti epidemiologi molekuler dan mekanisme resistensi 
carbapenem-non-susceptible Acinetobacter baumannii, Klebsiella pneumoniae  dan  Pseudomonas 
aeruginosa  di dua ICU di Rumah Sakit Rujukan Nasional di Jakarta, Indonesia. Setelah survei 
epidemiologi awal dilakukan, intervensi dirancang menggunakan serangkaian tindakan yang 
murah dan dapat untuk diterapkan pada ICU dengan sumber daya yang terbatas atau dapat 
diterapkan di seluruh wilayah di Indonesia. Dalam bab ini, temuan utama dirangkum dan dibahas 
berdasarkan tujuan penelitian. Selain itu, saran untuk penelitian lebih lanjut tentang berbagai 
topik juga disajikan. 
1. Tujuan 1: Untuk mendapatkan data dasar tentang epidemiologi dan karakteristik fenotipik 
dan genetik dari strain carbapenem-non-susceptible  Acinetobacter baumannii, 
Pseudomonas aeruginosa  dan  Klebsiella pneumoniae di ICU dengan sumber daya terbatas.
Total sebanyak 412 inklusi pasien dalam periode ini, 188 pasien dirawat di ICU dewasa 
dan 224 pasien di ICU IGD (ER-ICU). Secara keseluruhan, 38% pasien memiliki kultur positif 
dengan carbapenem-non-susceptible A. baumannii-calcoaceticus complex (CNAB) dan 14% pasien 
positif dengan carbapenem-non-susceptible K. pneumoniae (CNKP) selama dirawat di ICU. 
Carbapenem-non-susceptible  P. aeruginosa  (CNPA) diisolasi dari 12% pasien. (2-4) 
Kultur untuk skrining yang diambil pada hari pertama dirawat di ICU ditemukan bahwa 
17% pasien sudah terkolonisasi dengan CNAB, 5% membawa strain CNKP, dan 4% pasien 
membawa strain CNPA. (2-4) Dengan data ini, kita dapat menyimpulkan bahwa beberapa pasien 
sudah membawa strain carbapenem-non-susceptible saat mulai rawat di ICU. Pasien tersebut 




Gambar 1. Diagram Venn carbapenem-non-susceptible A. baumannii-calcoaceticus 
complex, K. pneumoniae dan P. aeruginosa pada saat admisi. 
Hal ini  harus meningkatkan kesadaran kita bahwa pasien yang dirawat di ICU adalah 
sumber penularan potensial dari strain tersebut. 
Selama dirawat di ICU, 26% pasien yang awalnya kultur-negatif mendapatkan 
carbapenem-non susceptible A. baumannii-calcoaceticus  complex, 9% carbapenem-non-
susceptible  K. pneumoniae dan 8% pasien positif carbapenem-non-susceptible P. aeruginosa. 
Tingkat akuisisi yang tertinggi adalah A.  baumanni-calcoaceticus complex (43 per 1000 hari 
pasien berisiko), diikuti oleh carbapenem-non-susceptible  K. pneumoniae  (25 per 1000 hari 
pasien berisiko) dan carbapenem-non-susceptible P. aeruginosa  (18/1000 hari pasien beresiko) 
(2-4) Sekali lagi, beberapa pasien memperoleh lebih dari satu spesies carbapenem-non-susceptible 
strain.( lihat Gambar 2)  
Akuisisi carbapenem-non-susceptible strain terjadi secara cepat setelah pasien masuk ke 
ICU, dalam waktu satu minggu, setengah dari pasien mendapatkan strain tersebut, dan pada hari 
12-14 lebih dari 80% pasien telah memperoleh starin resisten tersebut. Ini menunjukkan bahwa 
risiko akuisisi selalu ada dan selalu tinggi dalam kondisi ICU ini. Memang, faktor risiko yang paling 
konsisten untuk akuisisi strain resisten ini adalah penggunaan antibiotik karbapenem.
Chapter 10
290
Gambar 2. Diagram Venn carbapenem-non-susceptible A. baumannii-calcoaceticus 
complex, K. pneumoniae dan P. aeruginosa selama dirawat di ICU. 
Akuisisi strain carbapenem-non-susceptible dari ketiga spesies ini dikaitkan dengan luaran 
pasien yang buruk, lama tinggal pasien yang jauh lebih lama dan tingkat kematian yang  lebih 
tinggi (>40%) di antara mereka dengan carbapenem-non-susceptible dibandingkan dengan pasien 
yang tidak memperoleh strain seperti itu (< 30%). Pasien yang terinfeksi dengan dua spesies atau 
lebih strain carbapenem-non-susceptible memiliki tingkat kematian yang lebih tinggi (50%), di 
mana pasien yang hanya terinfeksi oleh  satu strain tersebut memiliki tingkat kematian yang lebih 
rendah (39,4%). Sebaliknya, pasien yang memperoleh carbapenem-susceptible K. pneumoniae  
atau  P. aeruginosa  memiliki tingkat kematian yang rendah (<20%), sesuai dengan tingkat 
keparahan penyakit mereka yang lebih rendah dan dengan paparan ventilasi mekanis dan 
antibiotik karbapenem yang lebih sedikit. Dengan demikian, pasien juga dapat memperoleh strain  
K. pneumoniae dan  P. aeruginosa yang sensitif  selama dirawat di ICU. Sebaliknya, hampir semua 
strain  A. baumannii yang beredar di ICU adalah carbapenem-non-susceptible.
Lingkungan ICU dapat mengakibatkan kondisi strain resisten antibiotik bertahan dan, 
bahkan berkembang biak. (5, 6) Skrining lingkungan dilakukan dua kali dalam fase dasar 
penelitian ini; dari total 400 sampel, kami menemukan enam isolat carbapenem-non-susceptible 
A. baumannii-calcoaceticus complex (kultur dari meja, rel/pinggir tempat tidur, wastafel, dan air 
keran). (2) Selain itu, satu sampel air (diambil dari konektor suction) menghasilkan strain 
carbapenem-non-susceptible K. pneumoniae. Luar biasanya, 16 strain carbapenem-non-susceptible 
P. aeruginosa  terisolasi dari lingkungan  tersebut (3, 4) Temuan ini sangat penting, karena jelas 
implikasinya bahwa lingkungan dapat berpotensi menjadi sumber penularan dari strain 
carbapenem-non-susceptible signifikan, dan harus menjadi target intervensi yang bertujuan untuk 





Skrining terhadap petugas kesehatan juga dilakukan sebagai potensi sumber penularan. 
Hanya satu isolasi dari tenaga kesehatan (tenggorokan) adalah CNAB,(2)dari 24  isolat K. 
pneumoniae  yang dikultur dari petugas kesehatan (dari 167 yang diskrining) tidak ada yang 
merupakan isolat carbapenem-non-susceptible,(4) strain P. aeruginosa yang diisolasi dari petugas 
kesehatan, tidak ada yang c carbapenem-non-susceptible. Hal ini menunjukkan bahwa HCW tidak 
memainkan peran penting dalam epidemiologi strain CNAB, CNKP and CNPA di ICU. (3) Namun, 
keterbatasan atau limitasi yang jelas dari penelitian ini adalah bahwa skrining HCW dilakukan 
hanya satu kali, dan hanya kultur dari swab tenggorok dan rektal (bukan dari tangan). Oleh karena 
itu, kita tidak bisa menilai dengan benar kontribusi HCW untuk akuisisi strain tersebut pada 
pasien ICU. Studi di masa depan yang berskala besar dan pengambilan sampel HCW berulang 
diperlukan untuk mendefinisikan peran mereka dengan benar dalam epidemiologi CNAB, CNKP 
dan CNPA di ICU. 
Resistensi karbapenem yang tinggi dimediasi oleh enzim karbapenemase. Enzim ini 
muncul terutama pada bakteri Gram-negatif seperti Klebsiella pneumoniae,  Pseudomonas 
aeruginosa  dan  Acinetobacter baumannii, dan mungkin intrinsik atau dimediasi oleh gen 
Carbapenemase-encoding yang dapat ditransfer. (7) 
A. baumannii memiliki kromosom oksisilinase (OXA-51 dan variannya) yang biasanya 
diekspresikan secara rendah, tetapi berpotensi berubah menjadi karbapenem resisten ketika 
diupregulasi setelah upstream insertion elemen Insertion tersebut ISAba1  atau ISAba9. Namun, 
itu adalah  kemampuan A. baumanni untuk memperoleh enzim karbapenemase, khususnya kelas 
Ambler B metallo-lactamases dan oxacillinases kelas D dan baru-baru ini karbapenemase kelas A 
juga, yang mengakibatkan penyebaran luas carbapenem-resistant A. baumannii. (7, 8) Dalam 
penelitian ini, kami menemukan gen blaOXA-23-like  pada 92% isolat termasuk isolat dari pasien, 
lingkungan dan dari petugas kesehatan. Gen blaOXA-23-like terdeteksi dalam satu isolat. Koeksistensi 
OXA-23 dengan oksisilinase dan karbapenemase lainnya ditemukan: OXA-23/OXA-58 (1 isolat), 
dan OXA-23/NDM-1 (4 isolat). Gen  blaOXA-23-like  selalu ditemukan berkombinasi dengan ISAba1 
insertion element upstream  ke OXA-23 β-laktamase. Gen intrinsik A. baumannii-calcoaceticus 
complex    blaOXA-51-like  didapatkan pada semua isolat. Dalam beberapa isolat yang diidentifikasi 
dengan  whole-genome sequencing (WGS),  gen blaOXA-51- like yang terlibat adalah  blaOXA-66 pada 13 
isolat dan blaOXA-68  pada satu isolat. (2) 
Resistensi terhadap karbapenem pada K. pneumoniae mungkin disebabkan oleh produksi 
enzim Ambler kelas A β-lactamases (misalnya KPC), kelas B metallo- β-lactamases (MBLs, misalnya 
VIM, IMP, NDM) atau oxacillinases kelas D (misalnya OXA-48 seperti enzim). (4, 8) Tes deteksi 
fenotipik CNKP menunjukkan bahwa 96% isolat menghasilkan enzim MBL. PCR gen 






termasuk isolat dari pasien dan lingkungan. Tidak ada satu isolat pun yang positif terhadap  gen 
blaKPC  atau  blaOXA-48 . 
 Resistensi terhadap antibiotik karbapenem pada P. aeruginosa biasanya disebabkan 
oleh kombinasi beberapa mekanisme resistensi, termasuk produksi β-lactamase, peningkatan 
aktivitas pompa efflux dan modifikasi membran luar atau produksi enzim karbapenemase 
sebagai mekanisme tunggal resistensi yang kuat; VIM, IMP dan GES-5 adalah enzim 
karbapenemase paling sering ditemukan di dunia. (3, 9) Dengan menggunakan analisis 
resistome, CNPA dijelaskan oleh adanya berbagai gen pengkode karbapenemase (blaGES-5,  blaVIM-
2-8,d an  blaIMP-1-7-43) dan dengan adanya mutasi porin oprD. (6) Pengujian fenotipik menunjukkan 
bahwa 57% isolat dalam penelitian kami menghasilkan enzim MBL. PCR menunjukkan adanya 
gen blaVIM dalam  30%  isolay dan  blaIMP dalam 19% isolat, termasuk isolat dari pasien dan 
lingkungan. Tidak ada isolat yang positif untuk  blaNDM.. Kehadiran gen non-MBL  blaGES-5  
terdeteksi dalam 20% isolat. (3) 
Simpulan, kami menemukan bahwa carbapenem-non-susceptible dari ketiga spesies ini sebagian besar berdasarkan pada produksi enzim β-laktamases, tetapi ketiga spesies ini tidak 
mengkode gen karbapenemase yang sama. 
Hospital-associated infections (HAI) yang disebabkan oleh strain patogen memiliki 
dampak yang dramatis. Untuk mengatasi masalah ini, tim pengendalian infeksi menggunakan 
berbagai teknik typing untuk membantu melacak sumber bakteri, untuk menentukan model 
penyebaran klon patogen dan, pada akhirnya, untuk menghambat atau lebih menghentikan 
penyebaran mikroba. Sebagian besar laboratorium mikrobiologi klinik di seluruh dunia saat ini 
rutin menggunakan teknik biologi molekuler untuk tujuan ini. Selama beberapa dekade terakhir 
Pulsed-Field Gel Electrophoresis (PFGE; berdasarkan fragmentasi genom bakteri oleh enzim 
tertentu) telah menjadi salah satu teknik yang paling umum digunakan di laboratorium diagnostik 
di seluruh dunia. Selain itu, multi-locus variable number of tandem repeats (VNTR) analysis (MLVA), 
multi-locus sequence typing (MLST, berdasarkan polimorfisme gen housekeeping dalam jumlah 
terbatas) juga digunakan. Selama beberapa tahun terakhir, whole-genome sequencing (WGS) telah 
menjadi metode yang disukai untuk surveilans epidemiologi molekuler penyakit menular. (6) 
Pada awal penelitian, kami juga menggunakan Raman spektroskopi sebagai metode cepat typing 
bakteri secara fenotipik. (10)Klebsiella pneumoniae dan   Acinetobacter baumannii,  tetapi teknik 
ini tidak dapat diterapkan pada P. aeruginosa  karena adanya  gangguan oleh pyocins yang terdapat 
intrinsik pada spesies ini. 
Typing dengan spektroskopi Raman menghasilkan lima klaster utama CNAB, klaster 
terbesar (CIPTO-31) terdiri dari isolat yang berasal dari pasien (skrining dan spesimen klinis) dan 
isolat dari lingkungan. MLST yang dilakukan untuk 14 isolat, menghasilkan adanya beberapa tipe 




jenis  ST yang sebelumnya sudah diidentifikasi (ST195, ST208, ST218, dan ST642) serta beberapa 
ST baru, dan alel baru untuk gen gpi  ditemukan dalam penelitian ini. (2) 
Analisis spektroskopi Raman juga menghasilkan adanya beberapa klaster CNKP. Ada tiga 
klaster utama, klaster terbesar (CIPTOKPN24) terdiri dari isolat yang diperoleh dari pasien 
(skrining dan spesimen klinis) dan ditemukan di kedua ICU sepanjang masa studi, sedangkan klon 
lain tampaknya bervariasi pada waktu tertentu. (4) Sebanyak 97 isolasi klinis dan 1 isolat dari 
lingkungan dianalisis lebih lanjut menggunakan metode genoyping MLVA, teridentifikasi 30 
genotipe yang berbeda. Pengelompokan strain oleh spektroskopi Raman menjadi tiga kelompok 
dominan sesuai dengan pengelompokan oleh MLVA, misalnya 20 strain Raman CIPTOKPN24 
semuanya merupakan milik satu kompleks klonal MLVA. Demikian juga keempat strain Raman 
CIPTOKPN30 milik satu kompleks klonal MLVA seperti yang ditemukan pada isolat CIPTOKPN27. 
(4) 
MLST mengungkapkan empat klaster utama CNPA (ST235, ST823, ST446 dan ST357) 
serta beberapa sequence types baru. Pada MLVA, lima klaster utama dibedakan menjadi  dua 
milik ST235 dan yang lainnya sesuai dengan ST823, ST446 dan ST357. Sebagian besar isolat 
milik ST235 (isolat pasien dan lingkungan), di mana 22 isolat memiliki gen blaIMP,24 isolat 
memiliki  gen blaGES-5  tetapi tidak ada isolat yang mengandung  gen blaVIM. Semua ST823 memilki 
gen blaVIM. 
Kami selanjutnya mengevaluasi lima jenis teknik typing molekuler dengan menggunakan 
isolat CNPA yang secara epidemiologis yang sudah diketahui karakteristiknya. Teknik tersebut 
adalah sebagai berikut Multi-Locus Variable Number of Tandem Repeat (VNTR) Analysis (MLVA), 
in-silico  seven-loci multi-locus sequence typing (MLST), core and whole genome MLST 
(cg/wgMLST), core Single Nucleotide Polymorphism (SNP) (cgSNP). Temuan kami menunjukkan 
bahwa tiga teknik terakhir (cgMLST, wgMLST dan cgSNP) memberikan tingkat resolusi tertinggi 
yang memungkinkan analisis epidemiologi lebih rinci dari wabah lokal dan penyebaran 
internasional. MLVA adalah alternatif yang cocok untuk typing  P. aeruginosa yang akurat, berguna 
dalam kondisi transisi bila WGS tidak bisa dilakukan. 
Dengan demikian, kesan secara keseluruhan adalah bahwa strain carbapenem-non susceptible 
dari tiga spesies yang ditargetkan oleh penelitian kami menunjukkan adanya endemisitas 
beberapa klon yang beredar di antara pasien ICU dan lingkungan ICU. 
Tujuan 2 dari penelitian ini:  Untuk mengembangkan metode intervensi yang dapat 
untuk diterapkan dalam seting ICU sumber daya terbatas - yang dapat secara signifikan 
mengurangi risiko akuisisi dan infeksi oleh carbapenem-non-susceptible A. baumannii, 
P. aeruginosa dan K. pneumoniae. 
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Sebagian besar HAI dapat dicegah melalui langkah-langkah pencegahan dan pengendalian 
infeksi (IPC) yang efektif. (11) Setelah fase 1, kami memperkenalkan bundel multimodal 
intervensi IPC yang awalnya terdiri dari langkah-langkah berikut  (12) dan melihat bab 8: 
1. Program multifaset peningkatan kepatuhan kebersihan tangan.
Berdasarkan program kebersihan tangan yang terdapat dalam pedoman Five Moments for
Hand Hygiene WHO. Program peningkatan kepatuhan kebersihan tangan mencakup
edukasi dengan mengujia pengetahuan dan sikap pra-dan pasca-kuesioner, umpan balik
kinerja dan pengingat, wawancara, dan role-models seperti yang telah dijelaskan
sebelumnya. (12)
2. Satu putaran kampanye desinfeksi lingkungan yang melibatkan seluruh lingkungan di
kedua ICU dengan menggunakan larutan natrium hipoklorit 1:100. Larutan disinfektan ini
digunakan pada dinding, lantai, pintu, tempat tidur (kasur dan rel tempat tidur), wastafel,
meja disamping, pompa infus dan pompa hisap dan tiang, monitor dan ventilator
termasuk kabel penghubung, di bagian atas meja termasuk ruang cuci yang berdekatan.
Selain itu, semua tirai di antara tempat tidur ditukar dengan yang bersih.
3. Desinfeksi lingkungan rutin dengan larutan natrium hipoklorit 1:100 yang mencakup
lantai, tempat tidur, dan lingkungan sekitar pasien. Ini dilakukan dua kali sehari. Untuk
kotoran yang terlihat, pertama kali dibersihkan dengan sikat dan air, sebelum
menggunakan larutan natrium hipoklorit. Prosedur intensif seperti yang dijelaskan di atas
diulang setiap dua minggu dalam fase ini. Tirai di antara tempat tidur diganti setiap 1-2 
bulan atau segera bila ada kotoran terlihat.
4. Pemberlakuan penatagunaan antibiotik (termasuk evaluasi harian semua resep antibiotik
pada hari kerja).
5. Semua pasien yang ditemukan positif untuk satu atau lebih carbapenem-non- susceptible
A. baumannii-calcoaceticus  complex,  K. pneumoniae, atau P. aeruginosa  dikohort di salah
satu sudut khusus di ICU. HCW mengenakan masker, gaun, dan sarung tangan ketika
mendekati dan memberikan perawatan untuk pasien yang kohort.
6. Mandi / membersihkan seluruh tubuh setiap hari dengan kain/washlap yang sudah
mengandung larutan chlorhexidine gluconate 2%. Washlap ini disiapkan dan dikemas
secara individual dalam kemasan plastik tertutup oleh unit farmasi rumah sakit.
7. Memperkenalkan larutan glukonat klorheksidin 2% untuk dekontaminasi orofaring. Botol 
yang mengandung larutan ini juga disiapkan dan disediakan oleh unit farmasi rumah sakit
dan digunakan per pasien. Dekontaminasi oral dilakukan 4 kali setiap hari.
Tujuan 3 dari penelitian: Untuk menerapkan dan menentukan efikasi intervensi (dikembangkan 




Kami mengukur pengetahuan hand hygene (HH) dan kepatuhan HH sebelum (di fase 
dasar) dan langsung setelah program multifaset (paska-intervensi) dan melakukan evaluasi 
ulang tiga tahun kemudian. Program peningkatan multifaset meliputi pendidikan, umpan balik, 
pengingat, wawancara dan penggunaan role-models. Ada peningkatan yang signifikan secara 
statistik dalam skor median pengetahuan HH secara keseluruhan pada paska-intervensi. 
Kepatuhan HH secara keseluruhan adalah 27% pada fase dasar dan secara signifikan meningkat 
menjadi 77% paska-intervensi. Untuk kelima momen HH, kepatuhan perawat dan dokter secara 
terpisah meningkat secara signifikan dari fase dasar ke fase paska intervensi, kecuali untuk 
“momen 3” (setelah paparan cairan tubuh), di mana pada fase dasar sudah tinggi. Sebagian besar 
tingkat kepatuhan secara signifikan lebih rendah di kedua kelompok petugas kesehatan setelah 
evaluasi tiga tahun kemudian, mereka pada dasarnya kembali ke tingkat pra-intervensi. Secara 
keseluruhan, kepatuhan HH terhadap perawat secara signifikan lebih baik daripada kepatuhan 
dokter. (12) Dengan demikian, menjaga kepatuhan HH  tinggi memerlukan pemantauan yang 
berkelanjutan dan intervensi rutin. 
Kami mengevaluasi efek intervensi terhadap akuisisi carbapenem-non-susceptible 
Acinetobacter baumannii-calcoaceticus  complex (CNAB),  Klebsiella pneumoniae  (CNKP), dan  
Pseudomonas aeruginosa  (CNPA). Menggunakan studi desain kuasi-eksperimental sebelum dan 
sesudah, secara keseluruhan untuk ketiga spesies ada “step change” yang signifikan, dari fase 1 
ke fase 3 dalam tingkat akuisisi strain carbapenem-non-susceptible. Penurunan signifikan dalam 
tingkat akuisisi keseluruhan strain carbapenem-non-susceptible dari ketiga spesies terutama 
disebabkan oleh penurunan akuisisi carbapenem-non-susceptible A. baumannii-calcoaceticus 
complex dan, pada tingkat yang lebih rendah,  K. pneumoniae. Menariknya, tingkat akuisisi  P. 
aeruginosa  hanya sedikit dipengaruhi oleh intervensi multimodal. Dalam masing-masing dari 
dua fase tidak ada tren ke penurunan atau peningkatan utama yang diamati dalam tingkat 
akuisisi strain resisten untuk salah satu dari tiga spesies secara terpisah atau untuk tiga spesies 
yang diambil bersama-sama, meskipun risiko akuisisi meningkat sedikit di fase 1. (lihat bab 8) 
Penggunaan WGS yang dikombinasi dengan data klinis, kami dapat melacak dengan 
akurat penyebaran endemik carbapenem-non-susceptible strain Pseudomonas aeruginosa selama 
periode 3 tahun di ICU. Kami menemukan bahwa jumlah transmisi dan akuisisi CNPA oleh 
pasien sangat bervariasi dari waktu ke waktu, tetapi secara keseluruhan, lajunya memang tidak 
berkurang secara signifikan oleh intervensi. Sumber di lingkungan ICU terlibat dalam transmisi 
dan akuisisi ini. Empat klon CNPA internasional berisiko tinggi (ST235, ST823, ST357, dan 
ST446) mendominasi, tetapi distribusi klon ini berubah secara signifikan setelah intervensi 
dilaksanakan. (6) Dengan demikian, intervensi multimodal dapat mengubah komposisi klon 
carbapenem-non-susceptible P. aeruginosa  tetapi tidak membasmi sumber ataupun 






Kami menyimpulkan bahwa intervensi multimodal yang bertujuan untuk mencegah 
akuisisi strain resisten patogen ICU merupakan usaha yang penting, dan pada dasarnya mampu 
dan mungkin cukup efektif untuk ICU di negara-negara berpenghasilan menengah ke bawah. 
Namun, intervensi multimodal berkemungkinan tidak sama efektifnya untuk semua spesies 
yang strain antibiotik-resisten. 
 
REKOMENDASI UNTUK PENELITIAN SELANJUTNYA 
 Studi kami dilakukan di dua ICU hanya di satu rumah sakit rujukan nasional di Jakarta, 
Indonesia. Karena Indonesia adalah negara yang luas dan terpadat keempat di dunia, data yang 
disajikan dalam tesis ini tidak dapat mewakili seluruh Indonesia. 
Di masa depan, program surveilans nasional untuk bakteri batang Gram-negatif negatif 
carbapenem-non-susceptible harus ditetapkan, di seluruh provinsi di Indonesia, dengan 
pengumpulan data epidemiologi, mekanisme resistensi fenotipik dan genotipik, dan analisis 
terkait kloning. Sistem deteksi awal harus diatur untuk pengenalan klon "berisiko tinggi" atau 
rute transmisi yang tanpa tersembunyi. Misalnya, adanya temuan kami bahwa beberapa pasien 
sudah membawa isolat carbapenem-non-susceptible pada saat masuk ke ICU, bisa menjadi 
potensi untuk penularan antar rumah sakit ketika pasien dirujuk, atau bahkan kemungkinan 
adanya keberadaan reservoir di masyarakat atau komunitas. Semua potensi Sumber dan rute 
penularan ini harus dieksplorasi atau diteliti lebih lanjut. 
Kami menemukan variasi yang terbatas pada gen karbapenemase di setiap spesies, 
CNAB hanya memiliki gen blaoxa-23  dan  blaoxa-51,  CNKP hanya membawa  blaNDM  dan CNPA 
membawa blaVIM,  blaGES-5  dan  blaIMP.. Apakah kita juga dapat menemukan gen pengkodean 
karbapenemase yang sama di antara isolate ICU dari ketiga spesies ini di provinsi lain di 
Indonesia? Itu masih dipertanyakan. Sistem surveilans akan menghasilkan data tentang hal ini. 
Kami menyimpulkan bahwa intervensi multimodal yang bertujuan untuk mencegah 
akuisisi strain resisten patogen ICU yang penting, mampu dan mungkin cukup efektif dalam ICU 
di negara-negara berpenghasilan menengah ke bawah, tetapi tidak untuk CNPA. Pembersihan 
lingkungan tampaknya menjadi bagian yang sangat penting dari intervensi dengan CNPA. 
Pseudomonas aeruginosa  adalah patogen yang unik, organisme ini dapat bertahan hidup selama 
periode jangka panjang di lingkungan yang lembab. Ada dua kemungkinan jalur transmisi untuk 
CNPA, yaitu melalui paparan air (limbah) yang tidak diproses dan melalui wastafel / keran yang 
terkontaminasi di rumah sakit. Hipotesis ini perlu dieksplorasi oleh upaya penelitian kolaboratif 
multicentre. 
Kami menemukan dalam penelitian ini, bahwa penggunaan antibiotik, terutama 
karbapenem, di ICU adalah faktor risiko independen utama untuk akuisisi strain carbapenem-




diperkenalkan dalam praktik sehari-hari di ICU danefeknya pada epidemiologi resistensi 
antimikroba dipelajari pada seting ini.  
Juga, penerapan intervensi tidak dipantau kecuali untuk kepatuhan kebersihan tangan. 
Studi di masa depan harus memonitor pembersihan lingkungan dengan cermat (dengan 
pengamatan praktik pembersihan, dan dengan lebih banyak kultur lingkungan), memantau 
penggunaan klorheksidin untuk dekontaminasi tubuh dan oral) dan yang terakhir, harus 
dipantau apakah pasien dengan kultur positif benar-benar dilakukan kohort di salah satu sudut 
ruangan atau ruangan yang terpisah. Ini semua harus dicatat dalam studi di masa depan, pada 
dasarnya memberikan data yang akurat tentang pelaksanaan intervensi multimodal. 
Akhirnya, ketika membangun fasilitas ICU baru, bahkan dalam seting sumber daya 
terbatas, seseorang harus lebih memperhatikan untuk menghindari terciptanya lingkungan khas 
untuk patogen ICU dan memberikan lebih banyak hambatan struktural untuk kelangsungan 
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